BRM targeting compounds and associated methods of use

Abstract

The present disclosure relates to bifunctional compounds, which find utility as modulators of SMARCA2 or BRM (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a ligand that binds to the Von Hippel-Lindau E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation / inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

Description

BRM TARGETING COMPOUNDS ANDASSOCIATED METHODS OF USECROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of U.S. Provisional Patent Application Serial No. 62 / 651,186, filed: 01 April 2018, entitled: BRM TARGETING PROTAC COMPOUNDS AND ASSOCIATED METHODS OF USE, and U.S. Provisional Patent Application Serial No. 62 / 797,754, filed: 28 January 2019, entitled: BRM TARGETING PROTAC COMPOUNDS AND ASSOCIATED METHODS OF USE, both of which are incorporated herein by reference in their entirety.FIELD OF THE INVENTION

[0002] The description provides bifunctional compounds comprising a target protein binding moiety and a E3 ubiquitin ligase binding moiety, and associated methods of use. The bifunctional compounds are useful as modulators of targeted ubiquitination, especially with respect to Switch / Sucrose Non Fermentable (S W I / S N F) - Re 1 atcd. Matrix- Associated, Actin-Dependent Regulator of Chromatin, Subfamily A, Member 2 (SMARCA2) (i.e., BRAHMA or BRM), which are degraded and / or otherwise inhibited by bifunctional compounds according to the present disclosure.BACKGROUND

[0003] Most small molecule drugs bind enzymes or receptors in tight and well-defined pockets. On the other hand, protein-protein interactions are notoriously difficult to target using small molecules due to their large contact surfaces and the shallow grooves or flat interfaces involved. E3 ubiquitin ligases (of which hundreds are known in humans) confer substrate specificity for ubiquitination, and therefore, are more attractive therapeutic targets than general proteasome inhibitors due to their specificity for certain protein substrates. The development of ligands of E3 ligases has proven challenging, in part due to the fact that they must disrupt protein-protein interactions. However, recent developments have provided specific ligands which bind to these ligases. For example, since the discovery of nutlins, the first small molecule E3 ligase inhibitors, additional compounds have been reported that target E3 ligases but the field remainsAVS0044US3 underdeveloped. For example, since the discovery of Nutlins, the first small molecule E3 ligase mouse double minute 2 homolog (MDM2) inhibitors, additional compounds have been reported that target MDM2 (i.e., human double minute 2 or HD M2) E3 ligases (J. Di, et al. Current Cancer Drug Targets (2011), 11(8), 987-994).

[0004] One E3 ligase with exciting therapeutic potential is the von Hippel-Lindau (VHL) tumor suppressor, the substrate recognition subunit of the E3 ligase complex VCB, which also consists of elongins B and C, Cul2 and Rbxl. The primary substrate of VHL is Hypoxia Inducible Factor la (HIF-la), a transcription factor that upregulates genes such as the pro-angiogenic growth factor VEGF and the red blood cell inducing cytokine erythropoietin in response to low oxygen levels. The first small molecule ligands of Von Hippel Lindau (VHL) to the substrate recognition subunit of the E3 ligase were generated, and crystal structures were obtained confirming that the compound mimics the binding mode of the transcription factor HIF-la, the major substrate of VHL.

[0005] Bifunctional compounds such as those that are described in U.S. Patent Application Publications 2015-0291562 and 2014-0356322 (incorporated herein by reference), function to recruit endogenous proteins to an E3 ubiquiuin ligase for degradation. In particular, the publications describe bifunctional or proteolysis targeting chimeric (PROTAC) compounds, which find utility as modulators of targeted ubiquitination of a variety of polypeptides and other proteins, which are then degraded and / or otherwise inhibited by the bifunctional compounds.

[0006] The Switch / Sucrose Non Fermentable (SWI / SNF) is a multi-subunit complex that modulates chromatic structure through the activity of two mutually exlusive helicase / ATPase catalytic subunits SWI / SNF-Rclatcd, Matrix- Associated, Actin-Dependent Regulator of Chromatin, Subfamily A, Member 2 (SMARCA2, BRAHMA or BRM) and SWI / SNF-Rclatcd, Matrix-Associated, Actin-Dependent Regulator of Chromatin, Subfamily A, Member 4 (SMARCA4 or BRG1). The core and the regulatory subunits couple ATP hydrolysis to the perturbation of histone-DNA contacts, thereby providing access points to transcription factors and cognate DNA elements that facilitate gene activation and repression.

[0007] Mutations in the genes encoding the twenty canonical SWI / SNF subunits are observed in nearly 20% of all cancers with the highest frenquency of mutations observed in rhabdoid tumors, female cancers (including ovarian, uterine, cerical and endometrial), lung adenocarcinoma, gastric adenocarcinoma, melanoma, esophageal, and feanal clear cell carcinoma. Despite having a highAVS0044US3 degree of homology, and their presumed overlapping functions, SMARCA2 and SMARCA4 have been reported as having different roles in cancer. For example, SMARCA4 is frequently mutated in primary tumors, while SMARCA2 inactivation is infrequent in tumor development. In fact, numerous types of cancer have been shown to be SMARCA4-related (e.g., cancers having a SMARCA4-mutation or a SMARCA4-deficiency, such as lack of expression), including, e.g., lung cancer (such as non-small cell lung cancer).

[0008] SMARCA2 has been demonstrated as one of the top essential genes in SMARCA4- related or-mutant cancer cell lines. This is because SMARCA4-deficient patient populations or cells depend exclusively on SMARCA2 activity— i.e., there is a greater incorporation of SMARCA2 into the complex to compensate for the SMARCA4 deficiency. Thus, SMARCA2 may be targeted in SMARCA4-related / deficient cancers. The co-occurrence of the deficiency of the expression of two (or more) genes that leads to cell death is known as, synthetic lethality. Accordingly, synethetic lethality can be leveraged in the treatment of certain SMARCA2 / SMARCA4-related cancers.

[0009] There is an ongoing need for effective treatment for diseases that are treatable by inhibiting or degrading SMARCA2 (i.e., BRAHMA or BRM). However, non-specific effects, and the inability to target and modulate SMARCA2 remains an obstacle to the development of effective treatments. As such, small-molecule therapeutic agents that target SMARCA2 and that leverage or potentiate VHL’s substrate specificity would be very useful.SUMMARY

[0010] The present disclosure describes bifunctional compounds which function to recruit endogenous proteins to an E3 ubiquitin ligase for degradation, and methods of using the same. In particular, the present disclosure provides bifunctional or proteolysis targeting chimeric (PROTAC) compounds, which find utility as modulators of targeted ubiquitination of a variety of polypeptides and other proteins, which are then degraded and / or otherwise inhibited by the bifunctional compounds as described herein. An advantage of the compounds provided herein is that a broad range of pharmacological activities is possible, consistent with the degradation / inhibition of targeted polypeptides from virtually any protein class or family. In addition, the description provides methods of using an effective amount of the compounds as described herein for theAVS0044US3 treatment or amelioration of a disease condition, such as cancer, e.g., SMARCA4-related / deficient cancer, such as lung cancer or non- small cell lung cancer.

[0011] As such, in one aspect the disclosure provides bifunctional or PROTAC compounds, which comprise an E3 ubiquitin ligase binding moiety (i.e., a ligand for an E3 ubquitin ligase or “ULM” group), and a moiety that binds a target protein (i.e., a protein / polypeptide targeting ligand or“PTM” group) such that the target protein / polypeptide is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. In a preferred embodiment, the ULM (ubiquitination ligase modulator) can be Von Hippel-Lindau E3 ubiquitin ligase (VHL) binding moiety (VLM). For example, the structure of the bifunctional compound can be depicted as:

[0012] The respective positions of the PTM and ULM moieties as well as their number as illustrated herein is provided by way of example only and is not intended to limit the compounds in any way. As would be understood by the skilled artisan, the bifunctional compounds as described herein can be synthesized such that the number and position of the respective functional moieties can be varied as desired.

[0013] In certain embodiments, the bifunctional compound further comprises a chemical linker (“L”). In this example, the structure of the bifunctional compound can be depicted as:where PTM is a protein / polypeptide targeting moiety, L is a linker, e.g., a bond or a chemical group coupling PTM to ULM, and ULM is a Von Hippel-Lindau E3 ubiquitin ligase (VHL) binding moiety (VLM).

[0014] For example, the structure of the bifunctional compound can be depicted as:wherein: PTM is a protein / polypeptide targeting moiety;“L” is a linker (e.g. a bond or a chemical linker group) coupling the PTM and a VLM, wherein VLM is Von Hippel-Lindau E3 ubiquitin ligase binding moiety that binds to VHL E3 ligase.AVS0044US3

[0015] In certain embodiments, the compounds as described herein comprise multiple independently selected ULMs, multiple PTMs, multiple chemical linkers or a combination thereof.

[0016] In additional embodiments, VLM can be hydroxyproline or a derivative thereof. Furthermore, other contemplated VLMs are included in U.S. Patent Application Publication No. 2014 / 03022523, which as discussed above, is incorporated herein in its entirety.

[0017] In certain embodiments,“L” is a bond. In additional embodiments, the linker“L” is a connector with a linear non-hydrogen atom number in the range of 1 to 20. The connector“L” can contain, but not limited to the functional groups such as ether, amide, alkane, alkene, alkyne, ketone, hydroxyl, carboxylic acid, thioether, sulfoxide, and sulfone. The linker can contain aromatic, heteroaromatic, cyclic, bicyclic and tricyclic moieties. Substitution with halogen, such as Cl, F, Br and I can be included in the linker. In the case of fluorine substitution, single or multiple fluorines can be included.

[0018] In certain embodiments, VLM is a derivative of trans- 3 -hydroxyproline, where both nitrogen and carboxylic acid in trans- 3 -hydroxyproline are functionalized as amides.

[0019] In an additional aspect, the description provides therapeutic compositions comprising an effective amount of a compound as described herein or salt form thereof, and a pharmaceutically acceptable carrier. The therapeutic compositions modulate protein degradation and / or inhibition in a patient or subject, for example, an animal such as a human, and can be used for treating or ameliorating disease states or conditions which are modulated through the degraded / inhibited protein. In certain embodiments, the therapeutic compositions as described herein may be used to effectuate the degradation of proteins of interest for the treatment or amelioration of a disease, e.g., cancer (including at least one of SWI / SNF associated cancer, a cancer with a SMARCA4 mutation, a cancer with a SMARCA4-deficiency, or a combination thereof), such as lung cancer (e.g., non small cell lung cancer). In yet another aspect, the present disclosure provides a method of ubiquitinating / degrading a target protein in a cell. In certain embodiments, the method comprises administering a bifunctional compound as described herein comprising a VLM, preferably linked through a linker moiety, as otherwise described herein, wherein the VLM is coupled to the PTM through a linker to target a protein for degradation. Degradation of the target protein will occur when the target protein is placed in proximity to the E3 ubiquitin ligase, thus resulting in degradation / inhibition of the effects of the target protein and the control of protein levels. The control of protein levels afforded by the present disclosure provides treatment of a disease state orAVS0044US3 condition, which is modulated through the target protein by lowering the level of that protein in the cells of a patient.

[0020] In still another aspect, the description provides methods for treating or ameliorating a disease, disorder or symptom thereof in a subject or a patient, e.g., an animal such as a human, comprising administering to a subject in need thereof a composition comprising an effective amount, e.g., a therapeutically effective amount, of a compound as described herein or salt form thereof, and a pharmaceutically acceptable carrier, wherein the composition is effective for treating or ameliorating the disease or disorder or symptom thereof in the subject.

[0021] In another aspect, the description provides methods for identifying the effects of the degradation of proteins of interest in a biological system using compounds according to the present disclosure.

[0022] The preceding general areas of utility are given by way of example only and are not intended to be limiting on the scope of the present disclosure and appended claims. Additional objects and advantages associated with the compositions, methods, and processes of the present disclosure will be appreciated by one of ordinary skill in the art in light of the instant claims, description, and examples. For example, the various aspects and embodiments of the disclosure may be utilized in numerous combinations, all of which are expressly contemplated by the present description. These additional aspects and embodiments are expressly included within the scope of the present disclosure. The publications and other materials used herein to illuminate the background of the disclosure, and in particular cases, to provide additional details respecting the practice, are incorporated by reference.BRIEF DESCRIPTION OF THE DRAWINGS

[0023] The accompanying drawings, which are incorporated into and form a part of the specification, illustrate several embodiments of the present disclosure and, together with the description, serve to explain the principles of the disclosure. The drawings are only for the purpose of illustrating an embodiment of the disclosure and are not to be construed as limiting the disclosure. Further objects, features and advantages of the disclosure will become apparent from the following detailed description taken in conjunction with the accompanying figures showing illustrative embodiments of the disclosure, in which:AVS0044US3

[0024] Figures 1A and IB. Illustration of general principle for PROTAC function. (A) Exemplary PROTACs comprise a protein targeting moiety (PTM; darkly shaded rectangle ), a ubiquitin ligase binding moiety (ULM; lightly shaded triangle), and optionally a linker moiety (L; black line ) coupling or tethering the PTM to the ULM. (B) Illustrates the functional use of the PROTACs as described herein. Briefly, the ULM recognizes and binds to a specific E3 ubiquitin ligase, and the PTM binds and recruits a target protein bringing it into close proximity to the E3 ubiquitin ligase. Typically, the E3 ubiquitin ligase is complexed with an E2 ubiquitin-conjugating protein, and either alone or via the E2 protein catalyzes attachment of ubiquitin ( dark circles) to a lysine on the target protein via an isopeptide bond. The poly-ubiquitinated protein (far right) is then targeted for degradation by the proteosomal machinery of the cell.DETAILED DESCRIPTION

[0025] The following is a detailed description provided to aid those skilled in the art in practicing the present disclosure. Those of ordinary skill in the art may make modifications and variations in the embodiments described herein without departing from the spirit or scope of the present disclosure. All publications, patent applications, patents, figures and other references mentioned herein are expressly incorporated by reference in their entirety.

[0026] Presently described are compositions and methods that relate to the surprising and unexpected discovery that an E3 ubiquitin ligase protein (e.g., Von Hippel-Lindau E3 ubiquitin ligase (VHL)) ubiquitinates a target protein once it and the target protein are placed in proximity by a bifunctional or chimeric construct that binds the E3 ubiquitin ligase protein and the target protein. Accordingly the present disclosure provides such compounds and compositions comprising an E3 ubiquintin ligase binding moiety (“ULM”) coupled to a protein target binding moiety (“PTM”), which result in the ubiquitination of a chosen target protein, which leads to degradation of the target protein by the proteasome (see Ligure 1). The present disclosure also provides a library of compositions and the use thereof.

[0027] In certain aspects, the present disclosure provides compounds which comprise a ligand, e.g., a small molecule ligand (i.e., having a molecular weight of below 2,000, 1,000, 500, or 200 Daltons), which is capable of binding to a ubiquitin ligase, such as VHL. The compounds also comprise a moiety that is capable of binding to target protein, in such a way that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and / or inhibition) of that protein.AVS0044US3Small molecule can mean, in addition to the above, that the molecule is non-peptidyl, that is, it is not generally considered a peptide, e.g., comprises fewer than 4, 3, or 2 amino acids. In accordance with the present description, the PTM, ULM or PROTAC molecule can be a small molecule.

[0028] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. The terminology used in the description is for describing particular embodiments only and is not intended to be limiting of the disclosure.

[0029] Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise (such as in the case of a group containing a number of carbon atoms in which case each carbon atom number falling within the range is provided), between the upper and lower limit of that range and any other stated or intervening value in that stated range is encompassed within the disclosure. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges is also encompassed within the disclosure, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either both of those included limits are also included in the disclosure.

[0030] The following terms are used to describe the present disclosure. In instances where a term is not specifically defined herein, that term is given an art-recognized meaning by those of ordinary skill applying that term in context to its use in describing the present disclosure.

[0031] The articles "a" and "an" as used herein and in the appended claims are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article unless the context clearly indicates otherwise. By way of example, "an element" means one element or more than one element.

[0032] The phrase "and / or," as used herein in the specification and in the claims, should be understood to mean "either or both" of the elements so conjoined, i.e., elements that are conjunctively present in some cases and disjunctively present in other cases. Multiple elements listed with "and / or" should be construed in the same fashion, i.e., "one or more" of the elements so conjoined. Other elements may optionally be present other than the elements specifically identified by the "and / or" clause, whether related or unrelated to those elements specifically identified. Thus, as a non-limiting example, a reference to "A and / or B", when used in conjunction with open-ended language such as "comprising" can refer, in one embodiment, to A onlyAVS0044US3(optionally including elements other than B); in another embodiment, to B only (optionally including elements other than A); in yet another embodiment, to both A and B (optionally including other elements); etc.

[0033] As used herein in the specification and in the claims, "or" should be understood to have the same meaning as "and / or" as defined above. For example, when separating items in a list, "or" or "and / or" shall be interpreted as being inclusive, i.e., the inclusion of at least one, but also including more than one, of a number or list of elements, and, optionally, additional unlisted items. Only terms clearly indicated to the contrary, such as“only one of’ or "exactly one of," or, when used in the claims, "consisting of," will refer to the inclusion of exactly one element of a number or list of elements. In general, the term "or" as used herein shall only be interpreted as indicating exclusive alternatives (i.e., "one or the other but not both") when preceded by terms of exclusivity, such as "either," "one of," "only one of," or "exactly one of."

[0034] In the claims, as well as in the specification above, all transitional phrases such as "comprising," "including," "carrying," "having," "containing," "involving," "holding," "composed of," and the like are to be understood to be open-ended, i.e., to mean including but not limited to. Only the transitional phrases "consisting of and "consisting essentially of shall be closed or semi- closed transitional phrases, respectively, as set forth in the United States Patent Office Manual of Patent Examining Procedures, Section 2111.03.

[0035] As used herein in the specification and in the claims, the phrase "at least one," in reference to a list of one or more elements, should be understood to mean at least one element selected from anyone or more of the elements in the list of elements, but not necessarily including at least one of each and every element specifically listed within the list of elements and not excluding any combinations of elements in the list of elements. This definition also allows that elements may optionally be present other than the elements specifically identified within the list of elements to which the phrase "at least one" refers, whether related or unrelated to those elements specifically identified. Thus, as a nonlimiting example, "at least one of A and B" (or, equivalently, "at least one of A or B," or, equivalently "at least one of A and / or B") can refer, in one embodiment, to at least one, optionally including more than one, A, with no B present (and optionally including elements other than B); in another embodiment, to at least one, optionally including more than one, B, with no A present (and optionally including elements other than A); in yet another embodiment,AVS0044US3 to at least one, optionally including more than one, A, and at least one, optionally including more than one, B (and optionally including other elements); etc.

[0036] It should also be understood that, in certain methods described herein that include more than one step or act, the order of the steps or acts of the method is not necessarily limited to the order in which the steps or acts of the method are recited unless the context indicates otherwise.

[0037] The terms "co-administration" and "co-administering" or“combination therapy” refer to both concurrent administration (administration of two or more therapeutic agents at the same time) and time varied administration (administration of one or more therapeutic agents at a time different from that of the administration of an additional therapeutic agent or agents), as long as the therapeutic agents are present in the patient to some extent, preferably at effective amounts, at the same time. In certain preferred aspects, one or more of the present compounds described herein, are coadministered in combination with at least one additional bioactive agent, especially including an anticancer agent. In particularly preferred aspects, the co-administration of compounds results in synergistic activity and / or therapy, including anticancer activity.

[0038] The term“compound”, as used herein, unless otherwise indicated, refers to any specific chemical compound disclosed herein and includes tautomers, regioisomers, geometric isomers, and where applicable, stereoisomers, including optical isomers (enantiomers) and other stereoisomers (diastereomers) thereof, as well as pharmaceutically acceptable salts and derivatives, including prodrug and / or deuterated forms thereof where applicable, in context. Deuterated small molecules contemplated are those in which one or more of the hydrogen atoms contained in the drug molecule have been replaced by deuterium.

[0039] Within its use in context, the term compound generally refers to a single compound, but also may include other compounds such as stereoisomers, regioisomers and / or optical isomers (including racemic mixtures) as well as specific enantiomers or enantiomerically enriched mixtures of disclosed compounds. The term also refers, in context to prodrug forms of compounds which have been modified to facilitate the administration and delivery of compounds to a site of activity. It is noted that in describing the present compounds, numerous substituents and variables associated with same, among others, are described. It is understood by those of ordinary skill that molecules which are described herein are stable compounds as generally described hereunder. When the bond is shown, both a double bond and single bond are represented or understood within the context of the compound shown and well-known rules for valence interactions.AVS0044US3

[0040] The term“ubiquitin ligase” refers to a family of proteins that facilitate the transfer of ubiquitin to a specific substrate protein, targeting the substrate protein for degradation. For example, an E3 ubiquitin ligase protein that alone or in combination with an E2 ubiquitin- conjugating enzyme causes the attachment of ubiquitin to a lysine on a target protein, and subsequently targets the specific protein substrates for degradation by the proteasome. Thus, E3 ubiquitin ligase alone or in complex with an E2 ubiquitin conjugating enzyme is responsible for the transfer of ubiquitin to targeted proteins. In general, the ubiquitin ligase is involved in polyubiquitination such that a second ubiquitin is attached to the first; a third is attached to the second, and so forth. Polyubiquitination marks proteins for degradation by the proteasome. However, there are some ubiquitination events that are limited to mono-ubiquitination, in which only a single ubiquitin is added by the ubiquitin ligase to a substrate molecule. Mono-ubiquitinated proteins are not targeted to the proteasome for degradation, but may instead be altered in their cellular location or function, for example, via binding other proteins that have domains capable of binding ubiquitin. Further complicating matters, different lysines on ubiquitin can be targeted by an E3 to make chains. The most common lysine is Lys48 on the ubiquitin chain. This is the lysine used to make polyubiquitin, which is recognized by the proteasome. As used herein, the term "alkyl", by itself or as part of another substituent, means, unless otherwise stated, a straight or branched chain hydrocarbon radical, having the number of carbon atoms designated (i.e., Ci-s means one to eight carbons). Absent a specific number of carbon atoms, an alkyl group provided herein is assumed to have one to twelve carbons, one to eight carbons, one to six carbons, or one to four carbons. Examples of alkyl groups include methyl, ethyl, n-propyl, iso-propyl, n-butyl, t- butyl, iso-butyl, sec-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like. Alkyl groups may be optionally substituted as provided herein. In some embodiments, the alkyl group is a Ci-6alkyl; in some embodiments, it is a CM alkyl.

[0041] U.S. Patent Application Serial No. 15 / 230,354, filed on August 5, 2016; and U.S. Patent Application Serial No. 14 / 371,956, filed on July 11, 2014, published as U.S. Patent Application Publication No. 2014 / 0356322; and U.S. Patent Application Serial No. 15 / 074,820, filed on March 18, 2016, published as U.S. Patent Application Publication No. 2016 / 0272639; and International Patent Application No. PCT / US2016 / 019328, filed February 24, 2016, published as International Patent Application Publication No. WO2016 / 138114, and International Patent Application No. PCT / US2016 / 023258, filed March 18, 2016, published as International Patent ApplicationAVS0044US3Publication No. WO2016 / 149668, and U.S. Non-Provisional Patent Application No. 15 / 885,671, filed 31 January 2018, published as U.S. Patent Application Publication No. 2018 / 0215731, all of which are incorporated herein by reference in their entirety. Furthermore, ah references cited herein are incorporated by reference herein in their entirety.

[0042] The term“optionally substituted”, as used in combination with a substituent defined herein, means that the substituent may, but is not required to be, substituted with one or more suitable functional groups or other substituents as provided herein. For example, a substituent may be optionally substituted with one or more of: halo, cyano, Ci-6alkyl, C3-6 cycloalkyl, C2-6 alkenyl, C2-6 alkynyl, halo(Ci-6)alkyl, Ci-6alkoxy, halo(Ci-6alkoxy), Ci-6alkylthio, Ci-6alkylamino, NFh, NH(CI-6alkyl), N(CI_6alkyl)2, NH(CI_6alkoxy), N(CI_6alkoxy)2, -C(0)NHCi_6alkyl, -C(0)N(Ci_6alkyl)2, -C(0)NH2, -C(0)Ci_6alkyl, -C(0)2Ci-6alkyl, -NHCO(CI-6alkyl), -N(CI_6alkyl)CO(Ci-6alkyl), -S(0)Ci-6alkyl, -S(0)2Ci-6alkyl, oxo, phenyl, benzyl, pyridinyl, pyrrazolyl, thiazolyl, isothiazolyl, or other 5 to 6 membered heteroaryl groups. In some embodiments, each of the above optional substituents are themselves optionally substituted by one or two groups.

[0043] The term“cycloalkyl” as used herein refers to a C3-12 cyclic alkyl group, and includes bridged and spirocycles (e.g., adamantine). Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cycloheptyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclo[2.2.l]heptanyl, bicyclo[3. l.l]heptanyl, bicyclo[4.l.0]heptanyl, spiro[3.3]heptanyl, and spiro[3.4]octanyl. In some embodiments, the cycloalkyl group is a C3-6 cycloalkyl.

[0044] The term“akenyl” as used herein refers to C2-12 alkyl group wherein at least two of the carbon atoms are sp2 hybridized and form a carbon-carbon double bond between them. An alkenyl group provided herein may contain more than one carbon-carbon double bond, but one is preferred. The alkyl portion of an alkenyl group provided herein may be substituted as provided above. In some embodiments, the alkenyl group is a C2-6 alkenyl.

[0045] The term“akynyl” as used herein refers to C2-12 alkyl group wherein at least two of the carbon atoms are sp hybridized and form a carbon-carbon triple bond between them. An alkynyl group provided herein may contain more than one carbon-carbon triple bond, but one is preferred. The alkyl portion of an alkynyl group provided herein may be substituted as provided above. In some embodiments, the alkynyl group is a C2-6 alkynyl.

[0046] The terms "alkoxy," "alkylamino" and“alkylthio”, are used in their conventional sense, and refer to those alkyl groups attached to the remainder of the molecule via an oxygen atomAVS0044US3(“oxy”), an amino group (“amino”) or thio group. The term“alkylamino” includes mono- di- alkylamino groups, the alkyl portions can be the same or different.

[0047] The terms "halo" by itself or as part of another substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom, but preferably fluorine or chlorine.

[0048] The term“halo(Ci-xalkyl)” refers to an alkyl that has l-x carbon atoms and that is substituted with one or more (e.g. 1, 2, 3, 4, 5, or 6) halo groups. For example the term includes an alkyl group having 1-6 carbon atoms that is substituted with one or more halo groups. Non limiting examples of the term halo(Ci-C6alkyl) include fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, and 2,2,2-trifluoroethyl.

[0049] The term“halo(Ci-xalkoxy)” refers to an alkoxy group that has l-x carbon atoms and that is substituted with one or more (e.g. 1, 2, 3, 4, 5, or 6) halo groups. For example the term includes an alkoxy group having 1-6 carbon atoms that is substituted with one or more halo groups. Non-limiting examples of the term halo(Ci-C6alkyl) include fluoromethoxy, difluoromethoxy, trifluoromethoxy, chloromethoxy, and 2,2,2-trifluoroethoxy.

[0050] The term“heteroalkyl” refers to a straight- or branched -chain alkyl group, e.g. having from 2 to 14 carbons, such as 2 to 10 carbons in the chain, one or more of which has been replaced by a heteroatom selected from S, O, P and N. Exemplary heteroalkyls include alkyl ethers, secondary and tertiary alkyl amines, alkyl amides, alkyl sulfides, and the like. The group may be a terminal group or a bridging group. As used herein reference to the normal chain when used in the context of a bridging group refers to the direct chain of atoms linking the two terminal positions of the bridging group.

[0051] The term“aryl” as used herein refers to a single all carbon aromatic ring or a multiple condensed all carbon ring system wherein at least one of the rings is aromatic. For example, in certain embodiments, an aryl group has 6 to 12 carbon atoms. Aryl includes a phenyl radical. Aryl also includes multiple condensed ring systems (e.g., ring systems comprising 2, 3 or 4 rings) having about 9 to 12 carbon atoms in which at least one ring is aromatic and wherein the other rings may be aromatic or not aromatic. Such multiple condensed ring systems are optionally substituted with one or more (e.g., 1, 2 or 3) oxo groups on any carbocycle portion of the multiple condensed ring system. The rings of the multiple condensed ring system can be connected to each other via fused, spiro and bridged bonds when allowed by valency requirements. It is to be understood that the point of attachment of a multiple condensed ring system, as defined above, canAVS0044US3 be at any position of the ring system including an aromatic or a carbocycle portion of the ring. Non-limiting examples of aryl groups include, but are not limited to, phenyl, indenyl, naphthyl, 1, 2, 3, 4-tetrahydronaphthyl, and the like.

[0052] The term“heteroaryl” as used herein refers to a single aromatic ring that has at least one atom other than carbon in the ring, wherein the atom is selected from the group consisting of oxygen, nitrogen and sulfur;“heteroaryl” also includes multiple condensed ring systems that have at least one such aromatic ring, which multiple condensed ring systems are further described below. Thus,“heteroaryl” includes single aromatic rings of from about 1 to 6 carbon atoms and about 1- 4 heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur. The sulfur and nitrogen atoms may also be present in an oxidized form provided the ring is aromatic. Exemplary heteroaryl ring systems include but are not limited to pyridyl, pyrimidinyl, oxazolyl or furyl. “Heteroaryl” also includes multiple condensed ring systems (e.g., ring systems comprising 2, 3 or 4 rings) wherein a heteroaryl group, as defined above, is condensed with one or more rings selected from heteroaryls (to form for example a naphthyridinyl such as l,8-naphthyridinyl), heterocycles, (to form for example a 1, 2, 3, 4-tetrahydronaphthyridinyl such as l,2,3,4-tetrahydro-l,8- naphthyridinyl), carbocycles (to form for example 5,6,7,8-tetrahydroquinolyl) and aryls (to form for example indazolyl) to form the multiple condensed ring system. Thus, a heteroaryl (a single aromatic ring or multiple condensed ring system) has about 1-20 carbon atoms and about 1-6 heteroatoms within the heteroaryl ring. A heteroaryl (a single aromatic ring or multiple condensed ring system) can also have about 5 to 12 or about 5 to 10 members within the heteroaryl ring. Multiple condensed ring systems may be optionally substituted with one or more (e.g., 1, 2, 3 or 4) oxo groups on the carbocycle or heterocycle portions of the condensed ring. The rings of a multiple condensed ring system can be connected to each other via fused, spiro and bridged bonds when allowed by valency requirements. It is to be understood that the individual rings of the multiple condensed ring system may be connected in any order relative to one another. It is also to be understood that the point of attachment of a multiple condensed ring system (as defined above for a heteroaryl) can be at any position of the multiple condensed ring system including a heteroaryl, heterocycle, aryl or carbocycle portion of the multiple condensed ring system. It is also to be understood that the point of attachment for a heteroaryl or heteroaryl multiple condensed ring system can be at any suitable atom of the heteroaryl or heteroaryl multiple condensed ring system including a carbon atom and a heteroatom (e.g., a nitrogen). Exemplary heteroaryls includeAVS0044US3 but are not limited to pyridyl, pyrrolyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrazolyl, thienyl, indolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, furyl, oxadiazolyl, thiadiazolyl, quinolyl, isoquinolyl, benzothiazolyl, benzoxazolyl, indazolyl, quinoxalyl, quinazolyl, 5, 6,7,8- tetrahydroisoquinolinyl benzofuranyl, benzimidazolyl, thianaphthenyl, pyrrolo[2,3-b]pyridinyl, quinazolinyl-4(3H)-one, triazolyl, 4,5,6,7-tetrahydro-lH-indazole and 3b,4,4a,5-tetrahydro-lH- cyclopropa[3,4]cyclo- penta[l,2-c]pyrazole. In one embodiment the term“heteroaryl” refers to a single aromatic ring containing at least one heteroatom. For example, the term includes 5- membered and 6-membered monocyclic aromatic rings that include one or more heteroatoms. Non-limiting examples of heteroaryl include but are not limited to pyridyl, furyl, thiazole, pyrimidine, oxazole, and thiadiazole.

[0053] The term“heterocyclyl” or“heterocycle” as used herein refers to a single saturated or partially unsaturated ring that has at least one atom other than carbon in the ring, wherein the atom is selected from the group consisting of oxygen, nitrogen and sulfur; the term also includes multiple condensed ring systems that have at least one such saturated or partially unsaturated ring, which multiple condensed ring systems are further described below. Thus, the term includes single saturated or partially unsaturated rings (e.g., 3, 4, 5, 6 or 7-membered rings) from about 1 to 6 carbon atoms and from about 1 to 3 heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur in the ring. The ring may be substituted with one or more (e.g., 1, 2 or 3) oxo groups and the sulfur and nitrogen atoms may also be present in their oxidized forms. Exemplary heterocycles include but are not limited to azetidinyl, tetrahydrofuranyl and piperidinyl. The term “heterocycle” also includes multiple condensed ring systems (e.g., ring systems comprising 2, 3 or 4 rings) wherein a single heterocycle ring (as defined above) can be condensed with one or more groups selected from heterocycles (to form for example a l,8-decahydronapthyridinyl ), carbocycles (to form for example a decahydroquinolyl) and aryls to form the multiple condensed ring system. Thus, a heterocycle (a single saturated or single partially unsaturated ring or multiple condensed ring system) has about 2-20 carbon atoms and 1-6 heteroatoms within the heterocycle ring. Such multiple condensed ring systems may be optionally substituted with one or more (e.g., 1, 2, 3 or 4) oxo groups on the carbocycle or heterocycle portions of the multiple condensed ring. The rings of the multiple condensed ring system can be connected to each other via fused, spiro and bridged bonds when allowed by valency requirements. It is to be understood that the individual rings of the multiple condensed ring system may be connected in any order relative toAVS0044US3 one another. Accordingly, a heterocycle (a single saturated or single partially unsaturated ring or multiple condensed ring system) has about 3-20 atoms including about 1-6 heteroatoms within the heterocycle ring system. It is also to be understood that the point of attachment of a multiple condensed ring system (as defined above for a heterocycle) can be at any position of the multiple condensed ring system including a heterocycle, aryl and carbocycle portion of the ring. It is also to be understood that the point of attachment for a heterocycle or heterocycle multiple condensed ring system can be at any suitable atom of the heterocycle or heterocycle multiple condensed ring system including a carbon atom and a heteroatom (e.g., a nitrogen). In one embodiment the term heterocycle includes a C2-20 heterocycle. In one embodiment the term heterocycle includes a C2-7 heterocycle. In one embodiment the term heterocycle includes a C2-5 heterocycle. In one embodiment the term heterocycle includes a C2-4 heterocycle. Exemplary heterocycles include, but are not limited to aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, homopiperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, tetrahydrofuranyl, dihydrooxazolyl, tetrahydropyranyl, tetrahydrothiopyranyl, 1,2, 3, 4- tetrahydroquinolyl, benzoxazinyl, dihydrooxazolyl, chromanyl, l,2-dihydropyridinyl, 2,3-dihydrobenzofuranyl, l,3-benzodioxolyl, l,4-benzodioxanyl, spiro [cyclopropane- l,l'-isoindolinyl] -3 '-one, isoindolinyl-l-one, 2-oxa-6-azaspiro[3.3]heptanyl, imidazolidin-2-one N-methylpiperidine, imidazolidine, pyrazolidine, butyrolactam, valerolactam, imidazolidinone, hydantoin, dioxolane, phthalimide, l,4-dioxane, thiomorpholine, thiomorpholine-S-oxide, thiomorpholine-S,S-oxide, pyran, 3-pyrroline, thiopyran, pyrone, tetrhydrothiophene, quinuclidine, tropane, 2-azaspiro[3.3]heptane, (lR,5S)-3- azabicyclo[3.2.l]octane, (ls,4s)-2-azabicyclo[2.2.2]octane, (lR,4R)-2-oxa-5- azabicyclo[2.2.2]octane and pyrrolidin-2-one. In one embodiment the term“heterocycle” refers to a monocyclic, saturated or partially unsaturated, 3-8 membered ring having at least one heteroatom. For example, the term includes a monocyclic, saturated or partially unsaturated, 4, 5, 6, or 7 membered ring having at least one heteroatom. Non-limiting examples of heterocycle include aziridine, azetidine, pyrrolidine, piperidine, piperidine, piperazine, oxirane, morpholine, and thiomorpholine. The term“9- or lO-membered heterobicycle” as used herein refers to a partially unsaturated or aromatic fused bicyclic ring system having at least one heteroatom. For example, the term 9- or lO-membered heterobicycle includes a bicyclic ring system having a benzo ring fused to a 5-membered or 6-membered saturated, partially unsaturated, or aromatic ring that contains one or more heteroatoms.AVS0044US3

[0054] As used herein, the term "heteroatom" is meant to include oxygen (O), nitrogen (N), sulfur (S) and silicon (Si). The nitrogen and sulfur can be in an oxidized form when feasible.

[0055] As used herein, the term "chiral" refers to molecules which have the property of non- superimposability of the mirror image partner, while the term "achiral" refers to molecules which are superimposable on their mirror image partner.

[0056] As used herein, the term "stereoisomers" refers to compounds which have identical chemical constitution, but differ with regard to the arrangement of the atoms or groups in space. As used herein a crossed lineindicates a mixture of E and Z stereoisomers.

[0057] As used herein a wavy line“·~ ~” or a dashed line“—” that intersects a bond in a chemical structure indicates the point of attachment of the bond that the wavy bond intersects in the chemical structure to the remainder of a molecule.

[0058] "Diastereomer" refers to a stereoisomer with two or more centers of chirality and whose molecules are not mirror images of one another. Diastereomers have different physical properties, e.g. melting points, boiling points, spectral properties, and reactivities. Mixtures of diastereomers can separate under high resolution analytical procedures such as electrophoresis and chromatography.

[0059] "Enantiomers" refer to two stereoisomers of a compound which are non- superimposable mirror images of one another.

[0060] Stereochemical definitions and conventions used herein generally follow S. P. Parker, Ed., McGraw-Hill Dictionary of Chemical Terms (1984) McGraw-Hill Book Company, New York; and Eliel, E. and Wilen, S., "Stereochemistry of Organic Compounds", John Wiley & Sons, Inc., New York, 1994. The compounds of the invention can contain asymmetric or chiral centers, and therefore exist in different stereoisomeric forms. It is intended that all stereoisomeric forms of the compounds of the invention, including but not limited to, diastereomers, enantiomers and atropisomers, as well as mixtures thereof such as racemic mixtures, form part of the present invention. Many organic compounds exist in optically active forms, i.e., they have the ability to rotate the plane of plane-polarized light. In describing an optically active compound, the prefixes D and L, or R and S, are used to denote the absolute configuration of the molecule about its chiral center(s). The prefixes d and 1 or (+) and (-) are employed to designate the sign of rotation of plane-polarized light by the compound, with (-) or 1 meaning that the compound is levorotatory. A compound prefixed with (+) or d is dextrorotatory. For a given chemical structure, theseAVS0044US3 stereoisomers are identical except that they are mirror images of one another. A specific stereoisomer can also be referred to as an enantiomer, and a mixture of such isomers is often called an enantiomeric mixture. A 50:50 mixture of enantiomers is referred to as a racemic mixture or a racemate, which can occur where there has been no stereoselection or stereo specificity in a chemical reaction or process. The terms "racemic mixture" and "racemate" refer to an equimolar mixture of two enantiomeric species, devoid of optical activity.

[0061] When a bond in a compound formula herein is drawn in a non-stereochemical manner (e.g. flat), the atom to which the bond is attached includes all stereochemical possibilities. When a bond in a compound formula herein is drawn in a defined stereochemical manner (e.g. bold, bold-wedge, dashed or dashed- wedge), it is to be understood that the atom to which the stereochemical bond is attached is enriched in the absolute stereoisomer depicted unless otherwise noted. In one embodiment, the compound may be at least 51% the absolute stereoisomer depicted. In another embodiment, the compound may be at least 80% the absolute stereoisomer depicted. In another embodiment, the compound may be at least 90% the absolute stereoisomer depicted. In another embodiment, the compound may be at least 95% the absolute stereoisomer depicted. In another embodiment, the compound may be at least 97% the absolute stereoisomer depicted. In another embodiment, the compound may be at least 98% the absolute stereoisomer depicted. In another embodiment, the compound may be at least 99% the absolute stereoisomer depicted.

[0062] As used herein, the term "tautomer" or "tautomeric form" refers to structural isomers of different energies which are interconvertible via a low energy barrier. For example, proton tautomers (also known as prototropic tautomers) include interconversions via migration of a proton, such as keto-enol and imine-enamine isomerizations. Valence tautomers include interconversions by reorganization of some of the bonding electrons.

[0063] As used herein, the term "solvate" refers to an association or complex of one or more solvent molecules and a compound of the invention. Examples of solvents that form solvates include, but are not limited to, water, isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid, and ethanolamine. The term "hydrate" refers to the complex where the solvent molecule is water.

[0064] As used herein, the term "protecting group" refers to a substituent that is commonly employed to block or protect a particular functional group on a compound. For example, an "amino-protecting group" is a substituent attached to an amino group that blocks or protects theAVS0044US3 amino functionality in the compound. Suitable amino-protecting groups include acetyl, trifluoroacetyl, t-butoxycarbonyl (BOC), benzyloxycarbonyl (CBZ) and 9- fluorenylmethylenoxycarbonyl (Fmoc). Similarly, a "hydroxy-protecting group" refers to a substituent of a hydroxy group that blocks or protects the hydroxy functionality. Suitable protecting groups include acetyl and silyl. A "carboxy-protecting group" refers to a substituent of the carboxy group that blocks or protects the carboxy functionality. Common carboxy-protecting groups include phenylsulfonylethyl, cyanoethyl, 2-(trimethylsilyl)ethyl, 2- (trimethylsilyl)ethoxymethyl, 2-(p-toluenesulfonyl)ethyl, 2-(p-nitrophenylsulfenyl)ethyl, 2- (diphenylphosphino)-ethyl, nitroethyl and the like. For a general description of protecting groups and their use, see P.G.M. Wuts and T.W. Greene, Greene's Protective Groups in Organic Synthesis 4thedition, Wiley-Interscience, New York, 2006.

[0065] As used herein, the term "pharmaceutically acceptable salts" is meant to include salts of the active compounds which are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein. When compounds of the present invention contain relatively acidic functionalities, base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent. Examples of salts derived from pharmaceutically-acceptable inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic, manganous, potassium, sodium, zinc and the like. Salts derived from pharmaceutically-acceptable organic bases include salts of primary, secondary and tertiary amines, including substituted amines, cyclic amines, naturally-occurring amines and the like, such as arginine, betaine, caffeine, choline, N,N'-dibenzylethylenediamine, diethylamine, 2- diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N- ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine and the like. When compounds of the present invention contain relatively basic functionalities, acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric,AVS0044US3 dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and the like, as well as the salts derived from relatively nontoxic organic acids like acetic, propionic, isobutyric, malonic, benzoic, succinic, suberic, fumaric, mandelic, phthalic, benzenesulfonic, p- tolylsulfonic, citric, tartaric, methanesulfonic, and the like. Also included are salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like (see, for example, Berge, S. M., et ah, "Pharmaceutical Salts", Journal of Pharmaceutical Science, 1977, 66, 1-19). Certain specific compounds of the present invention contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts.

[0066] The neutral forms of the compounds can be regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner. The parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents, but otherwise the salts are equivalent to the parent form of the compound for the purposes of the present invention.

[0067] In addition to salt forms, the present invention provides compounds which are in a prodrug form. As used herein the term "prodrug" refers to those compounds that readily undergo chemical changes under physiological conditions to provide the compounds of the present invention. Additionally, prodrugs can be converted to the compounds of the present invention by chemical or biochemical methods in an ex vivo environment. For example, prodrugs can be slowly converted to the compounds of the present invention when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent.

[0068] Prodrugs of the invention include compounds wherein an amino acid residue, or a polypeptide chain of two or more (e.g., two, three or four) amino acid residues, is covalently joined through an amide or ester bond to a free amino, hydroxy or carboxylic acid group of a compound of the present invention. The amino acid residues include but are not limited to the 20 naturally occurring amino acids commonly designated by three letter symbols and also includes phosphoserine, phosphothreonine, phosphotyrosine, 4-hydroxyproline, hydroxylysine, demosine, isodemosine, gamma-carboxyglutamate, hippuric acid, octahydroindole-2-carboxylic acid, statine, l,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, penicillamine, ornithine, 3-methylhistidine, norvaline, beta-alanine, gamma-aminobutyric acid, citrulline, homocysteine, homoserine, methyl-AVS0044US3 alanine, para-benzoylphenylalanine, phenylglycine, propargylglycine, sarcosine, methionine sulfone and tert-butylglycine.

[0069] Additional types of prodrugs are also encompassed. For instance, a free carboxyl group of a compound of the invention can be derivatized as an amide or alkyl ester. As another example, compounds of this invention comprising free hydroxy groups can be derivatized as prodrugs by converting the hydroxy group into a group such as, but not limited to, a phosphate ester, hemisuccinate, dimethylaminoacetate, or phosphoryloxymethyloxycarbonyl group, as outlined in Fleisher, D. et al., (1996) Improved oral drug delivery: solubility limitations overcome by the use of prodrugs Advanced Drug Delivery Reviews, 19: 115. Carbamate prodrugs of hydroxy and amino groups are also included, as are carbonate prodrugs, sulfonate esters and sulfate esters of hydroxy groups. Derivatization of hydroxy groups as (acyloxy)methyl and (acyloxy)ethyl ethers, wherein the acyl group can be an alkyl ester optionally substituted with groups including, but not limited to, ether, amine and carboxylic acid functionalities, or where the acyl group is an amino acid ester as described above, are also encompassed. Prodrugs of this type are described in J. Med. Chem., (1996), 39: 10. More specific examples include replacement of the hydrogen atom of the alcohol group with a group such as (Ci-6)alkanoyloxymethyl, l-((Ci-6)alkanoyloxy)ethyl, 1- methyl- l-((Ci-6)alkanoyloxy)ethyl, (Ci-6)alkoxycarbonyloxymethyl, N-(Ci-6)alkoxycarbonylaminomethyl, succinoyl, (Ci-6)alkanoyl, alpha- amino(Ci-4)alkanoyl, arylacyl and alpha-aminoacyl, or alpha-aminoacyl-alpha-aminoacyl, where each alpha-aminoacyl group is independently selected from the naturally occurring L- amino acids, P(0)(OH)2, -P(0)(0(Ci-6)alkyl)2or glycosyl (the radical resulting from the removal of a hydroxyl group of the hemiacetal form of a carbohydrate).

[0070] For additional examples of prodrug derivatives, see, for example, a) Design of Prodrugs, edited by H. Bundgaard, (Elsevier, 1985) and Methods in Enzymology, Vol. 42, p. 309-396, edited by K. Widder, et al. (Academic Press, 1985); b) A Textbook of Drug Design and Development, edited by Krogsgaard-Larsen and H. Bundgaard, Chapter 5 "Design and Application of Prodrugs," by H. Bundgaard p. 113-191 (1991); c) H. Bundgaard, Advanced Drug Delivery Reviews, 8: 1-38 (1992); d) H. Bundgaard, et al., Journal of Pharmaceutical Sciences, 77:285 (1988); and e) N. Kakeya, et al., Chem. Pharm. Bull., 32:692 (1984), each of which is specifically incorporated herein by reference.AVS0044US3

[0071] Additionally, the present invention provides for metabolites of compounds of the invention. As used herein, a "metabolite" refers to a product produced through metabolism in the body of a specified compound or salt thereof. Such products can result for example from the oxidation, reduction, hydrolysis, amidation, deamidation, esterification, deesterification, enzymatic cleavage, and the like, of the administered compound.

[0072] Metabolite products typically are identified by preparing a radiolabelled (e.g.,14C or3H) isotope of a compound of the invention, administering it parenterally in a detectable dose (e.g., greater than about 0.5 mg / kg) to an animal such as rat, mouse, guinea pig, monkey, or to man, allowing sufficient time for metabolism to occur (typically about 30 seconds to 30 hours) and isolating its conversion products from the urine, blood or other biological samples. These products are easily isolated since they are labeled (others are isolated by the use of antibodies capable of binding epitopes surviving in the metabolite). The metabolite structures are determined in conventional fashion, e.g., by MS, LC / MS or NMR analysis. In general, analysis of metabolites is done in the same way as conventional drug metabolism studies well known to those skilled in the art. The metabolite products, so long as they are not otherwise found in vivo, are useful in diagnostic assays for therapeutic dosing of the compounds of the invention.

[0073] The term“patient” or“subject” is used throughout the specification to describe an animal, preferably a human or a domesticated animal, to whom treatment, including prophylactic treatment, with the compositions according to the present disclosure is provided. For treatment of those infections, conditions or disease states which are specific for a specific animal such as a human patient, the term patient refers to that specific animal, including a domesticated animal such as a dog or cat or a farm animal such as a horse, cow, sheep, etc. In general, in the present disclosure, the term patient refers to a human patient unless otherwise stated or implied from the context of the use of the term.

[0074] The term“effective” is used to describe an amount of a compound, composition or component which, when used within the context of its intended use, effects an intended result. The term effective subsumes all other effective amount or effective concentration terms, which are otherwise described or used in the present application.

[0075] Compounds and Compositions

[0076] In one aspect, the description provides compounds comprising an E3 ubiquitin ligase binding moiety (“ULM”) that is a Von Hippel-Lindae E3 ubiquitin ligase (VHL) binding moietyAVS0044US3(VLM). In an exemplary embodiment, the ULM is coupled to a target protein binding moiety (PTM) via a chemical linker (L) according to the structure:(A) PTM-L-ULMwherein L is a bond or a chemical linker group, ULM is a E3 ubiquitin ligase binding moiety, and PTM is a target protein binding moiety. The number and / or relative positions of the moieties in the compounds illustrated herein is provided by way of example only. As would be understood by the skilled artisan, compounds described herein can be synthesized with any desired number and / or relative position of the respective functional moieties.

[0077] In another aspect, the present disclosure provides bifunctional or multifunctional compounds (e.g., PROTACs) useful for regulating protein activity by inducing the degradation of a target protein. In certain embodiments, the compound comprises a VLM coupled, e.g., linked covalently, directly or indirectly, to a moiety that binds a target protein (i.e., a protein targeting moiety or a“PTM”). In certain embodiments, the VLM and PTM are joined or coupled via a chemical linker (L). The VLM binds VHL, and the PTM recognizes a target protein and the interaction of the respective moieties with their targets facilitates the degradation of the target protein by placing the target protein in proximity to the ubiquitin ligase protein. An exemplary bifunctional compound can be depicted as: PTM— VLM.

[0078] In certain embodiments, the bifunctional compound further comprises a chemical linker (“L”). Lor example, the bifunctional compound can be depicted as: PTM— L— VLM, wherein the PTM is a protein / polypeptide targeting moiety, the L is a chemical linker, and the VLM is a VHL binding moiety.

[0079] In certain embodiments, the ULM (e.g., VLM) shows activity or binds to the E3 ubiquitin ligase (e.g., VHL) with an IC50 of less than about 200 mM. The IC50 can be determined according to any method known in the art, e.g., a fluorescent polarization assay.

[0080] In certain additional embodiments, the bifunctional compounds described herein demonstrate an activity with an IC50of less than about 100, 50, 10, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001 mM, or less than about 100, 50, 10, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001 pM, or less than about 100, 50, 10, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001 nM, or less than about 100, 50, 10, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001 pM.

[0081] In certain embodiments, where the compound comprises multiple ULMs, the ULMs are identical. In additional embodiments, the compound comprising a plurality of ULMs (e.g.,AVS0044US3ULM, ULM’, etc.), at least one PTM coupled to a ULM directly or via a chemical linker (L) or both. In certain additional embodiments, the compound comprising a plurality of ULMs further comprises multiple PTMs. In still additional embodiments, the PTMs are the same or, optionally, different. In still further embodiments, wherein the PTMs are different, the respective PTMs may bind the same protein target or bind specifically to a different protein target.

[0082] In certain embodiments, the compound may comprise a plurality of ULMs and / or a plurality of ULM’s. In further embodiments, the compound comprising at least two different ULMs, a plurality of ULMs, and / or a plurality of ULM’s further comprises at least one PTM coupled to a ULM or a ULM’ directly or via a chemical linker or both. In any of the embodiments described herein, a compound comprising at least two different ULMs can further comprise multiple PTMs. In still additional embodiments, the PTMs are the same or, optionally, different. In still further embodiments, wherein the PTMs are different the respective PTMs may bind the same protein target or bind specifically to a different protein target.

[0083] In additional embodiments, the description provides the compounds as described herein including their enantiomers, diastereomers, solvates and polymorphs, including pharmaceutically acceptable salt forms thereof, e.g., acid and base salt forms.

[0084] Exemplary VLMs

[0085] In certain embodiments the compounds as described herein include a means for binding an E3 ubiquitin ligase, e.g., Von Hippel-Lindau E3 ubiquitin ligase. In certain embodiments the ULM is VLM and comprises a chemical structure selected from the group ULM-a:wherein:a dashed line indicates the attachment of at least one PTM, another ULM or VLM (i.e.,VLM’), or a chemical linker moiety coupling at least one PTM, a ULM’ or a VLM’ to the other end of the linker;AVS0044US3X1, X2of Formula ULM-a are each independently selected from the group of a bond, O, NRY3, CRY3RY4, C=0, C=S, SO, and S02;RY3, RY4of Formula ULM-a are each independently selected from the group of H, linear or branched Ci-6alkyl, optionally substituted by 1 or more halo, optionally substituted Ci-6alkoxyl (e.g., optionally substituted by 0-3 Rpgroups);Rpof Formula ULM-a is 0, 1, 2, or 3 groups, each independently selected from the group H, halo, -OH, Ci-3 alkyl, C=0, alkyl, alkoxy or a combination thereof;W3of Formula ULM-a is selected from the group of an optionally substituted T, anoptionally substituted -T-N(RlaRlb)X3, optionally substituted -T-N(RlaRlb), optionally substituted -T-Aryl, an optionally substituted -T-Heteroaryl, an optionally substituted T- biheteroaryl, an optionally substituted -T-Heterocyclyl, an optionally substituted -T- biheterocyclyl, an optionally substituted -NR^T-Aryl, an optionally substituted -NR '-T- Heteroaryl or an optionally substituted -NR '-T-Hctcrocyclyl;X3of Formula ULM-a is C=0, R1, Rla, Rlb;each of R1, Rla, Rlbis independently selected from the group consisting of H, linear orbranched Ci-C6alkyl group optionally substituted by 1 or more halo or -OH groups, RY3C=0, RY3C=S, RY3SO, RY3S02, N(RY3RY4)C=0, N(RY3RY4)C=S, N(RY3RY4)SO, and N(RY3RY4)S02;T of Formula ULM-a is selected from the group of an optionally substituted alkyl, -(CH2)n- group, -(CH2)n-0-Ci-C6alkyl which is optionally substititued, linear, branched, or - (CH2)n- O-heterocyclyl which is optionally substituted, wherein each one of the methylene groups is optionally substituted with one or two substituents selected from the group of halogen, methyl, a linear or branched Ci-C6alkyl group optionally substituted by 1 or more halogen or -OH groups, an amino acid side chain optionally substituted or an optionally substituted heterocyclyl;W4of Formula ULM-a is an optionally substituted -NR 1 -T-Aryl wherein the aryl group may be optionally substituted with an optionally substituted 5-6 membered heteroaryl or an optionally substituted aryl, an optionally substituted -NR 1 -T-Heteroaryl group, wherein the heteroaryl is optionally substuted with an optionally substituted aryl or an optionally substituted heteroaryl, or an optionally substituted -NR 1 -T-Heterocyclyl, where -NR1 is covalently bonded to X2and R1is H or CH3, preferably H.AVS0044US3

[0086] In certain embodiments, Rpis modified to form a prodrug, including by an ester or ether linkage.

[0087] In any of the embodiments described herein, T is selected from the group of an optionally substituted alkyl, -(CH2)n- group, wherein each one of the methylene groups is optionally substituted with one or two substituents selected from the group of halogen, methyl, optionally substituted alkoxy, a linear or branched Ci-C6alkyl group optionally substituted by 1 or more halogen, C(O) NR'Rla, or NR'Rl aor R1and Rlaare joined to form an optionally substituted heterocyclyl, or -OH groups or an amino acid side chain optionally substituted; and n is 0 to 6, often 0, 1, 2, or 3, preferably 0 or 1.

[0088] In certain embodiments, W4of Formula ULM-a iswherein Rl4a,Ri4t>,are each independently selected from the group of H, haloalkyl (e.g., fluoroalkyl), optionally substituted alkyl, optionally substituted alkoxy, optionally substituted hydroxyl alkyl, optionally substituted alkylamine, optionally substituted heterolkyl, optionally substituted alkyl-heterocycloalkyl, optionally substituted alkoxy-heterocycloalkyl, COR%, CONR27aR27b, NHCOR26, or NHCH3COR26; and the other of Ri4aand Ri4bis H; or Ri4a,Ri4b,together with the carbon atom to which they are attached, form an optionally substituted 3 to 5 membered cycloalkyl, heterocycloalkyl, spirocycloalkyl or spiroheterocyclyl, wherein the spiroheterocyclyl is not epoxide or aziridine.

[0089] In any of the embodiments, W5of Formula ULM-a is selected from the group of an optionally substituted phenyl, an optionally substituted napthyl or an optionally substituted 5-10 membered heteroaryl,R15 of Formula ULM-a is selected from the group of H, halogen, CN, OH, N02, N Ri4aRi4b, ORi4a, CONRi4aRi4b, NRi4aCORi4b, S02NRi4aRi4b, NRi4a S02Ri4b, optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted haloalkoxy, optionallyAVS0044US3 subsituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, or optionally substituted heterocyclyl;

[0090] In additional embodiments, W4substituents for use in the present disclosure also include specifically (and without limitation to the specific compound disclosed) the W4substituents which are found in the identified compounds disclosed herein. Each of these W4substituents may be used in conjunction with any number of W3substituents which are also disclosed herein.

[0091] In certain additional embodiments, ULM-a, is optionally substituted by 0-3 Rpgroups in the pyrrolidine moiety. Each Rpis independently H, halo, -OH, Cl-3alkyl, C=0.

[0092] In any of the embodiments described herein, the W3, W4of Formula ULM-a can independently be covalently coupled to a linker which is attached one or more PTM groups. and wherein the dashed line indicates the site of attachment of at least one PTM, another ULM (ULM’) or a chemical linker moiety coupling at least one PTM or a ULM’ or both to ULM.

[0093] In certain embodiments, ULM is VHL and is represented by the structure:ULM-bwherein:W3of Formula ULM-b is selected from the group of an optionally substituted aryl, optionallysubstituted heteroaryl, or R 1 1R9and Rio of Formula ULM-b are independently hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted hydroxyalkyl, optionallyAVS0044US3 substituted heteroaryl, or haloalkyl, or R9, Rio, and the carbon atom to which they are attached form an optionally substituted cycloalkyl;R11of Formula ULM-b is selected from the group of an optionally substituted heterocyclyl, optionally substituted alkoxy, optionally substituted heteroaryl, optionally substitutedR12 of Formula ULM-b is selected from the group of H or optionally substituted alkyl;R13 of Formula ULM-b is selected from the group of H, optionally substituted alkyl,optionally substituted alkylcarbonyl, optionally substituted (cycloalkyl)alkylcarbonyl, optionally substituted aralkylcarbonyl, optionally substituted arylcarbonyl, optionally substituted (heterocyclyl)carbonyl, or optionally substituted aralkyl;Ri4a,Ri4bof Formula ULM-b, are each independently selected from the group of H, haloalkyl (e.g. fluoroalkyl), optionally substituted alkyl, optionally substitute alkoxy, aminomethyl, alkylaminomethyl, alkoxymethyl, optionally substituted hydroxyl alkyl, optionally substituted alkylamine, optionally substituted heterolkyl, optionally substituted alkyl- heterocycloalkyl, optionally substituted alkoxy-heterocycloalkyl, CONR27aR27b,CH2NHCOR26, or (CH2)N(CH3)COR26; and the other of Ri4a and Ri4b is H; or Rl4a,Ri4b, together with the carbon atom to which they are attached, form an optionally substituted 3 to 6 membered cycloalkyl, heterocycloalky, spirocycloalkyl or spiroheterocyclyl, wherein the spiroheterocyclyl is not epoxide or aziridine;W5of Formula ULM-b is selected from the group of a phenyl, napthyl, or a 5-10 membered heteroaryl,R15 of Formula ULM-b is selected from the group of H, halogen, CN, OH, NO2, NR27aR27b, OR27a, CONR27aR27b, NR27aCOR27b, S02NR27aR27b, NR 27a S02R27b, optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted haloalkoxy, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, or optionally substituted heterocyclyl;each Ri6of Formula ULM-b is independently selected from the group of halo, CN, optionally substituted alkyl, optionally substituted haloalkyl, hydroxy, or optionally substituted haloalkoxy;AVS0044US3 o of Formula ULM-b is 0, 1, 2, 3, or 4;Ris of Formula ULM-b is independently selected from the group of H, halo, optionally substituted alkoxy, cyano, optionally substituted alkyl, haloalkyl, haloalkoxy or a linker; each R26 is independently selected from H, optionally substituted alkyl or NR27aR27t>;each R27aand R27bis independently H, optionally substituted alkyl, or R27aand R27btogether with the nitrogen atom to which they are attached form a 4-6 membered heterocyclyl; andp of Formula ULM-b is 0, 1, 2, 3, or 4, and wherein the dashed line indicates the site of attachment of at least one PTM, another ULM (ULM’) or a chemical linker moiety coupling at least one PTM or a ULM’ or both to ULM.

[0094] In certain embodiments, R15 of Formulawherein Rn is H, halo optionally substituted C3-6cycloalkyl, optionally substituted Ci-6alkyl, optionally substituted Ci- ealkcnyl, and Ci-6haloalkyl; and Xa is S or O.

[0095] In certain embodiments, RI7of Formula ULM-b is selected from the group methyl, ethyl, isopropyl, and cyclopropyl.

[0096] In certain additional embodiments, R15 of Formula ULM-b is selected from the group consisting of:AVS0044US3

[0097] In certain embodiments, Rn of Formula ULM-b is selected from the group consisting of:AVS0044US3

[0098] In certain embodiments, Rl4a,Ri4bof Formula ULM-b, are each independently selected from the group of H, optionally substituted haloalkyl, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted hydroxyl alkyl, optionally substituted alkylamine, optionally substituted heterolkyl, optionally substituted alkyl-heterocycloalkyl, optionally substituted alkoxy-heterocycloalkyl, CH2OR30, CH2NHR30, CH2NCH3R30,CONR27aR27b, CH2CONR27aR27b, CH2NHCOR26, or CH2NCH3COR26; and the other of Ri4aand Ri4bis H; or Ri4a,Ri4b,together with the carbon atom to which they are attached, form an optionally substituted 3- to 6-membered cycloalkyl, heterocycloalkyl, spirocycloalkyl or spiroheterocyclyl, wherein the spiroheterocyclyl is not epoxide or aziridine, the saidspirocycloalkyl or spiroheterocycloalkyl itself being optionally substituted with an alkyl, a haloalkyl, or -COR33where R33is an alkyl or a haloalkyl,wherein R30 is selected from H, alkyl, alkynylalkyl, cycloalkyl, heterocycloalkyl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl or heteroarylalkyl further optionally substituted; R26 and R27 are as described above.

[0099] In certain embodiments, R15of Formula ULM-b is selected from H, halogen, CN,OH, NO2, NR27aR27b, OR27a, CONR27aR27b, NR27aCOR27b, S02NR27aR27b, NR27a S02R27b, optionally substituted alkyl, optionally substituted haloalkyl (e.g. optionally substituted fluoroalkyl), optionally substituted haloalkoxy, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, or optionally substituted heterocyclyl wherein optional substitution of the said aryl, heteroaryl, cycloalkyl and heterocycloalkyl includes CH2OR30, CH2NHR30, CH2NCH3R30, CONR27aR27b, CH2CONR27aR27b, CH2NHCOR26,, wherein R26, R27, R30and Ri4a are as described above.AVS0044US3

[0100] In certain embodiments, Rl4a,Ri4bof Formula ULM-b, are each independently selected from the group of H, optionally substituted haloalkyl, optionally substituted alkyl, CH2OR30, CH2NHR30, CH2NCH3R30, CONR27aR27b, CH2CONR27aR27b, CH2NHCOR26, or CH2NCH3COR26; and the other of Ri4aand Ri4bis H; or Ri4a, Ri4b, together with the carbon atom to which they are attached, form an optionally substituted 3- to 6-membered spirocycloalkyl or spiroheterocyclyl, wherein the spiroheterocyclyl is not epoxide or aziridine, the saidspirocycloalkyl or spiroheterocycloalkyl itself being optionally substituted with an alkyl, a haloalkyl, or -COR33where R33is an alkyl or a haloalkyl, wherein R30is selected from H, alkyl, alkynylalkyl, cycloalkyl, heterocycloalkyl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl or heteroarylalkyl further optionally substituted;R15of Formula ULM-b is selected from H, halogen, CN, OH, NO2, NR27aR27b, OR27a, CONR27aR27b, NR27aCOR27b, S02NR27aR27b, NR27a S02R27b, optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted haloalkoxy, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, or optionally substituted heterocyclyl wherein optional substitution of the said aryl, heteroaryl, cycloalkyl andheterocycloalkyl includes CH2OR30, CH2NHR30, CH2NCH3R30, CONR27aR27b, CH2CONR27aR27b,are as described above.

[0101] In certain embodiments, ULM has a chemical structure selected from the group of:ULM-c ULM-d ULM-e wherein:Ri of Formulas ULM-c, ULM-d, and ULM -e is H, ethyl, isopropyl, tert-butyl, sec-butyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl; optionally substituted alkyl,AVS0044US3 optionally substituted cycloalkyl, optionally substituted hydroxyalkyl, optionally substituted heteroaryl, or haloalkyl;Ri4aof Formulas ULM-c, ULM-d, and ULM-e is H, haloalkyl, optionally substituted alkyl, methyl, fluoromethyl, hydroxymethyl, ethyl, isopropyl, or cyclopropyl;R15 of Formulas ULM-c, ULM-d, and ULM-e is selected from the group consisting of H, halogen, CN, OH, N02,optionally substituted heteroaryl, optionally substituted aryl; optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted haloalkoxy, optionally substituted cycloalkyl, or optionally substituted heterocyclyl;X of Formulas ULM-c, ULM-d, and ULM-e is C, CH2, or C=0R3of Formulas ULM-c, ULM-d, and ULM-e is absent or an optionally substituted 5 or 6 membered heteroaryl; andthe dashed line indicates the site of attachment of at least one PTM, another ULM (ULM’) or a chemical linker moiety coupling at least one PTM or a ULM’ or both to ULM.

[0102] In certain embodiments, ULM comprises a group according to the chemical structure:ULM-fwherein:Ri4aof Formula ULM-f is H, haloalkyl, optionally substituted alkyl, methyl, fluoromethyl, hydroxymethyl, ethyl, isopropyl, or cyclopropyl;R9of Formula ULM-f is H;Rio of Formula ULM-f is H, ethyl, isopropyl, tert-butyl, sec -butyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl;AVS0044US3Rn of Formula ULM-f isor optionally substituted heteroaryl;p of Formula ULM-f is 0, 1, 2, 3, or 4;each Ris of Formula ULM-f is independently halo, optionally substituted alkoxy, cyano, optionally substituted alkyl, haloalkyl, haloalkoxy or a linker;R12 of Formula ULM-f is H, C=0;R of Formula ULM-f is H, optionally substituted alkyl, optionally substitutedalkylcarbonyl, optionally substituted (cycloalkyl)alkylcarbonyl, optionally substituted aralkylcarbonyl, optionally substituted arylcarbonyl, optionally substituted(heterocyclyl)carbonyl, or optionally substituted aralkyl,Ris of Formula ULM-f is selected from the group consisting of H, halogen, Cl, CN, OH, N02,optionally substituted haloalkyl, optionally substituted heteroaryl, optionally substituted aryl;AVS0044US3wherein the dashed line of Formula ULM-f indicates the site of attachment of at least one PTM, another ULM (ULM’) or a chemical linker moiety coupling at least one PTM or a ULM’ or both to ULM.

[0103] In certain embodiments, the ULM is selected from the following structures:AVS0044US3wherein n is 0 or 1.

[0104] In certain embodiments, the ULM is selected from the following structures:ULM-b4 ULM-b5 ULM-b6AVS0044US3ULM-c4 ULM-C5 ULM-c6AVS0044US3ULM-C13 ULM-C14 ULM-C15AVS0044US3ULM-d7 ULM-d8 ULM-d9 wherein, the phenyl ring in ULM-al through ULM -al5, ULM -bl through ULM-M2, ULM-cl through ULM-cl5 and ULM-dl through ULM-d9 is optionally substituted with fluorine, lower alkyl and alkoxy groups, and wherein the dashed line indicates the site of attachment of at least one PTM, another ULM (ULM’) or a chemical linker moiety coupling at least one PTM or a ULM’ or both to ULM-a.AVS0044US3

[0105] In one embodiment, the phenyl ring in ULM-al through ULM-al5, ULM-bl through ULM -b 12, ULM-cl through ULM-cl5 and ULM-dl through ULM-d9 can be functionalized as the ester to make it a part of the prodrug.

[0106] In certain embodiments, the hydroxyl group on the pyrrolidine ring of ULM-al through ULM-al 5, ULM-bl through ULM-M2, ULM-cl through ULM-cl5 and ULM-dl through ULM-d9, respectively, comprises an ester-linked prodrug moiety.

[0107] In any of the aspects or embodiments described herein, the ULM and where present, ULM’, are each independently a group according to the chemical structure:ULM-gor a pharmaceutically acceptable salt thereof, wherein:R1of ULM-g is an optionally substituted Ci-C6alkyl group, an optionally substituted - (CH2)nOH, an optionally substituted -(CH2)nSH, an optionally substituted (CH2)n-0-(Ci- Cejalkyl group, an optionally substituted (CH2)n-WCOCW-(Co-C6)alkyl group containing an epoxide moiety WCOCW where each W is independently H or a C1-C3 alkyl group, an optionally substituted -(CH2)nCOOH, an optionally substituted -(CH2)nC(0)-(Ci-C6alkyl), an optionally substituted -(CH2)nNHC(0)-R", an optionally substituted - (CH2)„C(0)- N(R")2, an optionally substituted -(CH2)„OC(0)- N(R")2, -(CH20)„H, an optionally substituted -(CH2)n0C(0)-(Ci-C6alkyl), an optionally substituted - (CH2)nC(0)-0-(Ci-C6alkyl), an optionally substituted -(CH20)nCOOH, an optionally substituted -(OCH2)nO-(Ci-C6 alkyl), an optionally substituted -(CH20)nC(0)-(Ci-C6 alkyl), an optionally substituted -(OCH2)nNHC(0)-R", an optionally substituted - (CH20)„C(0)-N(R")2, -(CH2CH20)„H, an optionally substituted -(CH2CH20)„C00H, an optionally substituted -(OCH2CH2)nO-(Ci-C6alkyl), an optionally substituted - (CH2CH20)nC(0)-(Ci-C6alkyl), an optionally substituted -(0CH2CH2)nNHC(0)-R", anAVS0044US3 optionally substituted -(CH2CH20)nC(0)-N(R'')2,an optionally substituted -S02Rs, an optionally substituted S(0)Rs, N02, CN or halogen (F, Cl, Br, I, preferably F or Cl); each R" of ULM-g is independently H or a Ci-C6alkyl group which may be optionallysubstituted with one or two hydroxyl groups or up to three halogen groups (preferably fluorine);Rs of ULM-g is a Ci-C6alkyl group, an optionally substituted aryl, heteroaryl or heterocyclyl group or a -(CH2)mN(R")2group;X and X’ of ULM-g are each independently C=0, C=S, -S(O), S(0)2, (preferably X and X’ are both C=0);R2of ULM-g is an optionally substituted -(CH2)n-(C=0)u(NR")v(S02)walkyl group, anoptionally substituted -(CH2)n-(C=0)u(NR")v(S02)wNRiNR2N group, an optionally substituted -(CH2)n-(C=0)u(NR")v(S02)w-Aryl, an optionally substituted -(CH2)n- (C=0)u(NR")v(S02)w-Heteroaryl, an optionally substituted -(CH2)n-(C=0)vNR" (SC V- Heterocyclyl, an optionally substituted -NR''-(CH2)n-C(0)u(NR'')v(S02)w-alkyl, an optionally substituted -NR''-(CH2)n-C(0)u(NR'')v(S02)w- NRINR2N, an optionally substituted -NR''-(CH2)n-C(0)u(NR'')v(S02)w-NR''C(0)RiN, an optionally substituted - NR''-(CH2)n-(C=0)u(NR'')v(S02)w-Aryl, an optionally substituted -NR"-(CH2)n- (C=0)u(NR")v(S02)w-Heteroaryl or an optionally substituted -NR''-(CH2)n-(C=0)vNR'' (S02)w-Heterocyclyl, an optionally substituted -XR2-alkyl group; an optionally substituted -XR2- Aryl group; an optionally substituted -XR2- Heteroaryl group; an optionally substituted -XR2- Heterocyclyl group;R3’of ULM-g is an optionally substituted alkyl, an optionally substituted -(CH2)n-(0)u(NR")v(S02)w-alkyl, an optionally substituted -(CH2)n-C(0)u(NR")v(S02)w-NRiNR2N, an optionally substituted -(CH2)n-C(0)u(NR'')v(S02)w-NR''C(0)RiN, an optionally substituted -(CH2)n-C(0)u(NR'')v(S02)w-C(0)(R'')2, an optionally substituted -(CH2)n- C(0)u(NR'')v(S02)w-Aryl, an optionally substituted -(CH2)„-C(0)U(NR'')V(S02)W- Heteroaryl, an optionally substituted -(CH2)n-C(0)u(NR")v(S02)w-Heterocyclyl, an optionally substituted -NR''-(CH2)n-C(0)u(NR'')v(S02)w-alkyl, an optionally substituted - NR''-(CH2)„-C(0)U(NR'')V(S02)W- NRINR2N, an optionally substituted -NR"-(CH2)„- C(0)U(NR")V(S02)W-NR"C(0)RIN, an optionally substituted -NR"-(CH2)n- C(0)u(NR'')v(S02)w-Aryl, an optionally substituted -NR''-(CH2)„-C(0)U(NR'')V(S02)W-AVS0044US3Heteroaryl, an optionally substituted -NR1-(CH2)n-C(0)u(NR'')v(S02)w-Heterocyclyl, an optionally substituted -0-(CH2)n-(C=0)u(NR")v(S02)w-alkyl, an optionally substituted - 0-(CH2)n-(C=0)u(NR")v(S02)w-NRiNR2N, an optionally substituted -0-(CH2)n- (C=0)U(NR")V(S02)W-NR''C(0)RIN, an optionally substituted -0-(CH2)n- (C=0)u(NR")v(S02)w-Aryl, an optionally substituted -0-(CH2)„-(C=0)u(NR'')v(S02)w- Heteroaryl or an optionally substituted -0-(CH2)n-(C=0)u(NR'')v(S02)w-Heterocyclyl; - (CH2)n-(V)n’-(CH2)n-(V)n’-alkyl group, an optionally substituted -(CH2)n-(V)n’-(CH2)n- (V)n’-Aryl group, an optionally substituted -(CH2)n-(V)n’-(CH2)n-(V)n’-Heteroaryl group, an optionally substituted -(CH2)n-(V)n’-(CH2)n-(V)n’-Heterocyclyl group, an optionally substituted -(CH2)n-N(Rr)(C=0)m’-(V)n’-alkyl group, an optionally substituted -(CH2)n- N(Rr)(C=0)m’-(V)n’-Aryl group, an optionally substituted -(CH2)n-N(Rr)(C=0)m’-(V)n’- Heteroaryl group, an optionally substituted -(CH2)n-N(Rr)(C=0)m’-(V)n’-Heterocyclyl group, an optionally substituted -XR3- alkyl group; an optionally substituted -XR3- Aryl group; an optionally substituted -XR3- Heteroaryl group; an optionally substituted -XR3- Heterocyclyl group;RIN and R2N of ULM-g are each independently H, Ci-C6alkyl which is optionally substituted with one or two hydroxyl groups and up to three halogen groups or an optionally substituted -(CH2)n-Aryl, -(CH2)n-Heteroaryl or -(CH2)n-Heterocyclyl group;V of ULM-g is O, S or NRi;each Rr of ULM-g is independently H or a C1-C3alkyl group;XR2and XR3of ULM-g are each independently an optionally substituted -CH2)n-, -CH2)n- CH(Xv)=CH(Xv)- (cis or trans), -CH2)n-CHºCH- , -(CH2CH20)n- or a C3-C6cycloalkyl group, where Xvis H, a halo or a C1-C3alkyl group which is optionally substituted; each m of ULM-g is independently 0, 1, 2, 3, 4, 5, 6;each m’ of ULM-g is independently 0 or 1 ;each n of ULM-g is independently 0, 1, 2, 3, 4, 5, 6;each n’ of ULM-g is independently 0 or 1;each u of ULM-g is independently 0 or 1 ;each v of ULM-g is independently 0 or 1 ;each w of ULM-g is independently 0 or 1 ; andAVS0044US3 any one or more of R1, R2, R3, X and X’ of ULM-g is optionally modified to be covalently bonded to the PTM group through a linker group when PTM is not ULM’, or when PTM is ULM’, any one or more of R1, R2, R3, X and X’ of each of ULM and ULM’ are optionally modified to be covalently bonded to each other directly or through a linker group, or a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.

[0108] In any of the aspects or embodiments described herein, the ULM and when present, ULM’, are each independently a group according to the chemical structure:ULM-hwherein:each of R1, R2and R3of ULM-h are the same as above and X is C=0, C=S, -S(O) group or a S(0)2group, more preferably a C=0 group, andany one or more of R1, R2and R3of ULM-h are optionally modified to bind a linker group to which is further covalently bonded to the PTM group when PTM is not ULM’, or when PTM is ULM’, any one or more of R1, R2, R3of each of ULM and ULM’ are optionally modified to be covalently bonded to each other directly or through a linker group, ora pharmaceutically acceptable salt, enantiomer, diastereomer, solvate or polymorph thereof.

[0109] In any of the aspects or embodiments described herein, the ULM, and when present, ULM’, are each independently according to the chemical structure:AVS0044US3ULM-iwherein:any one or more of R1, R2and R3of ULM-I are optionally modified to bind a linker group to which is further covalently bonded to the PTM group when PTM is not ULM’, or when PTM is ULM’, any one or more of R1, R2, R3of each of ULM and ULM’ are optionally modified to be covalently bonded to each other directly or through a linker group, ora pharmaceutically acceptable salt, enantiomer, diastereomer, solvate or polymorph thereof.

[0110] In further preferred aspects of the disclosure, R1of ULM-g through ULM-i is preferably a hydroxyl group or a group which may be metabolized to a hydroxyl or carboxylic group, such that the compound represents a prodrug form of an active compound. Exemplary preferred R1groups include, for example, -(CH2)nOH, (CH2)n-0-(Ci-C6)alkyl group, - (CH2)nCOOH, -(CH20)nH, an optionally substituted -(CH2)n0C(0)-(Ci-C6alkyl), or an optionally substituted -(CH2)nC(0)-0-(Ci-C6alkyl), wherein n is 0 or 1. Where R1is or contains a carboxylic acid group, a hydroxyl group or an amine group, the hydroxyl group, carboxylic acid group or amine (each of which may be optionally substituted), may be further chemically modified to provide a covalent link to a linker group to which the PTM group (including a ULM’ group) is bonded;

[0111] X and X’, where present, of ULM-g and ULM-h are preferably a C=0, C=S, - S(O) group or a S(0)2group, more preferably a C=0 group;

[0112] R2of ULM-g through ULM-i is preferably an optionally substituted -NH-T-Aryl, an optionally substituted -N(CH3)-T-Aryl, an optionally substituted -NH-T-Heteroaryl group, an optionally substituted -N(CH3)-T-Heteroaryl, an optionally substituted -NH-T-Heterocyclyl, orAVS0044US3 an optionally substituted -N(CH3)-T-Heterocyclyl preferably H and T is an optionally substituted -(CH2)n- group, wherein each one of the methylene groups may be optionally substituted with one or two substituents, preferably selected from halogen, an amino acid sidechain as otherwise described herein or a C1-C3 alkyl group, preferably one or two methyl groups, which may be optionally substituted; and n is 0 to 6, often 0, 1, 2 or 3, preferably 0 or 1. Alternatively, T may also be a -(CH20)n- group, a -(OCH2)n- group, a -(CH2CH20)n- group, a - (OCH2CH2)n- group, all of which groups are optionally substituted.

[0113] Preferred Aryl groups for R2of ULM-g through ULM-i include optionally substituted phenyl or naphthyl groups, preferably phenyl groups, wherein the phenyl or naphthyl group is connected to a PTM (including a ULM’ group) with a linker group and / or optionally substituted with a halogen (preferably F or Cl), an amine, monoalkyl- or dialkyl amine(preferably, dimethylamine), F, Cl, OH, COOH, Ci-C6alkyl, preferably CH3, CF3, OMe, OCF3, N02, or CN group (each of which may be substituted in ortho-, meta- and / or para- positions of the phenyl ring, preferably para-), an optionally substituted phenyl group (the phenyl group itself is optionally connected to a PTM group, including a ULM’, with a linker group), and / or optionally substituted with at least one of F, Cl, OH, COOH, CH3, CF3, OMe, OCF3, N02, or CN group (in ortho-, meta- and / or para- positions of the phenyl ring, preferably para-), a naphthyl group, which may be optionally substituted, an optionally substituted heteroaryl, preferably an optionally substituted isoxazole including a methylsubstituted isoxazole, an optionally substituted oxazole including a methylsubstituted oxazole, an optionally substituted thiazole including a methyl substituted thiazole, an optionally substituted isothiazole including a methyl substituted isothiazole, an optionally substituted pyrrole including a methylsubstituted pyrrole, an optionally substituted imidazole including a methylimidazole, an optionally substituted benzimidazole or methoxybenzylimidazole, an optionally substituted oximidazole ormethyloximidazole, an optionally substituted diazole group, including a methyldiazole group, an optionally substituted triazole group, including a methylsubstituted triazole group, an optionally substituted pyridine group, including a halo- (preferably, F) or methylsubstitutedpyridine group or an oxapyridine group (where the pyridine group is linked to the phenyl group by an oxygen), an optionally substituted furan, an optionally substituted benzofuran, an optionally substituted dihydrobenzofuran, an optionally substituted indole, indolizine or azaindolizine (2, 3, or 4-AVS0044US3 azaindolizine), an optionally substituted quinoline, an optionally substituted group according to the chemical structure:wherein:Scof ULM-g through ULM-i is CHRSS, NRure, or O;Rl li rof ULM-g through ULM-i is H, CN, N02, halo (preferably Cl or F), optionallysubstituted Ci-C6alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF3), optionally substituted 0(Ci-C6alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group -CºC-Rawhere Rais H or a Ci-C6alkyl group (preferably C1-C3 alkyl);Rssof ULM-g through ULM-i is H, CN, NO2, halo (preferably F or Cl), optionallysubstituted Ci-C6alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups), optionally substituted 0-(Ci-C6alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted -C(0)(Ci- C6alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups);RUREof ULM-g through ULM-i is H, a Ci-C6alkyl (preferably H or C1-C3 alkyl) or a - C(0)(Ci-C6alkyl) each of which groups is optionally substituted with one or two hydroxyl groups or up to three halogen, preferably fluorine groups, or an optionally substituted phenyl group, an optionally substituted heteroaryl, or an optionally substitutedAVS0044US3 heterocyclyl, preferably for example piperidine, morpholine, pyrrolidine,tetrahydrofuran) ;RPROof ULM-g through ULM -i is H, optionally substituted Ci-C6alkyl or an optionally substituted aryl (phenyl or napthyl), heteroaryl or heterocyclyl group selected from the group consisting of oxazole, isoxazole, thiazole, isothiazole, imidazole, diazole, oximidazole, pyrrole, pyrollidine, furan, dihydrofuran, tetrahydrofuran, thiene, dihydrothiene, tetrahydrothiene, pyridine, piperidine, piperazine, morpholine, quinoline, (each preferably substituted with a C1-C3alkyl group, preferably methyl or a halo group, preferably F or Cl), benzofuran, indole, indolizine, azaindolizine;Rprq1and Rpr°2 of ulm_§ Lliriiush lJLM' are each independently H, an optionally subsituted C1-C3 alkyl group or together form a keto group; andeach n of ULM-g through ULM-i is independently 0, 1, 2, 3, 4, 5, or 6 (preferably 0 or 1), or an optionally substituted heterocyclyl, preferably tetrahydrofuran, tetrahydrothiene, piperidine, piperazine or morpholine (each of which groups when substituted, are preferably substituted with a methyl or halo (F, Br, Cl), each of which groups may be optionally attached to a PTM group (including a ULM’ group) via a linker group.

[0114] In certain preferred aspects,through ULM-i is agroup, where RPROand n of ULM-g through ULM-i are the same as above.

[0115] Preferred heteroaryl groups for R2of ULM-g through ULM-i include an optionally substituted quinoline (which may be attached to the pharmacophore or substituted on any carbon atom within the quinoline ring), an optionally substituted indole, an optionally substituted indolizine, an optionally substituted azaindolizine, an optionally substituted benzofuran, including an optionally substituted benzofuran, an optionally substituted isoxazole,AVS0044US3 an optionally substituted thiazole, an optionally substituted isothiazole, an optionally substituted thiophene, an optionally substituted pyridine (2-, 3, or 4-pyridine), an optionally substituted imidazole, an optionally substituted pyrrole, an optionally substituted diazole, an optionally substituted triazole, a tetrazole, an optionally substituted oximidazole, or a group according to the chemical structure:wherein:Scof ULM-g through ULM-i is CHRSS, NRure, or O;RI II Tof ULM-g through ULM-i is H, CN, N02, halo (preferably Cl or F), optionallysubstituted Ci-C6alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF3), optionally substituted 0(Ci-C6alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group -CºC-Rawhere Raof ULM-g through ULM-i is H or a Ci-C6alkyl group (preferably C1-C3 alkyl);Rssof ULM-g through ULM-i is H, CN, NO2, halo (preferably F or Cl), optionallysubstituted Ci-C6alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups), optionally substituted 0-(Ci-C6alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted -C(0)(Ci- C6alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups);AVS0044US3RUREof ULM-g through ULM-i is H, a Ci-C6alkyl (preferably H or C1-C3 alkyl) or a - C(0)(Ci-C6alkyl), each of which groups is optionally substituted with one or two hydroxyl groups or up to three halogen, preferably fluorine groups, or an optionally substituted heterocyclyl, for example piperidine, morpholine, pyrrolidine,tetrahydrofuran, tetrahydrothiophene, piperidine, piperazine, each of which is optionally substituted, andYcof ULM-g through ULM-i is N or C-RYC, where RYCis H, OH, CN, N02, halo(preferably Cl or F), optionally substituted Ci-C6alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF3), optionally substituted 0(Ci-C6alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group -CºC-Rawhere Rais H or a Ci-C6alkyl group (preferably C1-C3 alkyl), each of which groups may be optionally connected to a PTM group (including a ULM’ group) via a linker group.

[0116] Preferred heterocyclylheterocyclyl groups for R2of ULM-g through ULM-i include tetrahydrofuran, tetrahydrothiene, tetrahydroquinoline, piperidine, piperazine, pyrrollidine, morpholine, oxane or thiane, each of which groups may be optionally substituted, or a group according to the chemical structure:preferably,group, wherein:RPROof ULM-g through ULM -i is H, optionally substituted Ci-C6alkyl or an optionally substituted aryl, heteroaryl or heterocyclyl group;AVS0044US3Rprq1and Rpr°2of ULM-g through ULM-i are each independently H, an optionallysubsituted C1-C3 alkyl group or together form a keto group andeach n of ULM-g through ULM-i is independently 0, 1, 2, 3, 4, 5, or 6 (often 0 or 1), each of which groups may be optionally connected to a PTM group (including a ULM’ group) via a linker group.

[0117] Preferred R2substituents of ULM-g through ULM-i also include specifically (and without limitation to the specific compound disclosed) the R2substituents which are found in the identified compounds disclosed herein (which includes the specific compounds which are disclosed in the present specification, and the figures which are attached hereto). Each of these R2substituents may be used in conjunction with any number of R3substituents which are also disclosed herein.

[0118] R3of ULM-g through ULM-i is preferably an optionally substituted -NH-T-Aryl, an optionally substituted -N(CI-C3alkyl)-T-Aryl, an optionally substituted -NH-T-Heteroaryl group, an optionally substituted -N(CI-C3alkyl)-T-Heteroaryl, an optionally substituted -NH-T- Heterocyclyl, or an optionally substituted -N(CI-C3alkyl)-T-Heterocyclyl, wherein T is an optionally substituted -(CH2)n- group, wherein each one of the methylene groups may be optionally substituted with one or two substituents, preferably selected from halogen, a C1-C3 alkyl group or the sidechain of an amino acid as otherwise described herein, preferably methyl, which may be optionally substituted; and n is 0 to 6, often 0, 1, 2, or 3 preferably 0 or 1.Alternatively, T may also be a -(CH20)n- group, a -(OCH2)n- group, a -(CH2CH20)n- group, a - (OCH2CH2)n- group, each of which groups is optionally substituted.

[0119] Preferred aryl groups for R3of ULM-g through ULM-i include optionally substituted phenyl or naphthyl groups, preferably phenyl groups, wherein the phenyl or naphthyl group is optionally connected to a PTM group (including a ULM’ group) via a linker group and / or optionally substituted with a halogen (preferably L or Cl), an amine, monoalkyl- or dialkyl amine (preferably, dimethylamine), an amido group (preferably a -(CH2)m-NRiC(0)R2group where m, Ri and R2are the same as above), a halo (often L or Cl), OH, CH3, CL3, OMe, OCL3, N02, ,CN or a S(0)2Rs group (Rs is a a Ci-C6alkyl group, an optionally substituted aryl, heteroaryl or heterocyclyl group or a -(CH2)m(R")2 group), each of which may be substituted in ortho-, meta- and / or para- positions of the phenyl ring, preferably para-), or an Aryl (preferably phenyl), Heteroaryl or Heterocyclyl. Preferably said substituent phenyl group is an optionallyAVS0044US3 substituted phenyl group (i.e., the substituent phenyl group itself is preferably substituted with at least one of F, Cl, OH, SH, COOH, CH3, CF3, OMe, OCF3, N02, CN or a linker group to which is attached a PTM group (including a ULM’ group), wherein the substitution occurs in ortho-, meta- and / or para- positions of the phenyl ring, preferably para-), a naphthyl group, which may be optionally substituted including as described above, an optionally substituted heteroaryl (preferably an optionally substituted isoxazole including a methylsubstituted isoxazole, an optionally substituted oxazole including a methylsubstituted oxazole, an optionally substituted thiazole including a methyl substituted thiazole, an optionally substituted pyrrole including a methylsubstituted pyrrole, an optionally substituted imidazole including a methylimidazole, a benzylimidazole or methoxybenzylimidazole, an oximidazole or methyloximidazole, an optionally substituted diazole group, including a methyldiazole group, an optionally substituted triazole group, including a methylsubstituted triazole group, a pyridine group, including a halo- (preferably, F) or methylsubstitutedpyridine group or an oxapyridine group (where the pyridine group is linked to the phenyl group by an oxygen) or an optionally substituted heterocyclyl (tetrahydrofuran, tetrahydrothiophene, pyrrolidine, piperidine, morpholine, piperazine, tetrahydroquinoline, oxane or thiane. Each of the aryl, heteroaryl or heterocyclyl groups may be optionally connected to a PTM group (including a ULM’ group) via a linker group.

[0120] Preferred Heteroaryl groups for R3of ULM-g through ULM-i include an optionally substituted quinoline (which may be attached to the pharmacophore or substituted on any carbon atom within the quinoline ring), an optionally substituted indole (including dihydroindole), an optionally substituted indolizine, an optionally substituted azaindolizine (2, 3 or 4-azaindolizine) an optionally substituted benzimidazole, benzodiazole, benzoxofuran, an optionally substituted imidazole, an optionally substituted isoxazole, an optionally substituted oxazole (preferably methyl substituted), an optionally substituted diazole, an optionally substituted triazole, a tetrazole, an optionally substituted benzofuran, an optionally substituted thiophene, an optionally substituted thiazole (preferably methyl and / or thiol substituted), an optionally substituted isothiazole, an optionally substituted triazole (preferably a 1,2, 3 -triazole substituted with a methyl group, a triisopropylsilyl group, an optionally substituted -(CH2)m-0- C i -C6alkyl group or an optionally substituted -(CH2)m-C(0)-0-Ci-C6alkyl group), an optionally substituted pyridine (2-, 3, or 4-pyridine) or a group according to the chemical structure:AVS0044US3wherein:Scof ULM-g through ULM-i is CHRSS, NRure, or O;Rl li rof ULM-g through ULM-i is H, CN, N02, halo (preferably Cl or F), optionallysubstituted Ci-C6alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF3), optionally substituted 0(Ci-C6alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group -CºC-Rawhere Rais H or a Ci-C6alkyl group (preferably C1-C3 alkyl);Rssof ULM-g through ULM-i is H, CN, NO2, halo (preferably F or Cl), optionallysubstituted Ci-C6alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups), optionally substituted 0-(Ci-C6alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted -C(0)(Ci- C6alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups);RUREof ULM-g through ULM-i is H, a Ci-C6alkyl (preferably H or C1-C3 alkyl) or a - C(0)(Ci-C6alkyl), each of which groups is optionally substituted with one or two hydroxyl groups or up to three halogen, preferably fluorine groups, or an optionally substituted heterocyclyl, for example piperidine, morpholine, pyrrolidine,tetrahydrofuran, tetrahydrothiophene, piperidine, piperazine, each of which is optionally substituted, andYcof ULM-g through ULM-i is N or C-RYC, where RYCis H, OH, CN, N02, halo(preferably Cl or F), optionally substituted Ci-C6alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF3), optionally substituted 0(Ci-C6AVS0044US3 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group -CºC-Rawhere Rais H or a Ci-C6alkyl group (preferably C1-C3 alkyl). Each of said heteroaryl groups may be optionally connected to a PTM group (including a ULM’ group) via a linker group.

[0121] Preferred heterocyclyl groups for R3of ULM-g through ULM-i include tetrahydroquinoline, piperidine, piperazine, pyrrollidine, morpholine, tetrahydrofuran, tetrahydrothiophene, oxane and thiane, each of which groups may be optionally substituted or a group according to the chemical structure:g p,wherein:RPROof ULM-g through ULM -i is H, optionally substituted Ci-C6alkyl or an optionally substituted aryl (phenyl or napthyl), heteroaryl or heterocyclyl group selected from the group consisting of oxazole, isoxazole, thiazole, isothiazole, imidazole, diazole, oximidazole, pyrrole, pyrollidine, furan, dihydrofuran, tetrahydrofuran, thiene, dihydrothiene, tetrahydrothiene, pyridine, piperidine, piperazine, morpholine, quinoline, (each preferably substituted with a C1-C3 alkyl group, preferably methyl or a halo group, preferably L or Cl), benzofuran, indole, indolizine, azaindolizine;Rprq1and Rpr°2of ULM-g through ULM-i are each independently H, an optionallysubsituted C1-C3 alkyl group or together form a keto group, andeach n of ULM-g through ULM-i is 0, 1, 2, 3, 4, 5, or 6 (preferably 0 or 1), wherein each of said heterocyclyl groups may be optionally connected to a PTM group (including a ULM’ group) via a linker group.

[0122] Preferred R3substituents of ULM-g through ULM-i also include specifically (and without limitation to the specific compound disclosed) the R3substituents which are found in the identified compounds disclosed herein (which includes the specific compounds which areAVS0044US3 disclosed in the present specification, and the figures which are attached hereto). Each of these R3substituents may be used in conjunction with any number of R2substituents, which are also disclosed herein.

[0123] In certain alternative preferred embodiments, R2of ULM-g through ULM-i is an optionally substituted -NRI-Xr2-alkyl group, -NRI-Xr2-Aryl group; an optionally substituted - NRi- XR2-HET, an optionally substituted -NRI-Xr2-Aryl-HET or an optionally substituted - NRi- XR2-HET- Aryl,wherein:Ri of ULM-g through ULM-i is H or a C1-C3alkyl group (preferably H);XR2’of ULM-g through ULM-i is an optionally substituted -CH2)n- , -CH2)n-CH(Xv)=CH(Xv)- (cis or trans), -(CH2)n-CHºCH- , -(CH2CH20)n- or a C3-C6cycloalkyl group; andXvof ULM-g through ULM-i is H, a halo or a C1-C3alkyl group which is optionallysubstituted with one or two hydroxyl groups or up to three halogen groups;Alkyl of ULM-g through ULM-i is an optionally substituted CI-C10 alkyl (preferably a Ci-C6alkyl) group (in certain preferred embodiments, the alkyl group is end-capped with a halo group, often a Cl or Br);Aryl of ULM-g through ULM-i is an optionally substituted phenyl or naphthyl group(preferably, a phenyl group); andHET of ULM-g through ULM-i is an optionally substituted oxazole, isoxazole, thiazole, isothiazole, imidazole, diazole, oximidazole, pyrrole, pyrollidine, furan, dihydrofuran, tetrahydrofuran, thiene, dihydrothiene, tetrahydrothiene, pyridine, piperidine, piperazine, morpholine, benzofuran, indole, indolizine, azaindolizine, quinoline (when substituted, each preferably substituted with a C1-C3alkyl group, preferably methyl or a halo group, preferably L or Cl) or a group according to the chemical structure:AVS0044US3Scof ULM-g through ULM-i is CHRSS, NRure, or O;Rl li rof ULM-g through ULM-i is H, CN, N02, halo (preferably Cl or F), optionallysubstituted Ci-C6alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF3), optionally substituted 0(Ci-C6alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group -CºC-Rawhere Rais H or a Ci-C6alkyl group (preferably C1-C3 alkyl);Rssof ULM-g through ULM-i is H, CN, NO2, halo (preferably F or Cl), optionallysubstituted Ci-C6alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups), optionally substituted 0-(Ci-C6alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted -C(0)(Ci- C6alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups);RUREof ULM-g through ULM-i is H, a Ci-C6alkyl (preferably H or C1-C3 alkyl) or a - C(0)(Ci-C6alkyl), each of which groups is optionally substituted with one or two hydroxyl groups or up to three halogen, preferably fluorine groups, or an optionally substituted heterocyclyl, for example piperidine, morpholine, pyrrolidine,tetrahydrofuran, tetrahydrothiophene, piperidine, piperazine, each of which is optionally substituted;AVS0044US3Ycof ULM-g through ULM-i is N or C-RYC, where RYCis H, OH, CN, N02, halo(preferably Cl or F), optionally substituted Ci-C6alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF3), optionally substituted 0(Ci-C6alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group -CºC-Rawhere Rais H or a Ci-C6alkyl group (preferably C1-C3alkyl);RPROof ULM-g through ULM -i is H, optionally substituted Ci-C6alkyl or an optionally substituted aryl (phenyl or napthyl), heteroaryl or heterocyclyl group selected from the group consisting of oxazole, isoxazole, thiazole, isothiazole, imidazole, diazole, oximidazole, pyrrole, pyrollidine, furan, dihydrofuran, tetrahydrofuran, thiene, dihydrothiene, tetrahydrothiene, pyridine, piperidine, piperazine, morpholine, quinoline, (each preferably substituted with a C1-C3alkyl group, preferably methyl or a halo group, preferably F or Cl), benzofuran, indole, indolizine, azaindolizine;Rprq1and Rpr°2of ULM-g through ULM-i are each independently H, an optionallysubsituted C1-C3alkyl group or together form a keto group, andeach n of ULM-g through ULM-i is independently 0, 1, 2, 3, 4, 5, or 6 (preferably 0 or 1).

[0124] Each of said groups may be optionally connected to a PTM group (including a ULM’ group) via a linker group.

[0125] In certain alternative preferred embodiments of the present disclosure, R3of ULM-g through ULM-i is an optionally substituted -(CH2)n-(V)n’-(CH2)n-(V)n’-RS3group, an optionally substituted-(CH2)n-N(Rr)(C=0)m-(V)n-RS3group, an optionally substituted -XR3- alkyl group, an optionally substituted -XR3-Aryl group; an optionally substituted -XR3-HET group, an optionally substituted -XR3-Aryl-HET group or an optionally substituted -XR3-HET- Aryl group,wherein:RS3is an optionally substituted alkyl group (C1-C10, preferably Ci-C6alkyl), an optionally substituted Aryl group or a HET group;Rr is H or a C1-C3 alkyl group (preferably H);V is O, S or NRr;XR3’is -(CH2)n- , -(CH2CH20)„-, -CH2)n-CH(Xv)=CH(Xv)- (cis or trans), -CH2)n-CHºCH- , or a C3-C6cycloalkyl group, all optionally substituted;AVS0044US3Xvis H, a halo or a C1-C3alkyl group which is optionally substituted with one or twohydroxyl groups or up to three halogen groups;Alkyl is an optionally substituted C1-C10alkyl (preferably a Ci-C6alkyl) group (in certain preferred embodiments, the alkyl group is end-capped with a halo group, often a Cl or Br);Aryl is an optionally substituted phenyl or napthyl group (preferably, a phenyl group); andHET is an optionally substituted oxazole, isoxazole, thiazole, isothiazole, imidazole, diazole, oximidazole, pyrrole, pyrollidine, furan, dihydrofuran, tetrahydrofuran, thiene, dihydrothiene, tetrahydrothiene, pyridine, piperidine, piperazine, morpholine, benzofuran, indole, indolizine, azaindolizine, quinoline (when substituted, each preferably substituted with a C1-C3alkyl group, preferably methyl or a halo group, preferably F or Cl), or a group according to the chemical structure:Scof ULM-g through ULM-i is CHRSS, NRure, or O;RI II Tof ULM-g through ULM-i is H, CN, N02, halo (preferably Cl or F), optionallysubstituted Ci-C6alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF3), optionally substituted 0(Ci-C6alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group -CºC-Rawhere Rais H or a Ci-C6alkyl group (preferably C1-C3alkyl);AVS0044US3Rssof ULM-g through ULM-i is H, CN, N02, halo (preferably F or Cl), optionallysubstituted Ci-C6alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups), optionally substituted 0-(Ci-C6alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted -C(0)(Ci- C6alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups);RUREof ULM-g through ULM-i is H, a Ci-C6alkyl (preferably H or C1-C3 alkyl) or a - C(0)(Co-C6alkyl), each of which groups is optionally substituted with one or two hydroxyl groups or up to three halogen, preferably fluorine groups, or an optionally substituted heterocyclyl, for example piperidine, morpholine, pyrrolidine,tetrahydrofuran, tetrahydrothiophene, piperidine, piperazine, each of which is optionally substituted;Ycof ULM-g through ULM-i is N or C-RYC, where RYCis H, OH, CN, N02, halo(preferably Cl or F), optionally substituted Ci-C6alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF3), optionally substituted 0(Ci-C6alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group -CºC-Rawhere Rais H or a Ci-C6alkyl group (preferably C1-C3alkyl);RPROof ULM-g through ULM -i is H, optionally substituted Ci-C6alkyl or an optionally substituted aryl (phenyl or napthyl), heteroaryl or heterocyclyl group selected from the group consisting of oxazole, isoxazole, thiazole, isothiazole, imidazole, diazole, oximidazole, pyrrole, pyrollidine, furan, dihydrofuran, tetrahydrofuran, thiene, dihydrothiene, tetrahydrothiene, pyridine, piperidine, piperazine, morpholine, quinoline, (each preferably substituted with a C1-C3alkyl group, preferably methyl or a halo group, preferably F or Cl), benzofuran, indole, indolizine, azaindolizine;Rprq1and Rpr°2of ULM-g through ULM-i are each independently H, an optionallysubsituted C1-C3alkyl group or together form a keto group;each n of ULM-g through ULM-i is independently 0, 1, 2, 3, 4, 5, or 6 (preferably 0 or 1); each m’ of ULM-g through ULM-i is 0 or 1 ; andeach n’ of ULM-g through ULM-i is 0 or 1;AVS0044US3 wherein each of said compounds, preferably on the alkyl, Aryl or Het groups, is optionally connected to a PTM group (including a ULM’ group) via a linker.

[0126] In alternative embodiments, R3’ of ULM-g through ULM-i is -(CH2)n-Aryl, -(CH2CH20)„-Aryl, -(CH2)„-HET or -(CH2CH20)„-HET,wherein:said Aryl of ULM-g through ULM-i is phenyl which is optionally substituted with one or two substitutents, wherein said substituent(s) is preferably selected from -(CH2)nOH, Ci-C6alkyl which itself is further optionally substituted with CN, halo (up to three halo groups), OH, -(CH2)nO(Ci-C6)alkyl, amine, mono- or di-(Ci-C6alkyl) amine wherein the alkyl group on the amine is optionally substituted with 1 or 2 hydroxyl groups or up to three halo (preferably F, Cl) groups, orsaid Aryl group of ULM-g through ULM-i is substituted with -(CH2)nOH, -(CH2)n-0-(Ci- C6)alkyl, -(CH2)„-0-(CH2)„-(Ci-C6)alkyl, -(CH2)„-C(O)(C0-C6) alkyl, -(CH2)„-C(0)0(Co- C6)alkyl, -(CH2)n-OC(0)(Co-C6)alkyl, amine, mono- or di-(Ci-C6alkyl) amine wherein the alkyl group on the amine is optionally substituted with 1 or 2 hydroxyl groups or up to three halo (preferably F, Cl) groups, CN, N02, an optionally substituted -(CH2)n-(V)m- CH2)n-(V)m’-(Ci-C6)alkyl group, a -(V)m’-(CH2CH20)n-RPEGgroup where V is O, S or NRr, Rr is H or a C1-C3 alkyl group (preferably H) and RPEGis H or a Ci-C6alkyl group which is optionally substituted (including being optionally substituted with a carboxyl group), orsaid Aryl group of ULM-g through ULM-i is optionally substituted with a heterocyclyl, including a heteroaryl, selected from the group consisting of oxazole, isoxazole, thiazole, isothiazole, imidazole, diazole, oximidazole, pyrrole, pyrollidine, furan, dihydrofuran, tetrahydrofuran, thiene, dihydrothiene, tetrahydrothiene, pyridine, piperidine, piperazine, morpholine, quinoline, benzofuran, indole, indolizine, azaindolizine, (when substituted each preferably substituted with a C1-C3 alkyl group, preferably methyl or a halo group, preferably F or Cl), or a group according to the chemical structure:AVS0044US3Scof ULM-g through ULM-i is CHRSS, NRure, or O;Rl li rof ULM-g through ULM-i is H, CN, N02, halo (preferably Cl or F), optionallysubstituted Ci-C6alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF3), optionally substituted 0(Ci-C6alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group -CºC-Rawhere Rais H or a Ci-C6alkyl group (preferably C1-C3 alkyl);Rssof ULM-g through ULM-i is H, CN, NO2, halo (preferably F or Cl), optionallysubstituted Ci-C6alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups), optionally substituted 0-(Ci-C6alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted -C(0)(Ci- C6alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups);RUREof ULM-g through ULM-i is H, a Ci-C6alkyl (preferably H or C1-C3 alkyl) or a - C(0)(Co-C6alkyl), each of which groups is optionally substituted with one or two hydroxyl groups or up to three halogen, preferably fluorine groups, or an optionally substituted heterocyclyl, for example piperidine, morpholine, pyrrolidine,tetrahydrofuran, tetrahydrothiophene, piperidine, piperazine, each of which is optionally substituted;Ycof ULM-g through ULM-i is N or C-RYC, where RYCis H, OH, CN, N02, halo(preferably Cl or F), optionally substituted Ci-C6alkyl (preferably substituted with one orAVS0044US3 two hydroxyl groups or up to three halo groups (e.g. CF3), optionally substituted 0(Ci-C6alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group -CºC-Rawhere Rais H or a Ci-C6alkyl group (preferably C1-C3alkyl);RPROof ULM-g through ULM -i is H, optionally substituted Ci-C6alkyl or an optionally substituted aryl (phenyl or napthyl), heteroaryl or heterocyclyl group selected from the group consisting of oxazole, isoxazole, thiazole, isothiazole, imidazole, diazole, oximidazole, pyrrole, pyrollidine, furan, dihydrofuran, tetrahydrofuran, thiene, dihydrothiene, tetrahydrothiene, pyridine, piperidine, piperazine, morpholine, quinoline, (each preferably substituted with a C1-C3alkyl group, preferably methyl or a halo group, preferably F or Cl), benzofuran, indole, indolizine, azaindolizine;Rprq1and Rpr°2of ULM-g through ULM-i are each independently H, an optionallysubsituted C1-C3alkyl group or together form a keto group;HET of ULM-g through ULM-i is preferably oxazole, isoxazole, thiazole, isothiazole,imidazole, diazole, oximidazole, pyrrole, pyrollidine, furan, dihydrofuran,tetrahydrofuran, thiene, dihydrothiene, tetrahydrothiene, pyridine, piperidine, piperazine, morpholine, quinoline, (each preferably substituted with a C1-C3alkyl group, preferably methyl or a halo group, preferably F or Cl), benzofuran, indole, indolizine, azaindolizine, or a group according to the chemical structure:Scof ULM-g through ULM-i is CHRSS, NRure, or O;AVS0044US3RI II Tof ULM-g through ULM-i is H, CN, N02, halo (preferably Cl or F), optionallysubstituted Ci-C6alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF3), optionally substituted 0(Ci-C6alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group -CºC-Rawhere Rais H or a Ci-C6alkyl group (preferably C1-C3 alkyl);Rssof ULM-g through ULM-i is H, CN, NO2, halo (preferably F or Cl), optionallysubstituted Ci-C6alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups), optionally substituted 0-(Ci-C6alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted -C(0)(Ci- C6alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups);RUREof ULM-g through ULM-i is H, a Ci-C6alkyl (preferably H or C1-C3 alkyl) or a - C(0)(Co-C6alkyl), each of which groups is optionally substituted with one or two hydroxyl groups or up to three halogen, preferably fluorine groups, or an optionally substituted heterocyclyl, for example piperidine, morpholine, pyrrolidine,tetrahydrofuran, tetrahydrothiophene, piperidine, piperazine, each of which is optionally substituted;Ycof ULM-g through ULM-i is N or C-RYC, where RYCis H, OH, CN, N02, halo(preferably Cl or F), optionally substituted Ci-C6alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF3), optionally substituted 0(Ci-C6alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group -CºC-Rawhere Rais H or a Ci-C6alkyl group (preferably C1-C3alkyl);RPROof ULM-g through ULM -i is H, optionally substituted Ci-C6alkyl or an optionally substituted aryl, heteroaryl or heterocyclyl group;Rprq1and Rpr°2of ULM-g through ULM-i are each independently H, an optionallysubsituted C1-C3alkyl group or together form a keto group;each m’ of ULM-g through ULM-i is independently 0 or 1 ; andeach n of ULM-g through ULM-i is independently 0, 1, 2, 3, 4, 5, or 6 (preferably 0 or 1), wherein each of said compounds, preferably on said Aryl or HET groups, is optionallyconnected to a PTM group (including a ULM’group) via a linker group.AVS0044US3

[0127] In still additional embodiments, preferred compounds include those according to the chemical structure:ULM-iwherein:R1of ULM-i is OH or a group which is metabolized in a patient or subject to OH;R2’of ULM-i is a -NH-CH2-Aryl-HET (preferably, a phenyl linked directly to a methyl substituted thiazole);R3’of ULM-i is a -CHRCR3’-NH-C(0)-R3p1group or a -CHRCR3’-R3p2group;Rcr3’of ULM-i is a C1-C4 alkyl group, preferably methyl, isopropyl or tert-butyl;R3P1of ULM-i is C1-C3 alkyl (preferably methyl), an optionally substituted oxetane group (preferably methyl substituted, a -(CH2)nOCH3 group where n is 1 or 2 (preferably 2), orCH3CH2Oagroup (the ethyl ether group is preferably meta-substituted on the phenyl moiety), a morpholino grop (linked to the carbonyl at the 2- or 3-position;group;Aryl of ULM-i is phenyl;HET of ULM-i is an optionally substituted thiazole or isothiazole; andR1®1of ULM-i is H or a halo group (preferably H);or a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof, wherein each of said compounds is optionally connected to a PTM group (including a ULM’ group) via a linker group.AVS0044US3

[0128] In certain aspects, bifunctional compounds comprising a ubiquitin E3 ligase binding moiety (ULM), wherein ULM is a group according to the chemical structure:ULM-jwherein:each Rs and R6of ULM-j is independently OH, SH, or optionally substituted alkyl or R5, R6, and the carbon atom to which they are attached form a carbonyl;R7of ULM-j is H or optionally substituted alkyl;E of ULM-j is a bond, C=0, or C=S;G of ULM-j is a bond, optionally substituted alkyl, -COOH or C=J;J of ULM-j is O or N-R8;Rs of ULM-j is H, CN, optionally substituted alkyl or optionally substituted alkoxy;M of ULM-j is optionally substituted aryl, optionally substituted heteroaryl, optionallysubstituted heterocyclyl or Rneach Rg and Rio of ULM-j is independently H; optionally substituted alkyl, optionallysubstituted cycloalkyl, optionally substituted hydroxyalkyl, optionally substituted thioalkyl, a disulphide linked ULM, optionally substituted heteroaryl, or haloalkyl; or R9, Rio, and the carbon atom to which they are attached form an optionally substituted cycloalkyl;Rn of ULM-j is optionally substituted heterocyclyl, optionally substituted alkoxy, optionallysubstituted heteroaryl, optionally substituted aryl, orR12 of ULM-j is H or optionally substituted alkyl;AVS0044US3R of ULM-j is H, optionally substituted alkyl, optionally substituted alkylcarbonyl,optionally substituted (cycloalkyl)alkylcarbonyl, optionally substituted aralkylcarbonyl, optionally substituted arylcarbonyl, optionally substituted (heterocyclyl)carbonyl, or optionally substituted aralkyl; optionally substituted (oxoalkyl)carbamate,each R14 of ULM-j is independently H, haloalkyl, optionally substituted cycloalkyl,optionally substituted alkyl, an azetidine, optionally substituted alkoxy, or optionally substituted heterocyclyl;R15 of ULM-j is H, CN, optionally substituted heteroaryl, haloalkyl, optionally substituted aryl, optionally substituted alkoxy, or optionally substituted heterocyclyl;each Ri6of ULM-j is independently halo, optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted CN, or optionally substituted haloalkoxy;each R25 of ULM-j is independently H or optionally substituted alkyl; or both R25 groups can be taken together to form an oxo or optionally substituted cycloalkyl group;R23 of ULM-j is H or OH;Zi, Z2, Z3, and Z4of ULM-j are independently C or N; ando of ULM-j is 0, 1, 2, 3, or 4, or a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.

[0129] In certain embodiments, wherein G of ULM-j is C=J, J is O, R7is H, each R14 is H, and o is 0.

[0130] In certain embodiments, wherein G of ULM-j is C=J, J is O, R7is H, each R14isH, R15is optionally substituted heteroaryl, and o is 0. In other instances, E is C=0 and M is

[0131] In certain embodiments, wherein E of ULM-j is C=0, R11is optionally substitutedheterocyclylAVS0044US3

[0132] In certain embodiments, wherein E of ULM-j is C=0, M is, and Rn is, each Ris isindependently H, halo, optionally substituted alkoxy, cyano, optionally substituted alkyl, haloalkyl, or haloalkoxy; and p is 0, 1, 2, 3, or 4.

[0133] In certain embodiments, each Rl4is independently substituted with at least one of H, hydroxyl, halo, amine, amide, alkoxy, alkyl, haloalkyl, or heterocyclic.

[0134] In certain embodiments, Ris of ULM-j is a group according tindependently H, halo, optionally substituted alkoxy, cyano, aminoalkyl, amidoalkyl, optionally substituted alkyl, haloalkyl, or haloalkoxy; and p is 0, 1, 2, 3, or 4.

[0135] In certain embodiments, ULM and where present, ULM’, are each independently a group according to the chemical structure:ULM-kwherein:G of ULM-k is C=J, J is O;AVS0044US3R7of ULM-k is H;each R14 of ULM-k is independently H, an amide, an alkyl, e.g., methyl, optionallysubstituted with one or more C1-C6 alkyl groups or C(0)NR’R”;R’and R” are each independently H, optionally substituted alkyl, or cycloalkyl;o of ULM-k is 0;R15 of ULM-k is defined as above for ULM-j;.Ri6of ULM-k is defined is as above for ULM-j; andR17 of ULM-k is H, halo, optionally substituted cycloalkyl, optionally substituted alkyl, optionally substituted alkenyl, and haloalkyl.

[0136] In other instances, RI7of ULM-k is alkyl (e.g., methyl) or cycloalkyl (e.g., cyclopropyl).

[0137] In other embodiments, ULM and where present, ULM’, are each independently a group according to the chemical structure:wherein:G of ULM-k is C=J, J is O;R7of ULM-k is H;each RHof ULM-k is H;o of ULM-k is 0; andR15 of ULM-k is selected from the group consisting of optionally substituted:AVS0044US3,

[0138] In other embodiments, ULM and where present, ULM’, are each independently a group according to the chemical structure:ULM-kwherein:E of ULM-k is C=0;R11 of ULM-k is selected from the group consisting of optionally substituted:AVS0044US3

[0139] In still other embodiments, a compound of the chemical structure,ULM-kwherein:E of ULM-k is C=0;AVS0044US3q of ULM-k is 1 or 2;R2Oof ULM-k is H, optionally substituted alkyl, optionally substituted cycloalkyl, optionallysubstituted aryl,R21 of ULM-k is H or optionally substituted alkyl; andR22of ULM-k is H, optionally substituted alkyl, optionally substituted alkoxy, or haloalkyl.

[0140] In any embodiment described herein, Rn of ULM-j or ULM-k is selected from the group consisting of:AVS0044US3AVS0044US3

[0141] In certain embodiments, Rn of ULM-j or ULM-k is selected from the group consisting of:AVS0044US3

[0142] In certain embodiments, ULM (or when present ULM’) is a group according to the chemical structure:AVS0044US3ULM-lwherein:X of ULM-l is O or S;Y of ULM-l is H, methyl or ethyl;R17 of ULM-l is H, methyl, ethyl, hydoxymethyl or cyclopropyl;M of ULM-l is is optionally substituted aryl, optionally substituted heteroaryl, or R11 R9 of ULM-l is H;Rio of ULM-l is H, optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted heteroaryl, optionally substituted aryl, optionally substituted hydroxyalkyl, optionally substituted thioalkyl or cycloalkyl;Rll of ULM-l is optionally substituted heteroaromatic, optionally substituted heterocyclyl,, R-12|— Npoptionally substituted aryl or ^13 ;R12 of ULM-l is H or optionally substituted alkyl; andR13 of ULM-l is H, optionally substituted alkyl, optionally substituted alkylcarbonyl,optionally substituted (cycloalkyl)alkylcarbonyl, optionally substituted aralkylcarbonyl, optionally substituted arylcarbonyl, optionally substituted (heterocyclyl)carbonyl, or optionally substituted aralkyl; optionally substituted (oxoalkyl)carbamate.

[0143] In some embodiments, ULM and where present, ULM’, are each independently a group according to the chemical structure:AVS0044US3ULM-mwherein:Y of ULM-m is H, methyol or ethylR9of ULM-m is H;Rio is isopropyl, tert-butyl, sec-butyl, cyclopentyl, or cyclohexyl;Rn of ULM-m is optionally substituted amide, optionally substituted isoindolinone, optionally substituted isooxazole, optionally substituted heterocyclyls.

[0144] In other preferred embodiments of the disclosure, ULM and where present, ULM’, are each independently a group according to the chemical structure:ULM-nwherein:R17 of ULM-n is methyl, ethyl, or cyclopropyl; andR9, RIO, and Rn of ULM-n are as defined above. In other instances, R9is H; andAVS0044US3Rio of ULM-n is H, alkyl, or or cycloalkyl (preferably, isopropyl, tert-butyl, sec -butyl,cyclopentyl, or cyclohexyl).

[0145] In other preferred embodiments of the disclosure, ULM and where present, ULM’, are each independently a group according to the chemical structure:ULM-o ULM-por a pharmaceutically acceptable salt thereof, wherein:Ri is H, optionally substituted alkyl or optionally substituted cycloalkyl;R3is an optionally substituted 5-6 membered heteroaryl;W5is optionally substituted phenyl, optionally substituted napthyl or optionally substituted pyridinyl;one of Ri4aand Ri4bis H, optionally substituted alkyl, optionally substituted haloalkyl (e.g., fluoroalkyl), optionally substituted alkoxy, optionally substituted hydroxyl alkyl, optionally substituted alkylamine, optionally substituted heterolkyl, optionally substituted alkyl-heterocycloalkyl, optionally substituted alkoxy-heterocycloalkyl, COR26, CONR27aR27b, NHCOR26, or NHCH3COR26; and the other of R i4a and Ri4b is H; or Ri4a, Ri4b,together with the carbon atom to which they are attached, form an optionally substituted 3 to 6 membered cycloalkyl, heterocycloalkyl, spirocycloalkyl or spiroheterocyclyl, wherein the spiroheterocyclyl is not epoxide or aziridine;R15 is CN, optionally substituted fluoroalkyl,AVS0044US3optionally substitutedwherein R28ais halo, optionally substituted alkyl or fluoroalkyl, oreach Ri6is independently selected from halo, CN, optionally substituted alkyl, optionally substituted haloalkyl, hydroxy, or haloalkoxy;each R26is independently H, optionally substituted alkyl or NR27aR27b;each R27aand R27bis independently H, optionally substituted alkyl, optionally substituted cycloalkyl, or R27aand R27btogether with the nitrogen atom to which they are attached form a 4-6 membered heterocyclyl;each R28is independently H, halogen, CN, optionally substituted aminoalkyl, optionally substituted amidoalkyl, optionally substituted haloalkyl, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted heteroalkyl, optionally substituted alkylamine, optionally substituted hydroxyalkyl, amine, optionally substituted alkynyl, or optionally substituted cycloalkyl;o is 0, 1 or 2; andp is 0, 1, 2, 3, or 4.

[0146] In any of the aspects or embodiments described herein, the ULM is of the formula:AVS0044US3 wherein:each of X4, X5, and X6is selected from CH and N, wherein no more than 2 are N;R1is Cl -6 alkyl;R3is the same as defined for ULM-o and ULM-pone of R14aand R14bis H, optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted alkoxy, optionally substituted hydroxyl alkyl, optionally substituted alkylamine, optionally substituted heterolkyl, optionally substituted alkyl- heterocycloalkyl, optionally substituted alkoxy-heterocycloalkyl, COR26, CONR27aR27b, NHCOR26, or NHCH3COR26; and the other of R14aand R14bis H; or R14aand R14b, together with the carbon atom to which they are attached, form an optionally substituted 3 to 5 membered cycloalkyl, heterocycloalkyl, spirocycloalkyl or spiroheterocyclyl, wherein the spiroheterocyclyl is not epoxide or aziridine;each R27aand R27bis independently H Ci-6alkyl or cyclolkyl;q is 1, 2, 3 or 4;R15is optionally substitutedRr¾ NRr-or CN;R28is H, methyl, CH2N(Me)2, CH2OH, CH20(Ci-4alkyl), CH2NHC(0)Ci-4alkyl, NH2,R28cis H, methyl, fluoro, or chloro; andR16is H, Ci-4alkyl, fluoro, chloro, CN, or Ci-4alkoxy.

[0147] In any aspect or embodiment described herein, R14aand R14bare selected from: H, Ci- 4 alkyl, Ci-4cycloalkyl, Ci-4haloalkyl, Ci-4hydroxyalkyl, CM alkyloxyalkyl, Ci-4alkyl-NR27aR27band CONR27aR27b.

[0148] In any aspect or embodiment described herein, at least one of R14aand R14bis H (e.g., both R14aand R14bare H).

[0149] In any aspect or embodiment described herein, at least one of R14aand R14bis optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted alkoxy, optionally substituted hydroxyl alkyl, optionally substituted alkylamine, optionally substituted heterolkyl, optionally substituted alkyl-heterocycloalkyl, optionally substituted alkoxy-heterocycloalkyl, COR26, CONR27aR27b, NHCOR26, or NHCH3COR26. Alternatively, in any aspect or embodimentAVS0044US3 described herein, one of R14aand R14bis optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted alkoxy, optionally substituted hydroxyl alkyl, optionally substituted alkylamine, optionally substituted heterolkyl, optionally substituted alkyl- heterocycloalkyl, optionally substituted alkoxy-heterocycloalkyl, COR26, CONR27aR27b, NHCOR26, or NHCH3COR26; and the other of R14aand R14bis H.

[0150] In any aspect or embodiment described herein, R14aand R14btogether with the carbon atom to which they are attached formwherein R23is selected from H, Ci-4alkyl, - C(0)Ci-4alkyl.

[0151] In other preferred embodiments of the disclosure, ULM and where present, ULM’, are each independently a group according to the chemical structure:ULM-q ULM-ror a pharmaceutically acceptable salt thereof, wherein:X is CH or N; andRi, R3, Ri4a, Ri4b, and R15 of ULM-q and ULM-r are the same as defined for ULM-o and ULM-P-

[0152] In any of the aspects or embodiments described herein, the ULM (or when present, ULM’) as described herein may be a pharmaceutically acceptable salt, enantiomer, diastereomer, solvate or polymorph thereof. In addition, in any of the aspects or embodiments described herein, the ULM (or when present, ULM’) as described herein may be coupled to a PTM directly via a bond or by a chemical linker.

[0153] In certain aspects of the disclosure, the ULM moiety is selected from the group consisting of:AVS0044US3AVS0044US3AVS0044US3AVS0044US3AVS0044US3AVS0044US3AVS0044US3AVS0044US3AVS0044US3AVS0044US3AVS0044US3AVS0044US3AVS0044US3AVS0044US3AVS0044US3AVS0044US3AVS0044US3AVS0044US3AVS0044US3AVS0044US3AVS0044US3AVS0044US3AVS0044US3AVS0044US3wherein the VLM may be connected to a PTM via a linker, as described herein, at anyappropriate location, including, e.g., an aryl, heteroary, phenyl, or phenyl of an indole group, optionally via any appropriate functional group, such as an amine, ester, ether, alkyl, or alkoxy.Exemplary Linkers

[0154] In certain embodiments, the compounds as described herein include a means for chemically coupling the PTM to the ULM, e.g., one or more PTMs chemically linked or coupled to one or more ULMs (e.g., at least one of VLM) via a chemical linker (L). In certain embodiments, the linker group L is a group comprising one or more covalently connected structural units (e.g., - ALi...(AL)q- or— (AL)q-), wherein ALI is a group coupled to PTM, and (AL)qis a group coupled toULM.

[0155] In any aspect or embodiment described herein, the linker (L) to ULM (e.g., VLM, ILM, CLM, or MLM) connection or coupling is a stable L-ULM connection. For example, in any aspect or embodiment described herein, when a linker (L) and a ULM is connected via a heteroatom, any subsequent heteroatom, if present, is separated by at least one single carbon atom (e.g., -CH2-), such as with an acetal or aminal group. By way of further example, in any aspect or embodiment described herein, when a linker (L) and a ULM is connected via a heteroatom, the heteroatom is not part of a ester.AVS0044US3

[0156] In any aspect or embodiment described herein, the linker group L is a bond or a chemical linker group represented by the formula -(AL)q-, wherein A is a chemical moiety and q is an integer from 1-100, and wherein L is covalently bound to the PTM and the ULM, and provides for sufficient binding of the PTM to the protein target and the ULM to an E3 ubiquitin ligase to result in target protein ubiquitination.

[0157] In any aspect or embodiment described herein, the linker group L is -(AL)q-, wherein:(AL)qis a group which is connected to at least one of a ULM (such as a VLM), PTM moiety, or a combination thereof;q of the linker is an integer greater than or equal to 1 ;each ALis independently selected from the group consisting of, a bond, CRL1RL2, O, S, SO, S02, NRL3, S02NRl3, SONRl3, CONRl3, NRL3CONRL4, NRL3S02NRL4, CO, CRL1=CRL2, CºC, SiRL1RL2, P(0)Rl1, P(0)ORl1, NRL3C(=NCN)NRL4, NRL3C(=NCN),NRL3C(=CN02)NRl4, C3-i icycloalkyl optionally substituted with 0-6 RL1and / or RL2groups, C5-13 spirocycloalkyl optionally substituted with 0-9 RL1and / or RL2groups, C3-nheterocyclyl optionally substituted with 0-6 RL1and / or RL2groups, C5- 13spiroheterocyclyl optionally substituted with 0-8 RL1and / or RL2groups, aryl optionally substituted with 0-6 RL1and / or RL2groups, heteroaryl optionally substituted with 0-6 RL1and / or RL2groups, where RL1or RL2, each independently are optionally linked to other groups to form cycloalkyl and / or heterocyclyl moiety, optionally substituted with 0-4 R1 5groups; andRl1, Rl2, Rl3, R1 4and R15are, each independently, H, halo, Ci-salkyl, OCi-salkyl, SCi-salkyl, NHCi-galkyl, N(Ci-8alkyl)2, C3-ncycloalkyl, aryl, heteroaryl, C3-nheterocyclyl, OCi- scycloalkyl, SCi-scycloalkyl, NHCi-scycloalkyl, N(Ci-8cycloalkyl)2, N(Ci-8cycloalkyl)(Ci- salkyl), OH, NH2, SH, S02Ci-8alkyl, P(0)(0Ci-8alkyl)(Ci-8alkyl), P(0)(0Ci-8alkyl)2, CC- Ci-8alkyl, CCH, CH=CH(Ci_8alkyl), C(Ci-8alkyl)=CH(Ci_8alkyl), C(Ci-8alkyl)=C(Ci_ 8alkyl)2, Si(OH)3, Si(Ci_8alkyl)3, Si(OH)(Ci_8alkyl)2, COCi_8alkyl, C02H, halogen, CN, CF3, CHF2, CH2F, N02, SFS, S02NHCi-8alkyl, S02N(Ci_8alkyl)2, SONHCi-salkyl, SON(Ci-8alkyl)2, CONHCi-salkyl, CON(Ci_8alkyl)2, N(Ci-8alkyl)CONH(Ci_8alkyl), N(Ci_ 8alkyl)CON(Ci-8alkyl)2, NHCONH(Ci_8alkyl), NHCON(Ci_8alkyl)2, NHCONH2, N(Ci_AVS0044US38alkyl) S 02NH(C i -salkyl) , N(Ci-salkyl) S02N(Ci-8alkyl)2, NH S02NH(Ci-8alkyl), NH S02N(Ci-8alkyl)2, NH S02NH2.

[0158] In certain embodiments, q of the linker is an integer greater than or equal to 0. In certain embodiments, q is an integer greater than or equal to 1.

[0159] In certain embodiments, e.g., where q of the linker is greater than 2, (AL)qis a group which is to ALIand (AL)qwherein the units ALcouple a PTM to a ULM.

[0160] In certain embodiments, e.g., where q of the linker is 2, (AL)qis a group which is connected to ALIand to a ULM or PTM.

[0161] In certain embodiments, e.g., where q of the linker is 1, the structure of the linker group L is -ALi-, and ALIis a group which is connected to a ULM moiety and a PTM moiety.

[0162] In certain embodiments, the unit ALof linker (L) comprises a group represented by a general structure selected from the group consisting of:-NR(CH2)n-(lower alkyl)-, -NR(CH2)n-(lower alkoxyl)-, -NR(CH2)n-(lower alkoxyl)-OCH2-, - NR(CH2)n-(lower alkoxyl)-(lower alkyl)-OCH2-, -NR(CH2)n-(cycloalkyl)-(lower alkyl)- OCH2-, -NR(CH2)„-(hetero cycloalkyl)-, -NR(CH2CH20)„-(lower alkyl)-0-CH2-, - NR(CH2CH20)„-(hetero cycloalkyl)-0-CH2-, -NR(CH2CH20)„-Aryl-0-CH2-, NR(CH2CH20)„-(hetero aryl)-0-CH2-, -NR(CH2CH20)„-(cyclo alkyl)-0-(hetero aryl)-0- CH2-, -NR(CH2CH20)„-(cyclo alkyl)-0-Aryl-0-CH2-, -NR(CH2CH20)„-(lower alkyl)- NH-Aryl-0-CH2-, -NR(CH2CH20)„-(lower alkyl)-0-Aryl-CH2, -NR(CH2CH20)„- cycloalkyl-O-Aryl-, -NR(CH2CH20)n-cycloalkyl-0-(heteroaryl)l-, -NR(CH2CH2)n- (cycloalkyl)-0-(heterocyclyl)-CH2,-NR(CH2CH2)n-(heterocyclyl)-(heterocydyl)-CH2, - N(RlR2)-(heterocyclyl)-CH2; wheren of the linker can be 0 to 10;R of the linker can be H, lower alkyl;Rl and R2 of the linker can form a ring with the connecting N.

[0163] In certain embodiments, the unit ALof linker (L) comprises a group represented by a general structure selected from the group consisting of:-N(R)-(CH2)m-0(CH2)„-0(CH2)o-0(CH2)p-0(CH2)q-0(CH2)r-OCH2-,-0-(CH2)m-0(CH2)„-0(CH2)o-0(CH2)p-0(CH2)q-0(CH2)r-OCH2-,-0-(CH2)m-0(CH2)„-0(CH2)o-0(CH2)p-0(CH2)q-0(CH2)r-0-;-N(R)-(CH2)m-0(CH2)„-0(CH2)o-0(CH2)p-0(CH2)q-0(CH2)r-0-;AVS0044US3-(CH2)m-0(CH2)n-0(CH2)o-0(CH2)p-0(CH2)q-0(CH2)r-0-;AVS0044US3;m, n, o, p, q, and r of the linker are independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20;when the number is zero, there is no N-0 or 0-0 bondR of the linker is H, methyl and ethyl;AVS0044US3X of the linker is H and Fwhere m of the linker can be 2, 3, 4, 5AVS0044US3AVS0044US3AVS0044US3AVS0044US3AVS0044US3AVS0044US3AVS0044US3AVS0044US3where each n and m of the linker can independently be 0, 1, 2, 3, 4, 5, 6.

[0164] In any aspect or embodiment described herein, the unit ALof linker (L) is selected from the group consisting of:AVS0044US3AVS0044US3AVS0044US3AVS0044US3wherein each m and n is independently selected from 0, 1, 2, 3, 4, 5 , or 6.

[0165] In any aspect or embodiment described herein, the unit ALof linker (L) is selected from the group consisting of:AVS0044US3AVS0044US3AVS0044US3AVS0044US3AVS0044US3AVS0044US3AVS0044US3AVS0044US3AVS0044US3AVS0044US3AVS0044US3AVS0044US3AVS0044US3AVS0044US3AVS0044US3AVS0044US3AVS0044US3AVS0044US3AVS0044US3AVS0044US3WO 2019 / 195201AVS0044US3AVS0044US3AVS0044US3AVS0044US3AVS0044US3AVS0044US3AVS0044US3AVS0044US3AVS0044US3, wherein each m, n, o, p, q, r, and s is independently 0, 1,2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20.

[0166] In any aspect or embodiment described herein, the unit ALof linker (L) is selected from the group consisting of:AVS0044US3AVS0044US3AVS0044US3AVS0044US3AVS0044US3AVS0044US3AVS0044US3AVS0044US3AVS0044US3AVS0044US3AVS0044US3AVS0044US3AVS0044US3AVS0044US3AVS0044US3

[0167] In any aspect or embodiment described herein, the linker unit or linker (L) comprises a group represented by a structure selected from the group consisting of: -0-(CH2)m-0(CH2)n-0(CH2)o-0(CH2)p-0(CH2)q-0(CH2)r-0(CH2)s-0(CH2)t-;-0-( CH2)m-0(CH2)n-0(CH2)o-0(CH2)p-0(CH2)q-0(CH2)r-0(CH2)s-0- ;-(CH2)m-0(CH2)n-0(CH2)o-0(CH2)p-0(CH2)q-0(CH2)r-0(CH2)s-0(CH2)t-;AVS0044US3-CH=CH(CH2)m-0(CH2)„-0(CH2)o-0(CH2)p-0(CH2)q-0(CH2)r-0(CH2)s-0(CH2)t-; -0(CH2)nNCH3C(=0)(CH2)m— ·AVS0044US3AVS0044US3AVS0044US3AVS0044US3, , , , , q, r, s and t are each independently selected from the integers 0, 1, 2, 3 and 4.

[0168] In any aspect or embodiment described herein, the linker (L) is selected from the group consisting of:AVS0044US3

[0169] In additional embodiments, the linker (L) comprises a structure selected from, but not limited to the structure shown below, where a dashed line indicates the attachment point to the PTM or ULM moieties:wherein:WL1and WL2are each independently absent, a 4-8 membered ring with 0-4 heteroatoms, optionally substituted with RQ, each RQis independently a H, halo, OH, CN, CF3, optionally substituted linear or branched Ci-C6alkyl, optionally substituted linear or branched Ci-C6alkoxy, or 2 RQgroups taken together with the atom they are attached to, form a 4-8 membered ring system containing 0-4 heteroatoms;YL1is each independently a bond, Ci-C6alkyl (linear, branched, optionally substituted) and optionally one or more C atoms are replaced with O; or Ci-C6alkoxy (linear, branched, optionally substituted);AVS0044US3 n is 0-10; andXindicates the attachment point to the PTM or ULM moieties.

[0170] In additional embodiments, the linker (L) comprises a structure selected from, but not limited to the structure shown below, where a dashed line indicates the attachment point to the PTM or ULM moieties:wherein:WL1and WL2are each independently absent, aryl, heteroaryl, cyclic, heterocyclyl, Ci-6alkyl and optionally one or more C atoms are replaced with O or N, Ci-6alkenyl and optionally one or more C atoms are replaced with O, Ci-6alkynyl and optionally one or more C atoms are replaced with O, bicyclic, biaryl, biheteroaryl, or biheterocyclyl, each optionally substituted with RQ, each RQis independently a H, halo, OH, CN, CF3, hydroxyl, nitro, C ºCH, C2-6alkenyl, C2-6 alkynyl, optionally substituted linear or branched Ci-C6alkyl, optionally substituted linear or branched Ci-C6alkoxy, optionally substituted OCi-3alkyl (e.g., optionally substituted by 1 or more -F), OH, NH2, NRY1RY2, CN, or 2 RQgroups taken together with the atom they are attached to, form a 4-8 membered ring system containing 0-4 heteroatoms;YL1is each independently a bond, NRYL1, O, S, NRYL2, CRYL1RYL2, C=0, C=S, SO, S02, Ci- C6alkyl (linear, branched, optionally substituted) and optionally one or more C atoms are replaced with O; Ci-C6alkoxy (linear, branched, optionally substituted);AVS0044US3QLis a 3-6 membered alicyclic or aromatic ring with 0-4 heteroatoms, optionally bridged, optionally substituted with 0-6 RQ, each RQis independently H, linear or branched Ci-6alkyl optionally substituted by 1 or more halo or Ci-6alkoxyl, or 2 RQgroups taken together with the atom they are attached to, form a 3-8 membered ring system containing 0-2 heteroatoms);RYL1 ,RYL2are each independently H, OH, Ci-6alkyl (linear, branched, optionally substituted by 1 or more halo, Ci-6alkoxyl), or R1, R2together with the atom they are attached to, form a 3-8 membered ring system containing 0-2 heteroatoms);n is 0-10; andXindicates the attachment point to the PTM or ULM moieties.

[0171] In additional embodiments, the linker group is optionally substituted (poly)ethyleneglycol having between 1 and about 100 ethylene glycol units, between about 1 and about 50 ethylene glycol units, between 1 and about 25 ethylene glycol units, between about 1 and 10 ethylene glycol units, between 1 and about 8 ethylene glycol units and 1 and 6 ethylene glycol units, between 2 and 4 ethylene glycol units, or optionally substituted alkyl groups interdispersed with optionally substituted, O, N, S, P or Si atoms. In certain embodiments, the linker is substituted with an aryl, phenyl, benzyl, alkyl, alkylene, or heterocyclyl group. In certain embodiments, the linker may be asymmetric or symmetrical.

[0172] In any of the embodiments of the compounds described herein, the linker group may be any suitable moiety as described herein. In one embodiment, the linker is a substituted or unsubstituted polyethylene glycol group ranging in size from about 1 to about 12 ethylene glycol units, between 1 and about 10 ethylene glycol units, about 2 about 6 ethylene glycol units, between about 2 and 5 ethylene glycol units, between about 2 and 4 ethylene glycol units.

[0173] In another embodiment, the present disclosure is directed to a compound which comprises a PTM group as described above, which binds to a target protein or polypeptide (e.g., SMARCA2, BRAHMA or BRM), which is ubiquitinated by a ubiquitin ligase and is chemically linked directly to the ULM group or through a linker moiety L, or PTM is alternatively a ULM’ group which is also a ubiquitin ligase binding moiety, which may be the same or different than the ULM group as described above and is linked directly to the ULM group directly or through the linker moiety; and L is a linker moiety as described above which may be present or absent andAVS0044US3 which chemically (covalently) links ULM to PTM, or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate or polymorph thereof.

[0174] In certain embodiments, the linker group L is a group comprising one or more covalently connected structural units independently selected from the group consisting of:The X is selected from the group consisting of O, N, S, S(O) and S02; n is integer from 1 to 5;Rl1is hydrogen or alkyl,is a mono- or bicyclic aryl or heteroaryl optionally substituted with 1-3 substituents selected from alkyl, halogen, haloalkyl, hydroxy, alkoxy orcyano; * is a mono- or bicyclic cycloalkyl or a heterocyclyl optionally substituted with 1-3 substituents selected from alkyl, halogen, haloalkyl, hydroxy, alkoxy or cyano; and the phenyl ring fragment can be optionally substituted with 1, 2 or 3 substituents selected from the grou consisting of alkyl, halogen, haloalkyl, hydroxy, alkoxy and cyano. In an embodiment, the linker group L comprises up to 10 covalently connected structural units, as described above.

[0175] Although the ULM group and PTM group may be covalently linked to the linker group through any group which is appropriate and stable to the chemistry of the linker, in preferred aspects of the present dislcosure, the linker is independently covalently bonded to the ULM group and the PTM group preferably through an amide, ester, thioester, keto group, carbamate (urethane), carbon or ether, each of which groups may be inserted anywhere on the ULM group and PTM group to provide maximum binding of the ULM group on the ubiquitin ligase and the PTM group on the target protein to be degraded. (It is noted that in certain aspects where the PTM group is a ULM group, the target protein for degradation may be the ubiquitin ligase itself). In certain preferred aspects, the linker may be linked to an optionally substituted alkyl, alkylene, alkenyl or alkynyl group, an aryl group or a heterocyclyl group on the ULM and / or PTM groups.AVS0044US3

[0176] Exemplary PTMs

[0177] In any aspect or embodiment of the present disclosure, the PTM group is a moiety, which binds to target proteins, such as Switch / Sucrose Non Fermentable (SWFSNF)-Related, Matrix-Associated, Actin-Dependent Regulator of Chromatin, Subfamily A, Member 2 (SMARCA2) or BRM. Thus, in any aspect or embodiment described herein, the PTM group is any moiety that binds to SMARCA2 or BRM protein specifically (binds to the target protein SMARCA2, BRAHMA or BRM).

[0178] In certain embodiments, the compounds as described herein include a means for binding a target protein, e.g., Brm. As such, in certain aspects, the disclosure provides a bifunctional compound having a means for binding Brm, and a means for binding VHL and a means for chemically coupling the means for binding Brm to the means for binding VHL.

[0179] The compositions described below exemplify some of the members of small molecule target protein binding moieties. Such small molecule target protein binding moieties also include pharmaceutically acceptable salts, enantiomers, solvates and polymorphs of these compositions, as well as other small molecules that may target SMARCA2. These binding moieties are linked to the ubiquitin ligase binding moiety preferably through a linker in order to present a target protein (to which the protein target moiety is bound) in proximity to the ubiquitin ligase for ubiquitination and degradation. Any protein (e.g., SMARCA2, BRAHMA or BRM), which can bind to a protein target moiety or PTM group and acted on or degraded by a ubiquitin ligase is a target protein according to the present disclosure.

[0180] The present disclosure may be used to treat a number of disease states and / or conditions; including any disease state and / or condition in which proteins are dysregulated (e.g., SMARCA4- deficiency / mutation) and where a patient would benefit from the degradation and / or inhibition of proteins, such as SMARCA2, BRAHMA or BRM.

[0181] In an additional aspect, the description provides therapeutic compositions comprising an effective amount of a compound as described herein or salt form thereof, and a pharmaceutically acceptable carrier, additive or excipient, and optionally an additional bioactive agent. The therapeutic compositions modulate protein degradation in a patient or subject, for example, an animal such as a human, and can be used for treating or ameliorating disease states or conditions which are modulated through the degraded protein. In certain embodiments, the therapeutic compositions as described herein may be used to effectuate the degradation of proteins of interestAVS0044US3 for the treatment or amelioration of a disease, e.g., cancer such as at least one of a SWI / SNF associated cancer, a SMARCA4-mutation associated cancer, a SMARCA4-deficient cancer, or a cancer with decreased expression of SMARCA4 relative to normal SMARCA4 expression (e.g., decreased expression relative to the expression of non-mutated SMARCA4 or SMARCA4 in a similarly situated non-cancerous cell with wildtype SMARCA4), including lung cancer or non small cell lung cancer. In any aspect or embodiment described herein, the disease is at least one of SWI / SNF associated cancer, a cancer with a SMARCA4 mutation, a cancer with a SMARCA4- deficiency, or a combination thereof, which may be lung cancer or a non-small cell lung cancer.

[0182] In certain additional embodiments, the therapeutic compositions as described herein may be used to effectuate the degradation of proteins of interest for the treatment or amelioration of a disease, e.g., cancer such as at least one of a SWI / SNF associated cancer, a SMARCA2- associated cancer or a cancer with normal or over-expression of SMARCA2.

[0183] In alternative aspects, the present disclosure relates to a method for treating a disease state or ameliorating the symptoms of a disease or condition in a subject in need thereof by degrading a protein or polypeptide through which a disease state or condition is modulated comprising administering to said patient or subject an effective amount, e.g., a therapeutically effective amount, of at least one compound as described hereinabove, optionally in combination with a pharmaceutically acceptable carrier, additive or excipient, and optionally an additional bioactive agent, wherein the composition is effective for treating or ameliorating the disease or disorder or symptom thereof in the subject. The method according to the present disclosure may be used to treat a large number of disease states or conditions including cancer, by virtue of the administration of effective amounts of at least one compound described herein. The disease state or condition may be a disease caused by a microbial agent or other exogenous agent such as a virus, bacteria, fungus, protozoa or other microbe or may be a disease state, which is caused by overexpression of a protein, which leads to a disease state and / or condition.

[0184] In another aspect, the description provides methods for identifying the effects of the degradation of proteins of interest in a biological system using compounds according to the present disclosure.

[0185] The term“target protein” is used to describe a protein or polypeptide, which is a target for binding to a compound according to the present disclosure and degradation by ubiquitin ligase hereunder. Such small molecule target protein binding moieties also includeAVS0044US3 pharmaceutically acceptable salts, enantiomers, solvates and polymorphs of these compositions, as well as other small molecules that may target a protein of interest. These binding moieties are linked to at least one ULM group (e.g. VLM) through at least one linker group L.

[0186] The protein target may be used in screens that identify compound moieties which bind to the protein and by incorporation of the moiety into compounds according to the present disclosure, the level of activity of the protein may be altered for therapeutic end result.

[0187] The term“protein target moiety” or PTM is used to describe a small molecule which binds to a target protein or other protein or polypeptide of interest, such as SMARCA2 or BRM, and places / presents that protein or polypeptide in proximity to an ubiquitin ligase such that degradation of the protein or polypeptide by ubiquitin ligase may occur. The compositions described below exemplify some of the members of the small molecule target proteins.

[0188] In any aspect or embodiment described herein, the PTM of the present disclosure has a chemical structure represented by:wherein:WPTMI is an optionally substituted 5-6-membered aryl or heteroaryl ring (e.g., a 5-6 member aryl or heteroaryl substituted with 0, 1, 2, or 3 substituents selected from hydroxy, halogen, alkoxy, alkyl, haloalkyl, phosphate, amino, alkylamino, cyano or combination thereof);WPTM2 is an optionally substituted 5-6-membered aryl or heteroaryl ring (e.g., a 5-6membered aryl or heteroaryl substituted with 0, 1, 2, or 3 substituents selected from hydroxy, halogen, alkoxy, alkyl, haloalkyl, amino, alkylamino and cyano);WPTM3 is an optionally substituted 5-6-membered aryl or heteroaryl ring (e.g., a 5-6membered aryl or heteroaryl substituted with 0, 1, 2, or 3 substituents selected from hydroxy, halogen, alkoxy, alkyl, haloalkyl, amino, alkylamino and cyano), or an optionally substituted 4-9 cycloalkyl or heterocyclyl, such as an optionally substitutedAVS0044US3 bridged bicycloalkyl and bridged biheterocyclyl rings (e.g. a 4-9 cycloalkyl or heterocyclyl substituted with 0, 1, or 2 substituents selected from hydroxy, halogen, alkoxy, alkyl, haloalkyl, amino, alkylamino and cyano);WPTM5 is absent (such that WPTM3 is connected directly to L (linker) or ULM) or anoptionally substituted alkyl, an optionally substituted 5-6-membered cycloalkyl, heterocycle, aryl or heteroaryl ring (e.g. a 5-6 membered cycloalkyl, heterocycle, aryl or heteroaryl substituted with 0, 1, or 2 substituents selected from hydroxy, halogen, alkoxy, alkyl, haloalkyl, amino, alkylamino and cyano); and / is the attachment point to the, linker, ULM group, ULM’group, VLM group, VLM’ group.

[0189] In any aspect or embodiment described herein, WPTMS is a piperidine.

[0190] In certain embmodiments, WPTMI comprises a phosphate substitution.

[0191] In any aspect or embodiment described herein, the PTM of the PROTAC of the present disclosure is represented by Formula I, wherein at least one of:WPTMI is an optionally substituted phenyl or a pyridyl (e.g., substituted as described herein, such as a phenyl substituted with a hydroxy or phosphate substituent with or without an additional optional substituent selected as described herein, e.g., substituted with 0, 1, 2, or 3 substituents selected from hydroxy, halogen, alkoxy, alkyl, haloalkyl, amino, alkylamino, cyano or combination thereof);WPTM2 is an optionally substituted 6-membered heteroaryl ring (e.g., substituted as described herein, such as a pyridazine substituted with amino group);WPTM3 is an optionally substituted 5-6-membered heteroaryl (e.g., a pyrazole, pyrrole,imidazole, oxazole, oxadiazole, or triazole);WPTMS is as described in any aspect or embodiment described herein (e.g., WPTMS may be absent or a pyridine ring); ora combination thereof.

[0192] In any aspect or embodiment described herein, for example, an embodiment that includes a PTM of Formula I, WPTM3 is a pyrazole or a 6-8-membered heterocyclyl (e.g., a piperazine or a diazabicyclooctane).

[0193] In any aspect or embodiment described herein, the PTM of the present disclosure has a chemical structure represented by:AVS0044US3wherein:WPTMI, WPTM2, and WPTMSare as described in any other aspect or embodiment described herein (e.g., WPTMSmay or may not be present, such that WPTM4 may be connected directly to L (linker) or the ULM);WPTM4 is an optionally substitute 5-7 cycloalkyl or heterocyclyl (e.g., 5-7 cycloalkyl or heterocyclyl substituted with 0, 1, 2, or 3 substituents selected from hydroxy, halogen, alkoxy, alkyl, haloalkyl, amino, alkylamino and cyano) that is fused with the WPTM2 ring; and / is the attachment point to the, linker, ULM group, ULM’group, VLM group, VLM’ groupgroup.

[0194] In any aspect or embodiment described herein, the PTM of the present disclosure is represented by Formula II, wherein WPTMI , WPTM2 and WPTMS are as described in any of the aspects or embodiment described herein, and WPTM4 is a piperazine ring. For example, in any aspect or embodiment described herein, WPTM2 and WPTM4 of Formula II taken together constitute a dihydropirazino[2,3-e]pyridazine as shown:

[0195] In any aspect or embodiment described herein, the PTM of the present disclosure has a chemical structure represented by:AVS0044US3wherein:WPTMI and WPTM2 are as described in any aspect or embodiment described herein;WPTM6 and WPTM7 are independently an optionally 4-7 cycloalkyl or heterocyclyl (e.g., each is independently a 4-7 cycloalkyl or heterocyclyl substituted with 0, 1, or 2 substituents selected from hydroxy, halogen, alkoxy, alkyl, haloalkyl, amino, alkylamino and cyano), and the rings of WPTM6 and WPTM7 are fused or linked via a spiro connection; and / is the attachment point to the, linker, ULM group, ULM’group, VLM group, VLM’ group.

[0196] In any aspect or embodiment described herein, the PTM of the present disclosure has a chemical structure represented by formula III, wherein WPTMI and WPTM2 are eachindependently selected as described in any aspect or embodiment described herein (e.g., WPTMI is a phenyl substituted with a hydroxy substituent with or without an additional optional substituent selected as described herein, WPTM2 is a pyridazine substituted with amino group), and W PTM6 and WPTM7 are a spirocyclic ring system, for example, a spirocyclic ring selected from:AVS0044US3

[0197] In any aspect or embodiment described herein, the PTM of the the present disclosure is respresnted by:wherein WPTMI , WPTM2, and WPTMS are as described in any other aspect or embodiment described herein.

[0198] In any aspect or embodiment described herein, the PTM of the present disclosure has the chemical structure represented by Formula IV, wherein at least one of:WPTMI is a phenyl substituted with a hydroxy or phosphate substituent with or without an additional optional substituent selected as described herein;WPTM2 is a pyridazine substituted with amino group;WPTMS is absent, a pyrazole ring, or a pyridine ring; ora combination thereof.

[0199] In any aspect or embodiment described herein, the PTM of the present disclosure is represented by:AVS0044US3Formula Vor a pharmaceutically acceptable salt thereof, wherein:WPTM3 is absent or an optionally substituted 5-6-membered heteroaryl, an optionally substituted 4-9 cycloalkyl or heterocyclyl ring, an optionally substituted bridged bicycloalkyl and bridged biheterocyclyl ring; andWPTM5 is an optionally substituted 5-6-membered heteroaryl or aryl, e.g., pyridine, or pyridazine.

[0200] In any aspect or embodiment described herein, the PTM of the present disclosure is represented by:Formula Vbor a pharmaceutically acceptable salt thereof, wherein:WPTM3 is an optionally substituted 5-6-membered heteroaryl, an optionally substituted 4- 9 cycloalkyl or heterocyclyl ring, an optionally substituted bridged bicycloalkyl and bridged biheterocyclyl ring;WPTM5 is an optionally substituted 5-6-membered heteroaryl or aryl, e.g., pyridine, or pyridazine;Rv is 0, 1, 2 or 3 substituents independently selected from hydroxy, halogen, alkoxy, alkyl, haloalkyl, phosphate, amino, alkylamino, cyano or a combination thereof.AVS0044US3

[0201] In certain embodiments, the hydroxyl group is modified with a phosphate group (i.e., a phosphoester group).

[0202] In any aspect or embodiment described herein, the PTM of the present disclosure has a chemical structure represented by:Formula (VI)WPTMIand WPTM2 are as described in any other aspect or embodiment described herein (e.g., WPTM5 may or may not be present, such that WPTM4 may be connected directly to L (linker) or the ULM);WPTM3 is an optionally substituted 5-7 cycloalkyl or heterocyclyl (e.g., 5-7 cycloalkyl orheterocyclyl substituted with 0, 1, 2, or 3 substituents selected from hydroxy, halogen, alkoxy, alkyl, haloalkyl, amino, alkylamino and cyano) that is fused with the WPTM2 ring;WPTM4 is an optionally substituted 5-7-membered aryl or heteroaryl ring (e.g., a 5-6 membered aryl or heteroaryl substituted with 0, 1, 2, or 3 substituents selected from hydroxy, halogen, alkoxy, alkyl, haloalkyl, amino, alkylamino and cyano), or an optionally substituted 4-9 cycloalkyl or heterocyclyl, such as an optionally substituted bridged bicycloalkyl and bridged biheterocyclyl rings (e.g. a 4-9 cycloalkyl or heterocyclyl substituted with 0, 1, or 2 substituents selected from hydroxy, halogen, alkoxy, alkyl, haloalkyl, amino, alkylamino and cyano);WPTM5 is absent (such that WPTM3 is connected directly to L (linker) or ULM) or an optionally substituted alkyl, an optionally substituted 5-6-membered cycloalkyl, heterocycle, aryl or heteroaryl ring (e.g. a 5-6 membered cycloalkyl, heterocycle, aryl or heteroaryl substitutedAVS0044US3 with 0, 1, or 2 substituents selected from hydroxy, halogen, alkoxy, alkyl, haloalkyl, amino, alkylamino and cyano), e.g., an optionally substituted pyrazole ring, or a pyridine ring; and / is the attachment point to the, linker, ULM group, ULM’group, VLM group, VLM’groupgroup.

[0203]

[0204] In any aspect or embodiment described herein, the PTM is selected from:AVS0044US3

[0205] In any aspect or embodiment described herein, the PTM is selected from:AVS0044US3AVS0044US3

[0206] In any aspect or embodiment described herein, the PTM is selected from the group consisting of:AVS0044US3

[0207] The compositions described herein exemplify some of the members of these types of small molecule target protein binding moieties. Such small molecule target protein bindingAVS0044US3 moieties also include pharmaceutically acceptable salts, enantiomers, solvates and polymorphs of these compositions, as well as other small molecules that may target a protein of interest. References which are cited herein below are incorporated by reference herein in their entirety.

[0208] Therapeutic Compositions

[0209] Pharmaceutical compositions comprising combinations of an effective amount of at least one bifunctional compound as described herein, and one or more of the compounds otherwise described herein, all in effective amounts, in combination with a pharmaceutically effective amount of a carrier, additive or excipient, represents a further aspect of the present disclosure.

[0210] The present disclosure includes, where applicable, the compositions comprising the pharmaceutically acceptable salts, in particular, acid or base addition salts of compounds as described herein. The acids which are used to prepare the pharmaceutically acceptable acid addition salts of the aforementioned base compounds useful according to this aspect are those which form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, acetate, lactate, citrate, acid citrate, tartrate, bitartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate [i.e., l,T-methylene-bis-(2-hydroxy-3 naphthoate)] salts, among numerous others.

[0211] Pharmaceutically acceptable base addition salts may also be used to produce pharmaceutically acceptable salt forms of the compounds or derivatives according to the present disclosure. The chemical bases that may be used as reagents to prepare pharmaceutically acceptable base salts of the present compounds that are acidic in nature are those that form non toxic base salts with such compounds. Such non-toxic base salts include, but are not limited to those derived from such pharmacologically acceptable cations such as alkali metal cations (eg., potassium and sodium) and alkaline earth metal cations (eg, calcium, zinc and magnesium), ammonium or water-soluble amine addition salts such as N-methylglucamine-(meglumine), and the lower alkanolammonium and other base salts of pharmaceutically acceptable organic amines, among others.

[0212] The compounds as described herein may, in accordance with the disclosure, be administered in single or divided doses by the oral, parenteral or topical routes. Administration of the active compound may range from continuous (intravenous drip) to several oralAVS0044US3 administrations per day (for example, Q.I.D.) and may include oral, topical, parenteral, intramuscular, intravenous, sub-cutaneous, transdermal (which may include a penetration enhancement agent), buccal, sublingual and suppository administration, among other routes of administration. Enteric coated oral tablets may also be used to enhance bioavailability of the compounds from an oral route of administration. The most effective dosage form will depend upon the pharmacokinetics of the particular agent chosen as well as the severity of disease in the patient. Administration of compounds according to the present disclosure as sprays, mists, or aerosols for intra-nasal, intra-tracheal or pulmonary administration may also be used. The present disclosure therefore also is directed to pharmaceutical compositions comprising an effective amount of compound as described herein, optionally in combination with a pharmaceutically acceptable carrier, additive or excipient. Compounds according to the present disclosure may be administered in immediate release, intermediate release or sustained or controlled release forms. Sustained or controlled release forms are preferably administered orally, but also in suppository and transdermal or other topical forms. Intramuscular injections in liposomal form may also be used to control or sustain the release of compound at an injection site.

[0213] The compositions as described herein may be formulated in a conventional manner using one or more pharmaceutically acceptable carriers and may also be administered in controlled-release formulations. Pharmaceutically acceptable carriers that may be used in these pharmaceutical compositions include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as prolamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene -polyoxypropylene-block polymers, polyethylene glycol and wool fat.

[0214] The compositions as described herein may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. The term "parenteral" as used herein includes subcutaneous, intravenous, intramuscular, intra- articular, intra- synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection orAVS0044US3 infusion techniques. Preferably, the compositions are administered orally, intraperitoneally or intravenously.

[0215] Sterile injectable forms of the compositions as described herein may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally- accep table diluent or solvent, for example as a solution in 1, 3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or di-glycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as Ph. Helv or similar alcohol.

[0216] The pharmaceutical compositions as described herein may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions. In the case of tablets for oral use, carriers which are commonly used include lactose and com starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried com starch. When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.

[0217] Alternatively, the pharmaceutical compositions as described herein may be administered in the form of suppositories for rectal administration. These can be prepared by mixing the agent with a suitable non-irritating excipient, which is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the dmg. Such materials include cocoa butter, beeswax and polyethylene glycols.

[0218] The pharmaceutical compositions as described herein may also be administered topically. Suitable topical formulations are readily prepared for each of these areas or organs. Topical application for the lower intestinal tract can be effected in a rectal suppository formulationAVS0044US3(see above) or in a suitable enema formulation. Topically-acceptable transdermal patches may also be used.

[0219] For topical applications, the pharmaceutical compositions may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers. Carriers for topical administration of the compounds of this disclosure include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water. In certain preferred aspects of the disclosure, the compounds may be coated onto a stent which is to be surgically implanted into a patient in order to inhibit or reduce the likelihood of occlusion occurring in the stent in the patient.

[0220] Alternatively, the pharmaceutical compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.

[0221] For ophthalmic use, the pharmaceutical compositions may be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with our without a preservative such as benzylalkonium chloride. Alternatively, for ophthalmic uses, the pharmaceutical compositions may be formulated in an ointment such as petrolatum.

[0222] The pharmaceutical compositions as described herein may also be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and / or other conventional solubilizing or dispersing agents.

[0223] The amount of compound in a pharmaceutical composition as described herein that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host and disease treated and the particular mode of administration. Preferably, the compositions should be formulated to contain between about 0.05 milligram to about 750 milligrams or more, more preferably about 1 milligram to about 600 milligrams, and even more preferably about 10 milligrams to about 500 milligrams of active ingredient, alone or in combination with at least one other compound according to the present disclosure.AVS0044US3

[0224] It should also be understood that a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the severity of the particular disease or condition being treated.

[0225] A patient or subject in need of therapy using compounds according to the methods described herein can be treated by administering to the patient (subject) an effective amount of the compound according to the present disclosure including pharmaceutically acceptable salts, solvates or polymorphs, thereof optionally in a pharmaceutically acceptable carrier or diluent, either alone, or in combination with other known therapeutic agents as otherwise identified herein.

[0226] These compounds can be administered by any appropriate route, for example, orally, parenterally, intravenously, intradermally, subcutaneously, or topically, including transdermally, in liquid, cream, gel, or solid form, or by aerosol form.

[0227] The active compound is included in the pharmaceutically acceptable carrier or diluent in an amount sufficient to deliver to a patient a therapeutically effective amount for the desired indication, without causing serious toxic effects in the patient treated. A preferred dose of the active compound for all of the herein-mentioned conditions is in the range from about 10 ng / kg to 300 mg / kg, preferably 0.1 to 100 mg / kg per day, more generally 0.5 to about 25 mg per kilogram body weight of the recipient / patient per day. A typical topical dosage will range from 0.01-5% wt / wt in a suitable carrier.

[0228] The compound is conveniently administered in any suitable unit dosage form, including but not limited to one containing less than lmg, 1 mg to 3000 mg, preferably 5 to 500 mg of active ingredient per unit dosage form. An oral dosage of about 25-250 mg is often convenient.

[0229] The active ingredient is preferably administered to achieve peak plasma concentrations of the active compound of about 0.00001-30 mM, preferably about 0.1-30 mM. This may be achieved, for example, by the intravenous injection of a solution or formulation of the active ingredient, optionally in saline, or an aqueous medium or administered as a bolus of the active ingredient. Oral administration is also appropriate to generate effective plasma concentrations of active agent.AVS0044US3

[0230] The concentration of active compound in the drug composition will depend on absorption, distribution, inactivation, and excretion rates of the drug as well as other factors known to those of skill in the art. It is to be noted that dosage values will also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed composition. The active ingredient may be administered at once, or may be divided into a number of smaller doses to be administered at varying intervals of time.

[0231] Oral compositions will generally include an inert diluent or an edible carrier. They may be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound or its prodrug derivative can be incorporated with excipients and used in the form of tablets, troches, or capsules. Pharmaceutically compatible binding agents, and / or adjuvant materials can be included as part of the composition.

[0232] The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a dispersing agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring. When the dosage unit form is a capsule, it can contain, in addition to material of the above type, a liquid carrier such as a fatty oil. In addition, dosage unit forms can contain various other materials which modify the physical form of the dosage unit, for example, coatings of sugar, shellac, or enteric agents.

[0233] The active compound or pharmaceutically acceptable salt thereof can be administered as a component of an elixir, suspension, syrup, wafer, chewing gum or the like. A syrup may contain, in addition to the active compounds, sucrose as a sweetening agent and certain preservatives, dyes and colorings and flavors.

[0234] The active compound or pharmaceutically acceptable salts thereof can also be mixed with other active materials that do not impair the desired action, or with materials that supplement the desired action, such as anti-cancer agents, including pembrolizumab, among others. In certainAVS0044US3 preferred aspects of the disclosure, one or more compounds according to the present disclosure are coadministered with another bioactive agent, such as an anti-cancer agent or a would healing agent, including an antibiotic, as otherwise described herein.

[0235] Solutions or suspensions used for parenteral, intradermal, subcutaneous, or topical application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. The parental preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

[0236] If administered intravenously, preferred carriers are physiological saline or phosphate buffered saline (PBS).

[0237] In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, poly orthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art.

[0238] Liposomal suspensions may also be pharmaceutically acceptable carriers. These may be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811 (which is incorporated herein by reference in its entirety). For example, liposome formulations may be prepared by dissolving appropriate lipid(s) (such as stearoyl phosphatidyl ethanolamine, stearoyl phosphatidyl choline, arachadoyl phosphatidyl choline, and cholesterol) in an inorganic solvent that is then evaporated, leaving behind a thin film of dried lipid on the surface of the container. An aqueous solution of the active compound are then introduced into the container. The container is then swirled by hand to free lipid material from the sides of the container and to disperse lipid aggregates, thereby forming the liposomal suspension.

[0239] Therapeutic Methods

[0240] In an additional aspect, the description provides therapeutic compositions comprising an effective amount of a compound as described herein or salt form thereof, and aAVS0044US3 pharmaceutically acceptable carrier. The therapeutic compositions modulate protein degradation in a patient or subject, for example, an animal such as a human, and can be used for treating or ameliorating disease states or conditions which are modulated through the degraded protein.

[0241] The terms“treat”,“treating”, and“treatment”, etc., as used herein, refer to any action providing a benefit to a patient for which the present compounds may be administered, including the treatment of any disease state or condition which is modulated through the protein to which the present compounds bind. Disease states or conditions, including cancer such as lung cancer, including non-small cell lung cancer, which may be treated using compounds according to the present disclosure are set forth hereinabove.

[0242] The description provides therapeutic compositions as described herein for effectuating the degradation of proteins of interest for the treatment or amelioration of a disease, e.g., cancer. In certain additional embodiments, the disease is multiple myeloma. As such, in another aspect, the description provides a method of ubiquitinating / degrading a target protein in a cell. In certain embodiments, the method comprises administering a bifunctional compound as described herein comprising, e.g., a ULM and a PTM, preferably linked through a linker moiety, as otherwise described herein, wherein the ULM is coupled to the PTM and wherein the ULM recognizes a ubiquitin pathway protein (e.g., an ubiquitin ligase, such as a VHL E3 ubiquitin ligase) and the PTM recognizes the target protein such that degradation of the target protein will occur when the target protein is placed in proximity to the ubiquitin ligase, thus resulting in degradation / inhibition of the effects of the target protein and the control of protein levels. The control of protein levels afforded by the present disclosure provides treatment of a disease state or condition, which is modulated through the target protein by lowering the level of that protein in the cell, e.g., cell of a patient. In certain embodiments, the method comprises administering an effective amount of a compound as described herein, optionally including a pharamaceutically acceptable excipient, carrier, adjuvant, another bioactive agent or combination thereof.

[0243] In additional embodiments, the description provides methods for treating or ameliorating a disease, disorder or symptom thereof in a subject or a patient, e.g., an animal such as a human, comprising administering to a subject in need thereof a composition comprising an effective amount, e.g., a therapeutically effective amount, of a compound as described herein or salt form thereof, and a pharmaceutically acceptable excipient, carrier, adjuvant, another bioactiveAVS0044US3 agent or combination thereof, wherein the composition is effective for treating or ameliorating the disease or disorder or symptom thereof in the subject.

[0244] In another aspect, the description provides methods for identifying the effects of the degradation of proteins of interest in a biological system using compounds according to the present disclosure.

[0245] In another embodiment, the present disclosure is directed to a method of treating a human patient in need for a disease state or condition modulated through a protein where the degradation of that protein will produce a therapeutic effect in the patient, the method comprising administering to a patient in need an effective amount of a compound according to the present disclosure, optionally in combination with another bioactive agent. The disease state or condition may be a disease caused by a microbial agent or other exogenous agent such as a virus, bacteria, fungus, protozoa or other microbe or may be a disease state, which is caused by overexpression of a protein, which leads to a disease state and / or condition

[0246] The term“disease state or condition” is used to describe any disease state or condition wherein protein dysregulation (i.e., the amount of protein expressed in a patient is elevated) occurs and where degradation of one or more proteins in a patient may provide beneficial therapy or relief of symptoms to a patient in need thereof. In certain instances, the disease state or condition may be cured.

[0247] Disease states or conditions which may be treated using compounds according to the present disclosure include, for example, asthma, autoimmune diseases such as multiple sclerosis, various cancers, ciliopathies, cleft palate, diabetes, heart disease, hypertension, inflammatory bowel disease, mental retardation, mood disorder, obesity, refractive error, infertility, Angelman syndrome, Canavan disease, Coeliac disease, Charcot-Marie-Tooth disease, Cystic fibrosis, Duchenne muscular dystrophy, Haemochromatosis, Haemophilia, Klinefelter's syndrome, Neurofibromatosis, Phenylketonuria, Polycystic kidney disease, (PKD1) or 4 (PKD2) Prader- Willi syndrome, Sickle-cell disease, Tay-Sachs disease, Turner syndrome.

[0248] The term "neoplasia" or“cancer” is used throughout the specification to refer to the pathological process that results in the formation and growth of a cancerous or malignant neoplasm, i.e., abnormal tissue that grows by cellular proliferation, often more rapidly than normal and continues to grow after the stimuli that initiated the new growth cease. Malignant neoplasms show partial or complete lack of structural organization and functional coordination with the normalAVS0044US3 tissue and most invade surrounding tissues, metastasize to several sites, and are likely to recur after attempted removal and to cause the death of the patient unless adequately treated. As used herein, the term neoplasia is used to describe all cancerous disease states and embraces or encompasses the pathological process associated with malignant hematogenous, ascitic and solid tumors. Exemplary cancers which may be treated by the present compounds either alone or in combination with at least one additional anti-cancer agent include squamous-cell carcinoma, basal cell carcinoma, adenocarcinoma, hepatocellular carcinomas, and renal cell carcinomas, cancer of the bladder, bowel, breast, cervix, colon, esophagus, head, kidney, liver, lung, neck, ovary, pancreas, prostate, and stomach; leukemias; benign and malignant lymphomas, particularly Burkitt's lymphoma and Non-Hodgkin's lymphoma; benign and malignant melanomas; myeloproliferative diseases; sarcomas, including Ewing's sarcoma, hemangio sarcoma, Kaposi's sarcoma, liposarcoma, myosarcomas, peripheral neuroepithelioma, synovial sarcoma, gliomas, astrocytomas, oligodendrogliomas, ependymomas, gliobastomas, neuroblastomas, ganglioneuromas, gangliogliomas, medulloblastomas, pineal cell tumors, meningiomas, meningeal sarcomas, neurofibromas, and Schwannomas; bowel cancer, breast cancer, prostate cancer, cervical cancer, uterine cancer, lung cancer, ovarian cancer, testicular cancer, thyroid cancer, astrocytoma, esophageal cancer, pancreatic cancer, stomach cancer, liver cancer, colon cancer, melanoma; carcinosarcoma, Hodgkin's disease, Wilms' tumor and teratocarcinomas. Additional cancers which may be treated using compounds according to the present disclosure include, for example, T-lineage Acute lymphoblastic Leukemia (T-ALL), T-lineage lymphoblastic Lymphoma (T-LL), Peripheral T-cell lymphoma, Adult T-cell Leukemia, Pre-B ALL, Pre-B Lymphomas, Large B-cell Lymphoma, Burkitts Lymphoma, B-cell ALL, Philadelphia chromosome positive ALL and Philadelphia chromosome positive CML.

[0249] The term“bioactive agent” is used to describe an agent, other than a compound according to the present disclosure, which is used in combination with the present compounds as an agent with biological activity to assist in effecting an intended therapy, inhibition and / or prevention / prophylaxis for which the present compounds are used. Preferred bioactive agents for use herein include those agents which have pharmacological activity similar to that for which the present compounds are used or administered and include for example, anti-cancer agents, antiviral agents, especially including anti-HIV agents and anti-HCV agents, antimicrobial agents, antifungal agents, etc.AVS0044US3

[0250] The term“additional anti-cancer agent” is used to describe an anti-cancer agent, which may be combined with compounds according to the present disclosure to treat cancer. These agents include, for example, everolimus, trabectedin, abraxane, TLK 286, AV-299, DN-101, pazopanib, GSK690693, RTA 744, ON 09l0.Na, AZD 6244 (ARRY- 142886), AMN-107, TKI-258, GSK461364, AZD 1152, enzastaurin, vandetanib, ARQ-197, MK-0457, MLN8054, PHA-739358, R-763, AT-9263, a FLT-3 inhibitor, a VEGFR inhibitor, an EGFR TK inhibitor, an aurora kinase inhibitor, a PIK-l modulator, a Bcl-2 inhibitor, an HD AC inhbitor, a c-MET inhibitor, a PARP inhibitor, a Cdk inhibitor, an EGFR TK inhibitor, an IGFR-TK inhibitor, an anti-HGF antibody, a PI3 kinase inhibitor, an AKT inhibitor, an mTORCl / 2 inhibitor, a JAK / STAT inhibitor, a checkpoint- 1 or 2 inhibitor, a focal adhesion kinase inhibitor, a Map kinase kinase (mek) inhibitor, a VEGF trap antibody, pemetrexed, erlotinib, dasatanib, nilotinib, decatanib, panitumumab, amrubicin, oregovomab, Lep-etu, nolatrexed, azd2l7l, batabulin, ofatumumab, zanolimumab, edotecarin, tetrandrine, rubitecan, tesmilifene, oblimersen, ticilimumab, ipilimumab, gossypol, Bio 111, 131-I-TM-601, ALT-110, BIO 140, CC 8490, cilengitide, gimatecan, IL13-PE38QQR, INO 1001, IPdRi KRX-0402, lucanthone, LY317615, neuradiab, vitespan, Rta 744, Sdx 102, talampanel, atrasentan, Xr 311, romidepsin, ADS-100380, sunitinib, 5-fluorouracil, vorinostat, etoposide, gemcitabine, doxorubicin, liposomal doxorubicin, 5'-deoxy-5-fluorouridine, vincristine, temozolomide, ZK-304709, seliciclib; PD0325901, AZD-6244, capecitabine, L-Glutamic acid, N- [4-[2-(2-amino-4,7-dihydro-4-oxo-lH- pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-, disodium salt, heptahydrate, camptothecin, PEG-labeled irinotecan, tamoxifen, toremifene citrate, anastrazole, exemestane, letrozole, DES(diethylstilbestrol), estradiol, estrogen, conjugated estrogen, bevacizumab, IMC-1C11, CHIR-258); 3-[5-(methylsulfonylpiperadinemethyl)- indolyl- quinolone, vatalanib, AG-013736, AVE-0005, goserelin acetate, leuprolide acetate, triptorelin pamoate, medroxyprogesterone acetate, hydroxyprogesterone caproate, megestrol acetate, raloxifene, bicalutamide, flutamide, nilutamide, megestrol acetate, CP-724714; TAK-165, HKI- 272, erlotinib, lapatanib, canertinib, ABX-EGF antibody, erbitux, EKB-569, PKI-166, GW- 572016, Ionafarnib, BMS-214662, tipifarnib; amifostine, NVP-LAQ824, suberoyl analide hydroxamic acid, valproic acid, trichostatin A, FK-228, SU11248, sorafenib, KRN951 , aminoglutethimide, arnsacrine, anagrelide, L-asparaginase, Bacillus Calmette-Guerin (BCG) vaccine, adriamycin, bleomycin, buserelin, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cladribine, clodronate, cyproterone, cytarabine, dacarbazine, dactinomycin,AVS0044US3 daunorubicin, diethylstilbestrol, epirubicin, fludarabine, fludrocortisone, fluoxymesterone, flutamide, gleevec, gemcitabine, hydroxyurea, idarubicin, ifosfamide, imatinib, leuprolide, levamisole, lomustine, mechlorethamine, melphalan, 6-mercaptopurine, mesna, methotrexate, mitomycin, mitotane, mitoxantrone, nilutamide, octreotide, oxaliplatin, pamidronate, pentostatin, plicamycin, porfimer, procarbazine, raltitrexed, rituximab, streptozocin, teniposide, testosterone, thalidomide, thioguanine, thiotepa, tretinoin, vindesine, l3-cis-retinoic acid, phenylalanine mustard, uracil mustard, estramustine, altretamine, floxuridine, 5-deooxyuridine, cytosine arabinoside, 6-mecaptopurine, deoxycoformycin, calcitriol, valrubicin, mithramycin, vinblastine, vinorelbine, topotecan, razoxin, marimastat, COL-3, neovastat, BMS-275291 , squalamine, endostatin, SU5416, SU6668, EMD121974, interleukin- 12, IM862, angiostatin, vitaxin, droloxifene, idoxyfene, spironolactone, finasteride, cimitidine, trastuzumab, denileukin diftitox,gefitinib, bortezimib, paclitaxel, cremophor-free paclitaxel, docetaxel, epithilone B, BMS- 247550, BMS-310705, droloxifene, 4-hydroxytamoxifen, pipendoxifene, ERA-923, arzoxifene, fulvestrant, acolbifene, lasofoxifene, idoxifene, TSE-424, HMR- 3339, ZK186619, topotecan, PTK787 / ZK 222584, VX-745, PD 184352, rapamycin, 40-O-(2-hydroxyethyl)-rapamycin, temsirolimus, AP-23573, RAD001, ABT-578, BC-210, LY294002, LY292223, LY292696, LY293684, LY293646, wortmannin, ZM336372, L-779,450, PEG-filgrastim, darbepoetin, erythropoietin, granulocyte colony-stimulating factor, zolendronate, prednisone, cetuximab, granulocyte macrophage colony- stimulating factor, histrelin, pegylated interferon alfa-2a, interferon alfa-2a, pegylated interferon alfa-2b, interferon alfa-2b, azacitidine, PEG-L- asparaginase, lenalidomide, gemtuzumab, hydrocortisone, interleukin-l l, dexrazoxane, alemtuzumab, all-transretinoic acid, ketoconazole, interleukin-2, megestrol, immune globulin, nitrogen mustard, methylprednisolone, ibritgumomab tiuxetan, androgens, decitabine, hexamethylmelamine, bexarotene, tositumomab, arsenic trioxide, cortisone, editronate, mitotane, cyclosporine, liposomal daunorubicin, Edwina-asparaginase, strontium 89, casopitant, netupitant, an NK-l receptor antagonist, palonosetron, aprepitant, diphenhydramine, hydroxyzine, metoclopramide, lorazepam, alprazolam, haloperidol, droperidol, dronabinol, dexamethasone, methylprednisolone, prochlorperazine, granisetron, ondansetron, dolasetron, tropisetron, pegfilgrastim, erythropoietin, epoetin alfa, darbepoetin alfa and mixtures thereof.

[0251] The term“anti-HIV agent” or“additional anti-HIV agent” includes, for example, nucleoside reverse transcriptase inhibitors (NRTI), other non-nucloeoside reverse transcriptaseAVS0044US3 inhibitors (i.e., those which are not representative of the present disclosure), protease inhibitors, fusion inhibitors, among others, exemplary compounds of which may include, for example, 3TC (Lamivudine), AZT (Zidovudine), (-)-FTC, ddl (Didanosine), ddC (zalcitabine), abacavir (ABC), tenofovir (PMPA), D-D4FC (Reverset), D4T (Stavudine), Racivir, L-FddC, L-FD4C, NVP (Nevirapine), DLV (Delavirdine), EFV (Efavirenz), SQVM (Saquinavir mesylate), RTV (Ritonavir), IDV (Indinavir), SQV (Saquinavir), NFV (Nelfinavir), APV (Amprenavir), LPV (Lopinavir), fusion inhibitors such as T20, among others, fuseon and mixtures thereof, including anti-HIV compounds presently in clinical trials or in development.

[0252] Other anti-HIV agents which may be used in coadministration with compounds according to the present disclosure include, for example, other NNRTI’s (i.e., other than the NNRTI’s according to the present disclosure) may be selected from the group consisting of nevirapine (BI-R6-587), delavirdine (U-90152S / T), efavirenz (DMP-266), UC-781 (N-[4-chloro- 3 -(3 -methyl-2-butenyloxy)phenyl] -2methyl3 -furancarbothiamide) , etravirine (TMC 125),Trovirdine (Ly300046.HCl), MKC-442 (emivirine, coactinon), HI-236, HI-240, HI-280, HI-281, rilpivirine (TMC-278), MSC-127, HBY 097, DMP266, Baicalin (TJN-151) ADAM-II (Methyl 3’ ,3’ -dichloro-4’ ,4”-dimethoxy-5’ ,5”-bis(methoxycarbonyl)-6,6-diphenylhexenoate), Methyl 3- Bromo-5-(l-5-bromo-4-methoxy-3-(methoxycarbonyl)phenyl)hept-l-enyl)-2-methoxybenzoate (Alkenyldiarylmethane analog, Adam analog), (5-chloro-3-(phenylsulfinyl)-2’- indolecarboxamide), AAP-BHAP (U-104489 or PNU-104489), Capravirine (AG-1549, S- 1153), atevirdine (U-87201E), aurin tricarboxylic acid (SD-095345), l-[(6-cyano-2-indolyl)carbonyl]-4- [3 -(isopropylamino)-2-pyridinyl]piperazine, 1 - [5- [ [N-(methyl)methylsulfonylamino] -2- indolylcarbonyl-4-[3-(isopropylamino)-2-pyridinyl]piperazine, l-[3-(Ethylamino)-2-[pyridinyl]- 4- [(5-hydroxy-2-indolyl)carbonyl]piperazine, 1 - [(6-Formyl-2-indolyl)carbonyl] -4- [3 -(isoprop ylamino)-2-pyridinyl]piperazine, 1 - [ [5-(Methylsulfonyloxy)-2-indoyly)carbonyl] -4- [3 - (isopropylamino)-2-pyridinyl]piperazine, U88204E, Bis(2-nitrophenyl)sulfone (NSC 633001), Calanolide A (NSC675451), Calanolide B, 6-Benzyl-5-methyl-2-(cyclohexyloxy)pyrimidin-4- one (D ABO-546), DPC 961, E-EBU, E-EBU-dm, E-EPSeU, E-EPU, Foscamet (Foscavir), HEPT ( 1 - [(2-Hydroxyethoxy)methyl] -6-(phenylthio)thymine) , HEPT -M ( 1 - [(2-Hydroxyethoxy)methyl]-6-(3-methylphenyl)thio)thymine), HEPT-S (l-[(2-Hydroxyethoxy)methyl]-6-(phenylthio)-2-thiothymine), Inophyllum P, L-737,l26, Michellamine A (NSC650898), Michellamine B (NSC649324), Michellamine F, 6-(3,5-Dimethylbenzyl)-l-[(2-AVS0044US3 hydroxyethoxy)methyl]-5-isopropyluracil, 6-(3,5-Dimethylbenzyl)-l-(ethyoxymethyl)-5- isopropyluracil, NPPS, E-BPTU (NSC 648400), Oltipraz (4-Methyl-5-(pyrazinyl)-3H-l,2- dithiole-3-thione), N-{2-(2-Chloro-6-fluorophenethyl]-N’-(2-thiazolyl)thiourea (PETT Cl, F derivative), N-{2-(2,6-Difluorophenethyl]-N’-[2-(5-bromopyridyl)]thiourea {PETT derivative), N-{2-(2,6-Difluorophenethyl]-N’-[2-(5-methylpyridyl)]thiourea {PETT Pyridyl derivative), N- [2-(3-Fluorofuranyl)ethyl]-N’-[2-(5-chloropyridyl)]thiourea, N-[2-(2-Fluoro-6- ethoxyphenethyl)]-N’-[2-(5-bromopyridyl)]thiourea, N-(2-Phenethyl)-N'-(2-thiazolyl)thiourea (LY-73497), L-697,639, L-697,593, L-697,66l, 3-[2-(4,7-Difluorobenzoxazol-2-yl)ethyl}-5- ethyl-6-methyl(pypridin-2(lH)-thione (2-Pyridinone Derivative), 3-[[(2-Methoxy-5,6-dimethyl- 3-pyridyl)methyl]amine]-5-ethyl-6-methyl(pypridin-2(lH)-thione, R82150, R82913, R87232, R88703, R89439 (Loviride), R90385, S-2720, Suramin Sodium, TBZ (Thiazolobenzimidazole, NSC 625487), Thiazoloisoindol-5-one, (+)(R)-9b-(3,5-Dimethylphenyl-2,3-dihydrothiazolo[2,3- a]isoindol-5(9bH)-one, Tivirapine (R86183), ETC-38 and UC-84, among others.

[0253] The term "pharmaceutically acceptable salt" is used throughout the specification to describe, where applicable, a salt form of one or more of the compounds described herein which are presented to increase the solubility of the compound in the gastic juices of the patient's gastrointestinal tract in order to promote dissolution and the bioavailability of the compounds. Pharmaceutically acceptable salts include those derived from pharmaceutically acceptable inorganic or organic bases and acids, where applicable. Suitable salts include those derived from alkali metals such as potassium and sodium, alkaline earth metals such as calcium, magnesium and ammonium salts, among numerous other acids and bases well known in the pharmaceutical art. Sodium and potassium salts are particularly preferred as neutralization salts of the phosphates according to the present disclosure.

[0254] The term "pharmaceutically acceptable derivative" is used throughout the specification to describe any pharmaceutically acceptable prodrug form (such as an ester, amide other prodrug group), which, upon administration to a patient, provides directly or indirectly the present compound or an active metabolite of the present compound.

[0255] General Synthetic Approaches

[0256] The synthetic realization and optimization of the bifunctional molecules as described herein may be approached in a step-wise or modular fashion. For example, identification of compounds that bind to the target molecules can involve high or medium throughput screeningAVS0044US3 campaigns if no suitable ligands are immediately available. It is not unusual for initial ligands to require iterative design and optimization cycles to improve suboptimal aspects as identified by data from suitable in vitro and pharmacological and / or ADMET assays. Part of the optimization / S AR campaign would be to probe positions of the ligand that are tolerant of substitution and that might be suitable places on which to attach the linker chemistry previously referred to herein. Where crystallographic or NMR structural data are available, these can be used to focus such a synthetic effort.

[0257] In a very analogous way one can identify and optimize ligands for an E3 Ligase, i.e. ULMs / VLMs.

[0258] With PTMs and ULMs (e.g. VLMs) in hand, one skilled in the art can use known synthetic methods for their combination with or without a linker moiety. Linker moieties can be synthesized with a range of compositions, lengths and flexibility and functionalized such that the PTM and ULM groups can be attached sequentially to distal ends of the linker. Thus a library of bifunctional molecules can be realized and profiled in in vitro and in vivo pharmacological and ADMET / PK studies. As with the PTM and ULM groups, the final bifunctional molecules can be subject to iterative design and optimization cycles in order to identify molecules with desirable properties.

[0259] In some instances, protecting group strategies and / or functional group interconversions (FGIs) may be required to facilitate the preparation of the desired materials. Such chemical processes are well known to the synthetic organic chemist and many of these may be found in texts such as“Greene's Protective Groups in Organic Synthesis” Peter G. M. Wuts and Theodora W. Greene (Wiley), and“Organic Synthesis: The Disconnection Approach” Stuart Warren and Paul Wyatt (Wiley).

[0260] Abbreviations:

[0261] ACN: acetonitrile

[0262] ADDP: 1 , 1’-(azodicarbonyl)dipiperidine

[0263] BAST: / V, / V-bis(2-methoxyethyl)aminosulfur trifluoride

[0264] BPO: benzoyl peroxide

[0265] Cbz: Carbonylbezyloxy

[0266] DAST: diethylaminosulfur trifluoride

[0267] DBE: l,2-dibromoethaneAVS0044US3

[0268] DCM: dichloromethane

[0269] DEAD: diethyl azodicarboxylate

[0270] DIAD: diisopropyl azodicarboxylate

[0271] DIBAL: disiobutylaluminium hydride

[0272] DIEA or DIPEA: diisopropylethylamine

[0273] DMA: / V, / V-dimethylacetamide

[0274] DMF: N,N-d\ methyl formamidc

[0275] DMP: Dess-Martin periodinane

[0276] EA: ethyl acetate

[0277] EDCI: l-ethyl-3-(3-dimethylaminopropyl)carbodiimide

[0278] HBTU: N,N,N’N’-tetramethyl-0-(l / / -benzotriazol-l-yl)uroniumhexafluoropho sphate

[0279] HMDS: bis9trimethylsilyl)amine

[0280] HMPA: hexamethylphosphoramide

[0281] LDA: lithium diisopropylamide

[0282] MCPBA: meta-chloroperoxybenzoic acid

[0283] MsCl: methanesulfonyl chloride

[0284] M.W: microwave

[0285] NBS: / V-bromosuccinimide

[0286] NMP: N-methylpyrrolidone

[0287] PCC: pyridinium chlorochromate

[0288] Pd- 118 or Pd(dtpf)Cl2: 1,1’ -bis(di-tert-butylphosphino)ferrocene dichloropalladium

[0289] Pd(dppf)Cl2: l,l’-bis(diphenylphosphino)ferrocene dichloropalladium

[0290] Pd(dba)2: bis(dibenzylideneacetone)palladium

[0291] Pd2(dba)3: Tris(dibenzylideneacetone)dipalladium

[0292] PPTS: pyridium p-tolunesulfonate

[0293] PTSA: p-toluenesulfonic acid

[0294] RuPhos-Pd-G3: XPhos-Pd-G3: [(2-dicyclohexylphosphino-2',6'-diisopropoxy-l,l'- biphenyl)-2-(2 '-amino- 1 , 1 '-biphenyl)] palladium(II) methanesulfonate

[0295] RuPhos-Pd-G2: Chloro[(2-dicyclohexylphosphino-2',6'-diisopropoxy-l,l'-biphenyl)- 2-(2 '-amino- 1 , 1 '-biphenyl)] palladium(II)AVS0044US3

[0296] SFC: supercritical fluid chromatography

[0297] t-BuXPhos-Pd-G3: [(2-di- / er / -butylphosphino-2',4',6'-triisopropyl-l,l'-biphenyl)-2-(2'-amino-l,l'-biphenyl)] palladium(II) methanesulfonate

[0298] TEA: trimethylamine

[0299] TFA: trifluoroacetic acid

[0300] TLC: thin layer chromatography

[0301] TMP: 2,2,6,6-tetramethylpiperidine

[0302] TEMPO: 2,2,6,6-tetramethylpiperidine-N-oxide

[0303] TosCl or TsCl: p-toluenesulfonyl chloride

[0304] TsOH: p-toluenesulfonic acid

[0305] XantPhos: 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene

[0306] XPhos: 2-dicyclohexylphosphino-2’4’6’-triisopropylbiphenyl

[0307] XPhos-Pd-G3: [(2-dicyclohexylphosphino-2',4',6'-triisopropyl-l,l'-biphenyl)-2-(2'- amino- 1,1 '-biphenyl)] palladium(II) methanesulfonate

[0308] 12354-85-7: bis(pentamethylcyclopentadienylrhodium dichloride)

[0309] Scheme 1AVS0044US3

[0310] As shown in Scheme 1, a compound having the WPTMS moiety contains a linking group L which includes a nucleophilic group, such as an amino group. Upon reaction with a compound having a good leaving group LG (for instance, a perfluorosulfonyl group C4F9SO3-), a coupling product is formed. The coupling product reacts with a monoprotected amine molecule WPTM3, under palladium-catalyzed conditions to attach the WPTM3 fragment. Following amine deprotection, a more reactive halogen atom selected from Z’ and Z” in WPTMS-WPTM3 undergoes nucleophilic substitution with the free amino group to form WPTMS -WPTM3-WPTM2, which then reacts with a WPTM2 boronic acid to furnish the PTM binding group including the WPTMS-WPTM3- WPTM2-WPTMI fragment. Following basic-catalyzed ester hydrolysis, the resulting acid is coupled with the ULM portion bearing an amino group to combine the PTM and ULM binding moieties in one molecule.

[0311] Scheme 2AVS0044US3L as a monoprotectedO-activation, then - diol, DIAD, PPh3(Mitsunobu reaction)leaving group displacement with

[0312] As shown in Scheme 2, a Mitsunobu reaction between a hydroxyl-containing moiety R3and a monoprotected diol including the linking group L results in a coupling product.Following O-deprotection, the free hydroxyl group is activated, for example as a sulfonate, and is subsequently displaced with the moiety WPTM5-WPTM3-WPTM2-WPTMI bearing an amino group at WPTM5. After ester hydrolysis, the resulting acid is coupled with the ULM portion bearing an amino group to combine the PTM and ULM binding moieties in one molecule.

[0313] Scheme 3

[0314] As shown in Scheme 3, a vinyl group is first introduced into a bis-halogenated derivative WPTM2. The resulting product then undergoes the palladium-catalyzed Heck coupling reaction with a halogenated moiety WPTM2 bearing a linking group L’ which includes anAVS0044US3 optionally protected amino group. To introduce the WPTMI moiety, the halide portion of WPTM2- WPTM5 is coupled with the appropriate boronic acid under Suzuki conditions, and the resulting amine reacts with the ULM-containing aldehyde to afford the PTM-ULM coupling product.

[0315] Scheme 4

[0316] Scheme 4 illustrates exemplary coupling reactions that are utilized for connecting the PTM-binding moiety WPTM5-WPTM3-WPTM2-WPTMI with the ULM-containing portion. Such reactions may include reductive amination using sodium cyanoborohydride as a reducing agent or condensation coupling reactions between a carboxylic acid and a diamine. A person of ordinary skill in the art would be able to select appropriate reagents and conditions to carry out the desired transformations.

[0317] Scheme 5AVS0044US3

[0318] As shown in Scheme 5, a Mitsunobu-type reaction between the hydroxyl-containing moieties R3and WPTMS results in a coupling product. The halogen atom at WPTMS is then displaced with the monoprotected diamine WPTM3 under Suzuki or Buchwald conditions.Following deprotection of the second amino group, a more reactive halogen atom attached to the WPTM2 moiety is displaced to form the WPTM5-WPTM3-WPTM2 fragment. The resulting monohalide is then reacted with an appropriate boronic acid under Suzuki conditions to afford the PTM-binding moiety WPTM5-WPTM3-WPTM2-WPTM2. Following ester hydrolysis, the resulting acid is then coupled with the ULM portion bearing an amino group to combine the PTM and ULM binding moieties in one molecule.

[0319] Scheme 6AVS0044US3having amino group-containinglinker L'

[0320] As shown in Scheme 6, the acetal-containing ULM moiety may undergo an acid- catalyzed hydrolysis under sufficiently mild conditions to form an aldehyde, which then reacts with the WPTM5-WPTM3-WPTM2-WPTM2 fragment having an amino group-containing linker L’ under reductive amination conditions to form the PTM-ULM coupling product. A person of ordinary skill in the art would be able to select appropriate reagents and conditions to carry out the desired transformations.

[0321] Scheme 7AVS0044US3 hydroxyl activationPGCO >Hhaving amino group-containing linker L'(SN2reaction)

[0322] As shown in Scheme 7, a Mitsunobu-type reaction between the hydroxyl-containing moieties R3and the monoprotected fluorinated diol provides a fluorine-containing intermediate. Following O-deprotection, the free hydroxyl group is activated (for example as a sulfonate) and subsequently displaced with the moiety WPTM5-WPTM3-WPTM2-WPTMI bearing an amino group at WPTM5. After ester hydrolysis, the resulting acid is coupled with the ULM portion bearing an amino group to combine the PTM and ULM binding moieties in one molecule.

[0323] Scheme 8AVS0044US3L'-OLG

[0324] As shown in Scheme 8, nucleophilic displacement of the leaving group in L’-OLG with a hydroxyl group-containing ester including R3results in a coupling product that combines the linkers L’ and L”. Subsequent basic hydrolysis and coupling of the resulting acid with the ULM portion bearing an amino group provides a ULM fragment to which two sequential linking groups L’ and L” are attached. N-deprotection of the amino group of L’ followed by a reductive amination with the WPTM5-WPTM3-WPTM2-WPTMI-L”’ aldehyde or a condensation with the WPTMS- WPTM3-WPTM2-WPTMI-L”’ carboxylic acid affords the PTM-ULM coupling product.

[0325] Scheme 9AVS0044US3

[0326] As shown in Scheme 9, nucleophilic displacement of the fluorine atom in the moiety WPTM5 with a hydroxyl group-containing compound having R3provides a WPTMS-L-R3halide, which is coupled under Suzuki or Buchwald conditions to a monoprotected diamine WPTMS. Following deprotection of the second amino group, the WPTM3-WPTMS-L-R3moiety is then reacted with bis-halogenated WPTM2 by a nucleophilic aromatic substitution to provide a monohalide. A subsequent Suzuki reaction with the appropriate boronic acid provides the WPTMI-WPTM2-WPTM3-WPTM5-L-R3ester. The basic hydrolysis and coupling with a ULM portion bearing an amino group provides the PTM-ULM coupling product.

[0327] One possible approach to synthesize exemplary compounds of the present disclosure is by following the general synthetic route detailed in the scheme below:AVS0044US3base, heat(SNAr reaction) (SNAr reaction)X = O, NH(Buchwald coupling or or Suzuki coupling)Pd catalyst, base, heat(Buchwald coupling or Suzuki coupling)Z, Z'= F, Cl or Br(Suzuki coupling)

[0328] One skilled in the art appreciates that a modified approach can be utilized to attach PTMs via different chemical linkers. For example, in cases where WPTMS is connected to L via a CH2group (X = CH2in the scheme above) one can envision an approach described in the scheme below:AVS0044US3

[0329] Alternatively, ifis not present, PTM of an exemplary compound represented by Formula I can be synthesized according to the general scheme below:Pd catal st

[0330] One skilled in the art will appreciate that the general approaches described herein can be modified to adapt to the specific nature of the WPTMI, WPTM2, WPTM3, WPTM4, WPTMS, WPTM6 and W PTM7 rings. For example, in some embodiments, exemplary compounds represented by Formula II can be prepared as described in the general synthetic scheme below where one skilled in the art would recognize that additional protection / deprotection steps may be required, dependending upon the specific chemical nature of the exemplary compound:n = 0-2 Suzuki coupling deprotection

[0331] In an embodiment, where X represents NH, the exemplary compound can be preparedAVS0044US3 according to one of the two schemes shown below below, depending on whether WPTMS is present:

[0332] Exemplary PTM represented by general Formula III can be prepared following the general approach described for compounds of Formula I when WPMTS is not present.

[0333] Examplary PTM represented by general Formula IV can be prepared according to the following general scheme:AVS0044US3, ca a ys , ,SNAr reaction Cu catalyst, Cu catalyst,Z = Br or I X = O, NH base, heat base, heatZ = Br or I Sonogashira coupling Sonogashira couplingp g

[0334] Example Svthesis of Examplary Compound 11

[0335] Step 1TsCI Et N

[0336] To a mixture of tert-butyl 2-(2-(2-hydroxyethoxy)ethoxy)acetate (l.5g, 6.8 mmol) and TEA (2.07 g, 20.5 mmol) in DCM (5mL) was added TsCl (1.95 g, 10.23 mmol) at 0°C. The resulting mixture was warmed to room temperature and stirred for 3 hours. The solution was quenched with water (20 mL), and extracted with DCM. The organic phase was washed with brine (20 mL x 2). The organic phase was dried over Na2S04, filtered and concentrated. Theresidue was purified by flash chromatography (CH2Cl2:MeOH 40:1) to give tert-butyl 2-(2-(2- (tosyloxy)ethoxy)ethoxy)acetate (2.14 g, mmol, 84% yield).

[0337] Step 2AVS0044US3

[0338] A mixture of 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazole(1.1 lg, 5.722 mmol), tert-butyl 2-(2-(2-(tosyloxy)ethoxy)ethoxy)acetate (2.14 g, 5.722 mmol) and Cs2C03(3.73 g, 1 l.444mmol) in dry DMF (10 mL) was heated to 75°C for 3 hours. The reaction mixture was then cooled to room temperature and diluted with EtOAc (30 mL). The organic layer was washed with water (10 mL) and brine (10 mL x 2), dried (Na2S04), filtered, and concentrated. The crude residue (2.8 g) was used in the next reaction without further purification.

[0339] Step 3

[0340] A mixture of tert-butyl 2-(2-(2-(4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH- pyrazol-l-yl)ethoxy)ethoxy)acetate (1.5 g, 3.79 mmol), 4-bromo-6-chloropyridazin-3-amine (l.lg, 5.69 mmol), PdCl2(dppf) (555mg, 0.758 mmol), tBuPHBF4(44lmg, 1.52 mmol) and Cs2C03(3.09 g, 9.48 mmol) in dioxane (10 ml) and water (lml) was heated to l00°C with stirring for 3 hour under N2. The solid was filtered off, and the filtrate was concentrated. The residue was purified by chromatography (CH2Cl2:MeOH 30:1) to give tert-butyl 2-(2-(2-(4-(3- amino-6-chloropyridazin-4-yl)-lH-pyrazol-l-yl)ethoxy)ethoxy)acetate (800 mg, 53% yield).

[0341] Step 4

[0342] A suspension of tert-butyl 2-(2-(2-(4-(3-amino-6-chloropyridazin-4-yl)-lH-pyrazol-l- yl)ethoxy)ethoxy)acetate (800 mg, 2.02 mmol), (2-hydroxyphenyl)boronic acid (418 mg, 3.03 mmol), cesium carbonate (1.65 g, 5.05 mmol), PdCl2(dppf) (444 mg, 0.606mmol), andlBu3PHBF4(352 mg, 1.212 mmol) in dioxane (10 mL) and water (1 mL) was heated to l00°C under nitrogen for 3 hours. The mixture was cooled to room temperature and the solid was filtered off. The filtrate was concentrated and purified by chromatography (CH2Cl2:MeOH 40:1) to afford tert-butyl 2-(2-(2-(4-(3-amino-6-(2-hydroxyphenyl)pyridazin-4-yl)-lH-pyrazol-l- yl)ethoxy)ethoxy)acetate (400 mg, 44% yield).AVS0044US3

[0343] Step 5

[0344] To a solution of tert-butyl 2-(2-(2-(4-(3-amino-6-(2-hydroxyphenyl)pyridazin-4-yl)- lH-pyrazol-l-yl)ethoxy)ethoxy)acetate (400 mg, O.88mmol) in THF / H20 (5 mL, 2:1) was added LiOH (111 mg, 2.64mmol) at 0°C. The mixture was stirred at 0°C for 2 hours. The reaction solution was quenched with 1 M HC1. The solution was dried (Na2S04), filtered andconcentrated under reduced pressure to afford crude 2-(2-(2-(4-(3-amino-6-(2- hydroxyphenyl)pyridazin-4-yl)-lH-pyrazol-l-yl)ethoxy)ethoxy)acetic acid (600 mg), which was used in the next step without further purification.

[0345] Step 6

[0346] To a solution of 2-(2-(2-(4-(3-amino-6-(2-hydroxyphenyl)pyridazin-4-yl)-lH- pyrazol-l-yl)ethoxy)ethoxy)acetic acid (200 mg crude), (2S,4R)-l-((S)-2-amino-3,3- dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (430 mg, 1 mmol), and DIPEA (516 mg, 4 mmol) in DMF (5mL) was added HATU (570 mg, 1.5 mmol) at 0°C. The reaction mixture was stirred at room temperature for 30 minutes. The mixture was extracted with ethyl acetate (50 mL). The combined organic phases were washed with brine (8 mL x 2), dried (Na2S04), and filtered. The organic layer was concentrated under reduced pressure. The residue was purified by prep TLC (6% MeOH in DCM) to afford (2S,4R)-l-((S)-2- (2-(2-(2-(4-(3-amino-6-(2-hydroxyphenyl)pyridazin-4-yl)-lH-pyrazol-l- yl)ethoxy)ethoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5- yl)benzyl)pyrrolidine-2-carboxamide (22 mg).AVS0044US3

[0347] 1HNMR (400 MHz, MeOD) : d 8.83 (s, 1H), 8.32 (s, 1H), 8.04 (d, J = 9.6 Hz, 2H), 7.78 (d, / = 7.6 Hz, 1H), 7.65 (d, / = 10.0 Hz, 1H), 7.39 (d, / = 8.0 Hz, 2H), 7.32-7.34 (m, 2H), 7.28 (m, 1H), 6.95 (d, / = 7.6 Hz 2H), 4.69 (d, / = 9.6 Hz 1H), 4.44-4.57 (m, 6H), 4.25-4.35 (m, 1H), 3.60-3.99 (m, 11H), 2.46 (s, 3H), 2.23 (m, 1H), 2.08 (m, 1H), 1.01 (s, 9H).

[0348] Exemplary Compound 5 was prepared using procedures analogous to those described above for Exemplary Compound 11 as well as procedures known and appreciated to those skilled in the art according to the scheme below:AVS0044US3

[0349] Procedures described for Exemplary Compound 11 and Exemplary Compound 5 were used to prepare: Exemplary Compound 1, Exemplary Compound 2, Exemplary Compound 3, Exemplary Compound 4.AVS0044US3

[0350] Exemplary Synthesis of Exemplary Compound 9

[0351] Step 1

[0352] To a solution of 3,6,9, l2-tetraoxatetradecane-l,l4-diol (13.5 g, 56.8 mmol) in anhydrous DMF (30 mL) was added 60% NaH (1.25 g, 31.2 mmol) at 0°C. The reaction mixture was stirred at room temperature for 0.5 hour. Then 4-bromo-2-fluoropyridine (5 g, 28.4 mmol) was added to the mixture dropwise, and the mixture was heated to 75°C for 2 hours. The reaction mixture was quenched with water (10 mL) and extracted with EA (200 mL). The organic phase was washed with brine (10 mL), dried (Na2S04) and concentrated under reduced pressure. The residue was purified by silica gel column to afford l4-((4-bromopyridin-2-yl)oxy)-3,6,9,l2- tetraoxatetradecan-l-ol (9.0 g, 22.9 mmol, 81% yield).

[0353] Step 2

[0354] To a solution of l4-((4-bromopyridin-2-yl)oxy)-3,6,9,l2-tetraoxatetradecan-l-ol (5.0 g, 12.7 mmol) in anhydrous THF (50 mL) was added 60% NaH (660 mg, 16.5 mmol) at 0°C. The reaction mixture was stirred at room temperature for 40 minutes. Then tert-butyl 2- bromoacetate (4.9 g, 25.4 mmol) was added dropwise to the mixture and stirred at room temperature overnight. The reaction mixture was quenched with 2N NH4Cl (10 mL) and extracted with EA (200 mL). Then the organic phase was washed with brine (10 mL), dried (Na2S04), and concentrated under reduced pressure. The residue was purified by silica gel column to afford tert-butyl l7-((4-bromopyridin-2-yl)oxy)-3,6,9,l2,l5-pentaoxaheptadecanoate (2.6 g, 5.13 mmol, 40% yield).

[0355] Step 3AVS0044US3

[0356] A mixture of tert-butyl l7-((4-bromopyridin-2-yl)oxy)-3,6,9,l2,l5- pentaoxaheptadecanoate (250 mg, 1.18 mmol), tert-butyl 3,8-diazabicyclo[3.2.l]octane-3- carboxylate (718 mg, 1.4 mmol), cesium carbonate (769 mg, 2.36 mmol), Pd2(dba)3(110 mg, 0.12 mmol) and XantPhos (138 mg, 0.24 mmol) in dioxane (5 mL) in a seal tube was heated to 1 l0°C under nitrogen overnight. The mixture was extracted with EA (100 mL). Then the organic phase was washed with water (10 mL), brine (10 mL), dried (Na2S04), and concentrated under reduced pressure. The residue was purified by silica gel column to afford tert-butyl 8-(2-((l9, 19- dimethyl- 17-oco-3,6,9, 12, 15, l8-hexaoxaicosyl)oxy)pyridin-4-yl)-3,8-diazabicyclo[3.2. l]octane- 3-carboxylate (550 mg, 0.86 mmol, 73 % yield).

[0357] Step 4

[0358] To a solution of tert-butyl 8-(2-((l9,l9-dimethyl-l7-oxo-3,6,9,l2,l5,l8- hexaoxaicosyl)oxy)pyridin-4-yl)-3,8-diazabicyclo[3.2.l]octane-3-carboxylate (550 mg, 0.86 mmol) in MeOH (l5mL) was added HC1 in dioxane (6N in dioxane) (5 ml, 30 mmol) at rt. The reaction mixture was stirred at room temperature for 1 hour. The mixture was concentrated under reduced pressure to afford crude methyl l7-((4-(3,8-diazabicyclo[3.2.l]octan-8-yl)pyridin-2- yl)oxy)-3,6,9,l2,l5-pentaoxaheptadecanoate (0.55 g).

[0359] Step 5

[0360] To a solution of crude methyl l7-((4-(3,8-diazabicyclo[3.2.l]octan-8-yl)pyridin-2- yl)oxy)-3,6,9,l2,l5-pentaoxaheptadecanoate (550 mg crude) in DMSO (5mL) were added 5- bromo-6-chloropyridazin-3-amine (526 mg, 2.71 mmol) and DIPEA (1.87 g, 14.5 mmol). The solution was stirred at l50°C overnight. The mixture was extracted with EA (60 mL). The organic phase was washed with water (8 mL) and brine (8 mL). The organic layer was dried (Na2S04), filtered and concentrated under reduced pressure. The residue was purified by silicaAVS0044US3 gel column chromatography to afford methyl l7-((4-((lR,5S)-3-(3-amino-6-chloropyridazin-4- yl)-3,8-diazabicyclo[3.2.l]octan-8-yl)pyridin-2-yl)oxy)-3,6,9,l2,l5-pentaoxaheptadecanoate (400 mg).

[0361] Step 6

[0362] To a solution of methyl l7-((4-((lR,5S)-3-(3-amino-6-chloropyridazin-4-yl)-3,8- diazabicyclo[3.2.l]octan-8-yl)pyridin-2-yl)oxy)-3,6,9,l2,l5-pentaoxaheptadecanoate (325 mg, 0.52 mmol) and (2-hydroxyphenyl)boronic acid (93 mg, 0.68 mmol) in dioxane (12 mL) and water (1.2 mL) were added cesium carbonate (542 mg, 1.66 mmol), PdCl2(dppf) (73.2 mg, 0.1 mmol) and i-Bu3PHBF4(58 mg, 0.2 mmol). The solution was stirred at l00°C under nitrogen atmosphere for 4 hours. The pH of the solution was adjusted to 5 with 1N HC1. The mixture was filtered and the filtrate was concentrated under reduced pressure to afford the crude l7-((4- ((lR,5S)-3-(3-amino-6-(2-hydroxyphenyl)pyridazin-4-yl)-3,8-diazabicyclo[3.2.l]octan-8- yl)pyridin-2-yl)oxy)-3,6,9,l2,l5-pentaoxaheptadecanoic acid (300 mg), which was used in the next step without further purification.

[0363] Step 7

[0364] To a solution of crude l7-((4-((lR,5S)-3-(3-amino-6-(2-hydroxyphenyl)pyridazin-4- yl)-3,8-diazabicyclo[3.2.l]octan-8-yl)pyridin-2-yl)oxy)-3,6,9,l2,l5-pentaoxaheptadecanoic acid (80 mg, 0.12 mmol) and (2S,4R)-l-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4- methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (108 mg, 0.24 mmol) in DMF (5mL) were added DIPEA (124 mg, 0.96 mmol) and HATU (92 mg, 0.24 mmol) at 0°C. The reactionAVS0044US3 mixture was stirred at rt for 30 minutes. The mixture was extracted with EA (50 mL). The organic phase was washed with water (8 mL) and brine (8 mL). The organic layer was dried (Na2S04), filtered and concentrated under reduced pressure. The residue was purified by prep TLC (6% MeOH in DCM) to afford (2S,4R)-l-((S)-20-((4-((lR,5S)-3-(3-amino-6-(2- hydroxyphenyl)pyridazin-4-yl)-3,8-diazabicyclo[3.2.l]octan-8-yl)pyridin-2-yl)oxy)-2-(tert- butyl)-4-oxo-6,9,l2,l5,l8-pentaoxa-3-azaicosanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5- yl)benzyl)pyrrolidine-2-carboxamide (20 mg, 0.018 mmol, 15.0% yield).

[0365] 1H NMR (400 MHz, MeOD): d 8.74 (s, 1H), 7.68-7.66 (m, 2H), 7.34-7.28 (m, 5H), 7.18-7.10 (m, 1H), 6.80-6.78 (m, 2H), 6.43-6.40 (m, 1H), 6.10 (s, 1H), 4.60-4.20 (m, 9H), 3.92- 3.89 (m, 2H), 3.80-3.64 (m, 4H), 3.71-3.45 (m, 16H), 3.10-3.00 (m, 1H), 3.00-2.90 (m, 2H), 2.37-2.34 (m, 1H), 2.35 (s, 3H), 2.18-1.99 (m, 6H), 0.92 (s, 9H).

[0366] Using analogous procedures, Exemplary Compounds 7, 8, 10 and 35 were prepared.

[0367] Exemplary Synthesis of Exemplary Compound 6

[0368] Step 1TEMPO Phl(OAc)

[0369] To a solution of 2-(2-(2-(2-((4-bromopyridin-2-yl)oxy)ethoxy)ethoxy)ethoxy)ethan- l-ol (3.49 g, 10 mmol) [prepared using procedure analogous to that described for example A2979] in DCM (50 mL) and H20 (25 mL) were added PhI(OAc)2(9.66 g, 30 mmol) and TEMPO (312 mg, 2 mmol). The reaction mixture was stirred at room temperature for 2 hours. The mixture was extracted with EA (100 mL). The organic phase was washed with water (10 ml) and brine (10 ml). The organic layer was dried (Na2S04), filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to afford 2-(2- (2-(2-((4-bromopyridin-2-yl)oxy)ethoxy)ethoxy)ethoxy)acetic acid (3.5 g, 9.64 mmol, 96% yield).

[0370] Step 2AVS0044US3

[0371] To a solution of 2-(2-(2-(2-((4-bromopyridin-2-yl)oxy)ethoxy)ethoxy)ethoxy)acetic acid (3.0 g, 8.26 mmol) in MeOH (30 mL) was added SOCl2(4.0 g, 33.9 mmol) dropwise at 0°C. The reaction mixture was stirred at room temperature for 4 hours. The pH of the solution was adjusted to ~8 with saturated NaHC03. The mixture was extracted with DCM (100 mL). The organic phase was washed with water (10 mL) and brine (10 mL). The organic layer was dried (Na2S04), filtered and concentrated under reduced pressure to afford methyl 2-(2-(2-(2-((4- bromopyridin-2-yl)oxy)ethoxy)ethoxy)ethoxy)acetate (2.9 g, 7.69 mmol, 93% yield).

[0372] Methyl 2-(2-(2-(2-((4-bromopyridin-2-yl)oxy)ethoxy)ethoxy)ethoxy)acetate was converted to the final compound, (2S,4R)-l-((2S)-l4-((4-(3-(3-amino-6-(2- hydroxyphenyl)pyridazin-4-yl)-3,8-diazabicyclo[3.2.l]octan-8-yl)pyridin-2-yl)oxy)-2-(tert- butyl)-4-oxo-6,9,l2-trioxa-3-azatetradecanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5- yl)benzyl)pyrrolidine-2-carboxamide (Exemplary Compound 6) using procedures analogous to those described for Exemplary Compound 9.

[0373] 1HNMR (400 MHz, MeOD): d 8.82 (s, 1H), 7.76-7.74 (m, 2H), 7.42-7.34 (m, 5H), 7.22-7.18 (m, 1H), 6.89-6.86 (m, 2H), 6.53-6.52 (m, 1H), 6.16 (s, 1H), 4.66-4.28 (m, 9H), 4.01-4.00 (m, 2H), 3.82-3.60 (m, 12H), 3.31-3.29 (m, 1H), 3.10-3.08 (m, 2H), 2.51-2.50 (m, 1H), 2.49 (s, 3H), 2.29-2.05 (m, 6H), 2.42-2.29 (m, 2H), 1.01 (s, 9H).

[0374] Exemplary Synthesis of Exemplary Compound 20

[0375] Step 1

[0376] To a solution of 3,6,9,l2,l5-pentaoxaheptadecane-l,l7-diol (4 g, 14.2 mmol) and Et3N (8.6 g, 85.2 mmol)in DCM (50 mL) was added TsCl (8.1 g, 42.6 mmol). The reaction mixture was stirred at room temperature for 1 hour. The mixture was partitioned between EtOAc (100 mL) and water (10 mL). The organic phase was washed with brine (10 mL). The combined organic layers were dried (Na2S04), filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to afford 3,6,9,12,15- pentaoxaheptadecane-l,l7-diyl bis(4-methylbenzenesulfonate) (6.0 g, 10.2 mmol, 72% yield).

[0377] Step 2AVS0044US3

[0378] To a solution of 3,6,9,l2,l5-pentaoxaheptadecane-l,l7-diyl bis(4- methylbenzenesulfonate) (3.5 g, 5.93 mmol) in anhydrous DMF (20 mL) were added 4-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazole (1.15 g, 5.93 mmol) and Cs2C03(3.87 g,11.86 mmol). The reaction mixture was stirred at 75°C for 0.5 hour. The mixture was cooled to rt and partitioned between EtOAc (200 mL) and water (20 mL). The organic phase was washed with brine (20 mL). The combined organic layers were dried (Na2S04), filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to afford l7-(4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazol-l-yl)-3,6,9,l2,l5- pentaoxaheptadecyl 4-methylbenzenesulfonate (0.6 g, 0.98 mmol, 16.5% yield).

[0379] Step 3

[0380] To a solution of l7-(4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazol-l- yl)-3,6,9,l2,l5-pentaoxaheptadecyl 4-methylbenzenesulfonate (0.3 g, 0.49 mmol) and (2S,4R)- 4-hydroxy-N-(2-hydroxy-4-(4-methylthiazol-5-yl)benzyl)-l-((S)-3-methyl-2-(l-oxoisoindolin-2- yl)butanoyl)pyrrolidine-2-carboxamide (268 mg, 0.49 mmol) in DMF (5 mL) was added K2C03(135 mg, 0.98 mmol). The mixture was stirred at 80°C under nitrogen atmosphere for 2 hours. The mixture was extracted with EA (80 mL). The organic phase was washed with water (10 mL) and brine (10 mL). The organic layer was dried (Na2S04), filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to afford aAVS0044US3 mixture of (2S,4R)-4-hydroxy-l-((S)-3-methyl-2-(l-oxoisoindolin-2-yl)butanoyl)-N-(4-(4- methylthiazol-5-yl)-2-((l7-(4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazol-l-yl)- 3,6,9,l2,l5-pentaoxaheptadecyl)oxy)benzyl)pyrrolidine-2-carboxamide and (l-(l7-(2-(((2S,4R)- 4-hydroxy-l-((S)-3-methyl-2-(l-oxoisoindolin-2-yl)butanoyl)pyrrolidine-2- carboxamido)methyl)-5-(4-methylthiazol-5-yl)phenoxy)-3,6,9,l2,l5-pentaoxaheptadecyl)-lH- pyrazol-4-yl)boronic acid (270 mg, 0.27 mmol, 56% yield).

[0381] Step 4

[0382] To a solution of the mixture of (2S,4R)-4-hydroxy-l-((S)-3-methyl-2-(l- oxoisoindolin-2-yl)butanoyl)-N-(4-(4-methylthiazol-5-yl)-2-((l7-(4-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)-lH-pyrazol-l-yl)-3,6,9,l2,l5-pentaoxaheptadecyl)oxy)benzyl)pyrrolidine-2- carboxamide and (l-(l7-(2-(((2S,4R)-4-hydroxy-l-((S)-3-methyl-2-(l-oxoisoindolin-2- yl)butanoyl)pyrrolidine-2-carboxamido)methyl)-5-(4-methylthiazol-5-yl)phenoxy)-3,6,9,l2,l5- pentaoxaheptadecyl)-lH-pyrazol-4-yl)boronic acid (270 mg, 0.27 mmol) and 5-bromo-6- chloropyridazin-3-amine (85 mg, 0.41 mmol) in dioxane (20 mL) and water (2 mL) were added cesium carbonate (220 mg, 0.68 mmol), PdCl2(dppf) (40 mg, 0.054 mmol) and / -BU3PHBF4 (31 mg, 0.11 mmol). The solution was stirred at l00°C under nitrogen atmosphere for 4 hours. The mixture was concentrated under reduced pressure. The residue was purified by silica gel columnAVS0044US3 chromatography to afford (2S,4R)-N-(2-((l7-(4-(3-amino-6-chloropyridazin-4-yl)-lH-pyrazol-l- yl)-3,6,9,l2,l5-pentaoxaheptadecyl)oxy)-4-(4-methylthiazol-5-yl)benzyl)-4-hydroxy-l-((S)-3- methyl-2-(l-oxoisoindolin-2-yl)butanoyl)pyrrolidine-2-carboxamide (175 mg, 0.18 mmol, 67% yield).

[0383] Step 5

[0384] To a solution of (2S,4R)-N-(2-((l7-(4-(3-amino-6-chloropyridazin-4-yl)-lH-pyrazol- l-yl)-3,6,9,l2,l5-pentaoxaheptadecyl)oxy)-4-(4-methylthiazol-5-yl)benzyl)-4-hydroxy-l-((S)-3- methyl-2-(l-oxoisoindolin-2-yl)butanoyl)pyrrolidine-2-carboxamide (175 mg, 0.18 mmol) and (2-hydroxyphenyl)boronic acid (32 mg, 0.23 mmol) in dioxane (15 mL) and water (1.5 mL) were added cesium carbonate (176 mg, 0.54 mmol), PdCl2(dppf) (53 mg, 0.072 mmol) and t- BU3PHBF4(42 mg, 0.144 mmol). The solution was stirred at l00°C under nitrogen atmosphere for 4 hours. The mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to afford (2S,4R)-N-(2-((l7-(4-(3-amino-6-(2- hydroxyphenyl)pyridazin-4-yl)-lH-pyrazol-l-yl)-3,6,9,l2,l5-pentaoxaheptadecyl)oxy)-4-(4- methylthiazol-5-yl)benzyl)-4-hydroxy- 1 -((S )-3 -methyl-2-( 1 -oxoisoindolin-2- yl)butanoyl)pyrrolidine-2-carboxamide (24 mg, 0.023 mmol, 13% yield).AVS0044US3

[0385] 1HNMR (400 MHz, MeOD): d 8.84 (s, 1H), 8.28 (s, 1H), 8.05 (d, J = 12.4 Hz, 2H), 7.38-7.81 (m, 6H), 7.36-7.37 (m, 1H), 6.98-7.00(m, 2H), 6.92 (d, J = 7.6 Hz, 2H), 1 -A.59 (m, 9H), 4.15-4.16 (m, 2H), 3.83-3.96 (m, 6H), 3.46-3.56 (m, 16H), 2.46 (s, 3H), 2.44-2.45 (m, 1H), 2.21-2.22 (m, 1H), 2.09-2.10 (m, 1H), 1.03 (d, J = 6.4 Hz, 3H), 0.82 (d, J = 6.4 Hz, 3H).

[0386] Using procedures analogous to those described for Exemplary Compound 20, Exemplary Compounds 12, 13, and 21 were prepared.

[0387] Exemplary Synthesis of Exemplary Compound 14

[0388] Step 1

[0389] Into a 250-mL round-bottom flask, was placed a solution of 4-(tetramethyl- 1,3,2- dioxaborolan-2-yl)-lH-pyrazole (1.5 g, 7.73 mmol, 1.00 equiv) in dioxane / H20 (1:1) (60 mL), 4- bromo-6-chloropyridazin-3-amine (1.7 g, 8.16 mmol, 1.20 equiv), Pd(PPh3)4(800 mg, 0.69 mmol, 0.10 equiv), potassium carbonate (2.9 g, 20.98 mmol, 3.00 equiv). The resulting solution was stirred overnight at l00°C in an oil bath. The residue was applied onto a silica gel column with dichloromethane / methanol (10:1). This resulted in 1.0 g (66%) of 6-chloro-4-(lH-pyrazol- 4-yl)pyridazin-3-amine as a white solid.

[0390] Step 2

[0391] Into a l0-mL sealed tube, was placed a solution of 6-chloro-4-(lH-pyrazol-4- yl)pyridazin-3-amine (390 mg, 1.99 mmol, 1.00 equiv) in dioxane (4 mL), [2- (methoxymethoxy)phenyl]boronic acid (546 mg, 3.00 mmol, 1.50 equiv), Pd(PPh3)4(300 mg, 0.26 mmol, 0.20 equiv), a solution of potassium carbonate (552 mg, 3.99 mmol, 2.00 equiv) inAVS0044US3 water (2 mL). The resulting solution was stirred for 12 hours at l00°C in an oil bath. The resulting mixture was concentrated under vacuum. The residue was applied onto a silica gel column with dichloromethane / methanol (10:1). This resulted in 120 mg (20%) of 6-[2- (methoxymethoxy)phenyl]-4-(lH-pyrazol-4-yl)pyridazin-3-amine as a yellow solid.

[0392] Step 3

[0393] Into a 50-mL round-bottom flask, was placed a solution of 6-[2- (methoxymethoxy)phenyl]-4-(lH-pyrazol-4-yl)pyridazin-3-amine (100 mg, 0.34 mmol, 1.00 equiv) in N,N-dimethylformamide (10 mL), 2-[2-(2-[[(4-methylbenzene)sulfonyl]oxy] ethoxy)ethoxy]ethan-l-ol (100 mg, 0.33 mmol, 1.00 equiv), potassium carbonate (91 mg, 0.66 mmol, 2.00 equiv). The resulting solution was stirred for 12 hours at 70°C in an oil bath. The resulting solution was extracted with ethyl acetate (20 mL x3) and the organic layers combined and concentrated under vacuum. The residue was applied onto a silica gel column with dichloromethane / methanol (10:1). This resulted in 100 mg (69%) of 2-[2-[2-(4-[3-amino-6-[2- (methoxymethoxy)phenyl]pyridazin-4-yl]- lH-pyrazol- l-yl)ethoxy] ethoxy] ethan- l-ol as yellow oil.

[0394] Step 4

[0395] Into a lOO-mL round-bottom flask, was placed a solution of 2-[2-[2-(4-[3-amino-6-[2- (methoxymethoxy)phenyl]pyridazin-4-yl]- lH-pyrazol- l-yl)ethoxy] ethoxy] ethan- l-ol (100 mg, 0.23 mmol, 1.00 equiv) in dichloromethane (20 mL), 4-toluene sulfonyl chloride (66.0 mg, 0.35 mmol, 1.50 equiv), triethylamine (47 mg, 0.46 mmol, 2.00 equiv), 4-dimethylaminopyridine (10 mg, 0.08 mmol, 0.30 equiv). The resulting solution was stirred for 16 hours at room temperature. The resulting solution was extracted with ethyl acetate (20 mL x 3) and the organic layersAVS0044US3 combined and concentrated under vacuum. The residue was applied onto a silica gel column eluting with dichloromethane / methanol (10:1). This resulted in 100 mg (74%) of 2-[2-[2-(4-[3- amino-6-[2-(methoxymethoxy)phenyl]pyridazin-4-yl]-lH-pyrazol-l-yl)ethoxy]ethoxy]ethyl 4- methylbenzene- 1 -sulfonate as a yellow oil.

[0396] Step 5

[0397] Into a 50-mL round-bottom flask, was placed a solution of 2-[2-[2-(4-[3-amino-6-[2- (methoxymethoxy)phenyl]pyridazin-4-yl]- lH-pyrazol- l-yl)ethoxy] ethoxy] ethyl 4- methylbenzene- 1 -sulfonate (120 mg, 0.2 mmol, 1.00 equiv) in N,N-dimethylformamide (5 mL), (2S,4R)-4-hydroxy-l-[2-(3-hydroxy-l,2-oxazol-5-yl)-3-methylbutanoyl]-N-[[4-(4-methyl-l,3- thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide (130 mg, 0.2 mmol, 1.00 equiv)[prepared as described by Qian, Y. et al. in WO 2017 / 030814], potassium carbonate (100 mg, 0.4 mmol, 2.00 equiv). The resulting solution was stirred for 12 hours at 70°C. The resulting solution was extracted with ethyl acetate (20 mL x 3), and the organic layers were combined and concentrated under vacuum. The residue was applied onto a silica gel column eluting with dichloromethane / methanol (10:1). This resulted in 90 mg of (2S,4R)-l-[2-[3-(2-[2-[2-(4-[3- amino-6-[2-(methoxymethoxy)phenyl]pyridazin-4-yl]- lH-pyrazol- l-yl)ethoxy]ethoxy]ethoxy)-AVS0044US31 ,2-oxazol-5-yl] -3 -methylbutanoyl] -4-hydroxy-N- [ [4-(4-methyl- 1 ,3 -thiazol-5- yl)phenyl]methyl]pyrrolidine-2-carboxamide as a colorless oil.

[0398] Step 6

[0399] Into a 50-mL round-bottom flask, was placed a solution of (2S,4R)-l-[2-[3-(2-[2-[2- (4-[3-amino-6-[2-(methoxymethoxy) phenyl]pyridazin-4-yl]-lH-pyrazol-l- yl)ethoxy] ethoxy] ethoxy)- 1 ,2-oxazol-5-yl] -3 -methylbutanoyl] -4-hydroxy-N- [ [4-(4-methyl- 1,3- thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide (90.0 mg, 0.10 mmol, 1.00 equiv) in i- propanol (2 mL) and tetrahydrofuran (2 mL), and a solution of concentrated hydrogen chloride solution (12N , 2 mL) was added. The resulting solution was stirred for 1 hour at room temperature. The resulting mixture was concentrated under vacuum. The crude product was purified by Prep-HPLC with the following conditions: Column: XBridge C18 OBD Prep Column , 100A, 5 pm, 19 mm X 250 mm; Mobile Phase A:Water(0. l%FA), Mobile Phase B: ACN; Flow rate: 20 mL / min; Gradient: 32% B to 41% B in 8 min; 254 nm; Rt: 70 min. This resulted in 56 mg (65%) of (2S,4R)-l-[2-(3-[2-[2-(2-[4-[3-amino-6-(2-hydroxyphenyl)pyridazin-AVS0044US34-yl] - 1 H-pyrazol- 1 -yl] ethoxy)ethoxy] ethoxy] - 1 ,2-oxazol-5-yl)-3 -methylbutanoyl] -4-hydroxy-N- [[4-(4-methyl-l,3-thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide as a white solid.

[0400] The product was purified by Chiral-Prep-HPLC with the following conditions:Column, CHIRAL ART Cellulose-SB, 2*25cm,5um; mobile phase, Hex— HPLC and ethanol— HPLC (hold 50% ethanol— HPLC in 24 min); Detector, UV 220 / 254nm. This resulted in 17.8 mg (34% ) of (2S ,4R)- 1 - [(2S )-2-(3 - [2- [2-(2- [4- [3 -amino-6-(2-hydroxyphenyl)pyridazin-4-yl] - 1 H- pyrazol- 1 -yl] ethoxy)ethoxy] ethoxy] - 1 ,2-oxazol-5-yl)-3 -methylbutanoyl] -4-hydroxy-N- [ [4-(4- methyl-l,3-thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide as a white solid [ ' H NMR (300 MHz, CD3OD): d 8.82 (d, J = 11.1 Hz, 1H), 8.29 - 8.18 (m, 1H), 8.11-7.89 (m, 2H), 7.80 (d, J = 8.2 Hz, 1H), 7.48-7.41 (m, 1H), 7.37-7.30 (m, 3H), 7.30 - 7.19 (m, 1H), 6.95-6.83 (m, 2H), 5.89 (s, 1H), 4.59- 4.41 (m, 2H), 4.40-4.30 (m, 4H), 4.27- 4.11 (m, 2H), 3.86 (q, J = 5.3 Hz, 2H), 3.75- 3.59 (m, 6H), 3.56 (s, 3H), 2.42 (d, J = 5.0 Hz, 3H), 2.36 - 2.10 (m, 2H), 2.04-2.01 (m, J = 13.1, 8.1, 4.7 Hz, 1H), 1.26 (s, 1H), 0.99 (d, J = 6.6 Hz, 3H), 0.83 (d, J = 6.8 Hz, 3H)] and 24.4 mg (47%) of (2S,4R)-l-[(2R)-2-(3-[2-[2-(2-[4-[3-amino-6-(2-hydroxyphenyl)pyridazin-4-yl]- 1 H-pyrazol- 1 -yl] ethoxy)ethoxy] ethoxy] - 1 ,2-oxazol-5-yl)-3 -methylbutanoyl] -4-hydroxy-N- [ [4- (4-methyl-l,3-thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide [ ' H NMR (300 MHz, CD3OD): d 8.82 (d, J = 6.6 Hz, 1H), 8.26 (dd, J = 3.1, 0.8 Hz, 1H), 8.10 -7.96 (m, 2H), 7.86 - 7.75 (m, 1H), 7.45-7.30 (m, 4H), 7.25-7.22 (m, 1H), 6.96- 6.84 (m, 2H), 5.88 (s, 1H), 4.70- 4.42 (m, 3H), 4.41- 4.33 (m, 3H), 4.28 - 4.17 (m, 2H), 3.87 (t, J = 5.0 Hz, 3H), 3.85 -3.63 (m, 2H), 3.59-3.57 (m, 6H), 2.41 (d, J = 12.2 Hz, 3H), 2.38-2.33(m, 1H), 2.25-2.12 (m, 1H), 2.06-2.02 (m, 1H), 1.26 (s, 1H), 0.97 (dd, J = 6.6, 1.8 Hz, 3H), 0.80 (dd, J = 6.6, 1.8 Hz, 3H)] as a white solid.

[0401] Exemplary Compounds 16, 17, 18, and 19 were prepared wsing procedures described above for Exemplary Compound 14 and Exemplary Compound 15.

[0402] Exemplary Synthesis of Exemplary Compound 22

[0403] Step 1

[0404] Into a 250-mL round-bottom flask, was placed (Z)-4-(benzyloxy)-N- hydroxybutcarbonimidoyl chloride (8.7 g, 38.21 mmol, 1.00 equiv), but-3-yn-l-ol (3.3 g, 47.08AVS0044US3 mmol, 1.23 equiv), ethyl acetate (70 mL), water(70 mL), sodium bicarbonate (4.0 g, 47.61 mmol, 1.25 equiv). The resulting solution was stirred for 2 hours at 25°C. The resulting solution was extracted with ethyl acetate and washed with saturated sodium chloride aqueous solution. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column eluting with ethyl acetate / petroleum ether (1:1). This resulted in 5.9 g (59%) of 2-[3-[3-(benzyloxy)propyl]-l,2-oxazol-5-yl]ethan-l-ol as a yellow oil.

[0405] Step 2

[0406] Into a lOO-mL round-bottom flask, was placed 2-[3-[3-(benzyloxy)propyl]-l,2- oxazol-5-yl]ethan-l-ol (550.0 mg, 2.10 mmol, 1.00 equiv), acetone (30 mL), Cr203(100.0 mg), sulfuric acid (0.25 mL), water(l mL). The resulting solution was stirred for 1 hour at 25°C. The resulting solution was diluted with water. The resulting solution was extracted with ethyl acetate and washed with saturated sodium chloride aqueous solution. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. This resulted in 420 mg (72%) of 2- [3-[3-(benzyloxy)propyl]-l,2-oxazol-5-yl]acetic acid as a yellow oil.

[0407] Step 3

[0408] Into a 250-mL round-bottom flask, was placed ethyl 2-[3-[3-(benzyloxy)propyl]-l,2- oxazol-5-yl] acetate (8.0 g, 26.37 mmol, 1.00 equiv), ethanol (50 mL), sulfuric acid (0.1 mL). The resulting solution was stirred for 1.5 hours at 70°C. The resulting mixture was concentrated under vacuum. The crude product was purified by Flash-Prep-HPLC with the following conditions: Column, C18 silica gel; mobile phase, acetonitrile:water = 0:100 increasing to acetonitrile:water = 60:40 within 49 min; Detector, UV 220 nm. This resulted in 4.5 g (56%) of ethyl 2-[3-[3-(benzyloxy)propyl]-l,2-oxazol-5-yl]acetate as a light yellow oil.

[0409] Step 4AVS0044US3, ,

[0410] Into a 250-mL 3-necked round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed ethyl 2-[3-[3-(benzyloxy)propyl]-l,2-oxazol-5-yl]acetate (4.5 g, 14.83 mmol, 1.00 equiv) and tetrahydrofuran (70 mL). This was followed by the addition of a solution of t-BuOK (2.0 g, 17.82 mmol, 1.20 equiv) in tetrahydrofuran (17.8 mL) dropwise with stirring at 0°C in 20 minutes. To this was added 2-iodopropane (3.01 g, 17.71 mmol, 1.19 equiv) dropwise with stirring at 0°C in 2 minutes. The resulting solution was stirred for 2 hours at 25°C. The reaction was then quenched by the water. The resulting solution was extracted with ethyl acetate and washed with saturated sodium chloride aqueous solution. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. This resulted in 4.3 g (84%) of ethyl 2-[3-[3-(benzyloxy)propyl]-l,2-oxazol-5-yl]-3-methylbutanoate as an orange oil.

[0411] Step 5

[0412] Into a 250-mL 3-necked round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed ethyl 2-[3-[3-(benzyloxy)propyl]-l,2-oxazol-5-yl]-3- methylbutanoate (4.2 g, 12.16 mmol, 1.00 equiv) and dichloromethane (100 mL). This was followed by the addition of a solution of BBr3(5.17 g, 20.64 mmol, 1.70 equiv) indichloromethane (20.7 mL) dropwise with stirring at -78°C in 30 minutes. The resulting solution was stirred for 2 hours at -78°C. The reaction was then quenched. The resulting solution was extracted with dichloromethane and washed with saturated sodium chloride aqueous solution. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The crude product was purified by Flash-Prep-HPLC with the following conditions: Column, C18 silica gel; mobile phase, acetonitrile:water = 0:100 increasing to acetonitrile:water = 23:76 within 25 min; Detector, UV 220 nm. This resulted in 2.6 g (84%) of ethyl 2-[3-(3- hydroxypropyl)-l,2-oxazol-5-yl]-3-methylbutanoate as an orange oil.

[0413] Step 6AVS0044US3

[0414] Into a lOO-mL round-bottom flask, was placed ethyl 2-[3-(3-hydroxypropyl)-l,2- oxazol-5-yl]-3-methylbutanoate (1.2 g, 4.70 mmol, 1.00 equiv), ethanol (20 mL), water (10 mL), sodium hydroxide (1.9 g, 47.50 mmol, 10.0 equiv). The resulting solution was stirred for 1 overnight at room temperature. The pH value of the solution was adjusted to 6 with hydrogen chloride (2M). The resulting solution was extracted with ethyl acetate and washed with saturated sodium chloride. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. This resulted in 800 mg (75%) of 2-[3-(3-hydroxypropyl)-l,2-oxazol-5-yl]-3- methylbutanoic acid as a yellow oil.

[0415] Step 7

[0416] Into a lOO-mL round-bottom flask, was placed 2-[3-(3-hydroxypropyl)-l,2-oxazol-5- yl]-3-methylbutanoic acid (800 mg, 3.52 mmol, 1.00 equiv), (2S,4R)-4-hydroxy-N-[[4-(4- methyl-l,3-thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide hydrochloride (1.24 g, 3.50 mmol, 1.00 equiv), N,N-dimethylformamide (15 mL), N-ethyl-N-isopropylpropan-2-amine (1.82 g, 14.08 mmol, 4.00 equiv), T3P (1.77 g, 1.20 equiv). The resulting solution was stirred for 2 hours at room temperature. The reaction was then quenched by water. The resulting solution was extracted with ethyl acetate and washed with saturated sodium chloride. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column eluting with dichloromethane / methanol (5:1). The collected fractions were combined and concentrated under vacuum. This resulted in 870 mg (53%) of (2S,4R)-4-hydroxy- 1 - [ [3 -(3 -hydroxypropyl)- 1 ,2-oxazol-5-yl] carbonyl] -N- [ [4-(4-methyl- 1 ,3 -thiazol-5- yl)phenyl]methyl]pyrrolidine-2-carboxamide as a yellow solid.

[0417] Step 8AVS0044US3

[0418] Into a 50-mL round-bottom flask, was placed (2S,4R)-4-hydroxy-l-[2-[3-(3- hydroxypropyl)- 1 ,2-oxazol-5-yl] -3 -methylbutanoyl] -N - [ [4-(4-methyl- 1 ,3 -thiazol-5- yl)phenyl]methyl]pyrrolidine-2-carboxamide (870 mg, 1.65 mmol, 1.00 equiv), dichloromethane (10 mL), 4-methylbenzene-l-sulfonyl chloride (377 mg, 1.98 mmol, 1.20 equiv), triethylamine (334.0 mg, 3.30 mmol, 2.00 equiv), 4-dimethylaminopyridine (40 mg, 0.33 mmol, 0.20 equiv). The resulting solution was stirred for 4 hours at room temperature. The resulting solution was extracted with dichloromethane and washed with water and saturated sodium chloride. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column eluting with dichloromethane / methanol (10: 1). The collected fractions were combined and concentrated under vacuum. This resulted in 600 mg (53%) of 3-(5-[l-[(2S,4R)-4-hydroxy-2-([[4-(4-methyl-l,3-thiazol-5- yl)phenyl] methyl] carbamoyl)pyrrolidin- 1 -yl] -3 -methyl- 1 -oxobutan-2-yl] - 1 ,2-oxazol-3 -yl)propyl 4-methylbenzene-l- sulfonate as a yellow solid.

[0419] Step 9

[0420] Into a 50-mL round-bottom flask, was placed 2-(2-hydroxyethoxy)ethan-l-ol (273.0 mg, 2.57 mmol, 5.00 equiv) and N,N-dimethylformamide (5 mL). Sodium hydride (41.0 mg, 1.71 mmol, 2.00 equiv) added under 0°C, followed by the addition, after 20 minutes, of 3-(5-[l- [(4S )-4-hydroxy- 1 -( [ [4-(4-methyl- 1 ,3 -thiazol-5-yl)phenyl] methyl] carbamoyl)pyrrolidin-2-yl] -3 - methyl-l-oxobutan-2-yl]-l,2-oxazol-3-yl)propyl 4 -methylbenzene-l- sulfonate (350.0 mg, 0.51AVS0044US3 mmol, 1.00 equiv). The resulting solution was stirred for 4 hours at room temperature. Reaction mixture was diluted with water and extracted with DCM. Organic phase was dried over sodium sulfate and concentrated, and the residue was subjected to flash chromatography. This resulted in 160 mg (51%) of (4S)-4-hydroxy-2-[2-(3-[3-[2-(2-hydroxyethoxy)ethoxy]propyl]-l,2-oxazol-5- yl)-3 -methylbutanoyl] -N - [ [4-(4-methyl- 1 ,3 -thiazol-5 -yl)phenyl] methyl] pyrrolidine- 1 - carboxamide as a yellow oil.

[0421] Step 10

[0422] Into a 50-mL round-bottom flask, was placed (2S,4R)-4-hydroxy-l-[2-(3-[3-[2-(2- hydroxyethoxy)ethoxy]propyl] - 1 ,2-oxazol-5-yl)-3 -methylbutanoyl] -N - [ [4-(4-methyl- 1 ,3 -thiazol- 5-yl)phenyl]methyl]pyrrolidine-2-carboxamide (160 mg, 0.26 mmol, 1.00 equiv),dichloromethane (5 mL), 4-methylbenzene-l-sulfonyl chloride (59 mg, 0.31 mmol, 1.20 equiv), triethylamine (53 mg, 0.52 mmol, 2.00 equiv), 4-dimethylaminopyridine (6 mg, 0.05 mmol, 0.20 equiv). The resulting solution was stirred for 5 hours at room temperature. The resulting solution was extracted with dichloromethane and washed with water. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column eluting with dichloromethane / methanol (12: 1). The collected fractions were combined and concentrated under vacuum. This resulted in 72 mg (36%) of 2-[2-[3-(5-[l- [(2S ,4R)-4-hydroxy-2-( [ [4-(4-methyl- 1 ,3 -thiazol-5-yl)phenyl] methyl] carbamoyl)pyrrolidin- 1 - yl] -3 -methyl- 1 -oxobutan-2-yl] - 1 ,2-oxazol-3 -yl)propoxy] ethoxy] ethyl 4-methylbenzene- 1 - sulfonate as a yellow oil.

[0423] Step 11AVS0044US3

[0424] Into a 50-mL round-bottom flask, was placed 2-[2-[3-(5-[l-[(2S,4R)-4-hydroxy-2- ([ [4-(4-methyl- 1 ,3 -thiazol-5-yl)phenyl] methyl] carbamoyl)pyrrolidin- 1 -yl] -3 -methyl- 1 -oxobutan- 2-yl]-l,2-oxazol-3-yl)propoxy]ethoxy]ethyl 4-methylbenzene-l- sulfonate (70 mg, 0.09 mmol, 1.00 equiv), 6-[2-(methoxymethoxy)phenyl]-4-(lH-pyrazol-4-yl)pyridazin-3-amine (27 mg, 0.09 mmol, 1.00 equiv), acetonitrile (2 mL), potassium carbonate (38 mg, 0.27 mmol, 3.00 equiv).The resulting solution was stirred for 1 overnight at 80°C. The resulting solution was extracted with ethyl acetate and washed with water. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column with dichloromethane / methanol (10: 1). The collected fractions were combined and concentrated under vacuum. This resulted in 30 mg (37%) of (2S,4R)-l-[2-[3-(3-[2-[2-(4-[3-amino-6-[2- (methoxymethoxy)phenyl]pyridazin-4-yl]-lH-pyrazol-l-yl)ethoxy]ethoxy]propyl)-l,2-oxazol-5- yl] -3 -methylbutanoyl] -4-hydroxy-N- [ [4-(4-methyl- 1 ,3 -thiazol-5-yl)phenyl] methyl]pyrrolidine-2- carboxamide as a yellow oil.

[0425] Step 12AVS0044US3

[0426] Into a 50-mL round-bottom flask, was placed (2S,4R)-l-[2-[3-(3-[2-[2-(4-[3-amino- 6-[2-(methoxymethoxy)phenyl]pyridazin-4-yl]-lH-pyrazol-l-yl)ethoxy]ethoxy]propyl)-l,2- oxazol-5-yl] -3 -methylbutanoyl] -4-hydroxy-N- [ [4-(4-methyl- 1 ,3 -thiazol-5- yl)phenyl]methyl]pyrrolidine-2-carboxamide (27.0 mg, 0.03 mmol, 1.00 equiv), methanol (2 mL), hydrogen chloride (aq) (0.5 mL). The resulting solution was stirred for 1 overnight at room temperature. The resulting solution was diluted with water. The pH value of the solution was adjusted to 8 with sodium carbonate. The resulting solution was extracted with ethyl acetate and washed with water. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The crude product was purified by Prep-HPLC with the following conditions: Column: XBridge Shield RP18 OBD Column, 5um, l9*l50mm; Mobile Phase A: Water (0.05%NH3H20), Mobile Phase B: acetonitrile; Flow rate: 20 mL / min; Gradient: 34% B to 47% B in 8 min; 220 nm. This resulted in 7.6 mg (30%) of (2S,4R)-l-[2-(3-[3-[2-(2-[4-[3-amino-6-(2- hydroxyphenyl)pyridazin-4-yl]-lH-pyrazol-l-yl]ethoxy)ethoxy]propyl]-l,2-oxazol-5-yl)-3- methylbutanoyl] -4-hydroxy-N- [ [4-(4-methyl- 1 ,3 -thiazol-5-yl)phenyl] methyl]pyrrolidine-2- carboxamide as a white solid.

[0427] ‘H-NMR: (400 MHz, CD3OD ) 58.89-8.83 (m, 1H), 8.31-8.26 (m, 1H), 8.08-8.03 (m, 2H), 7.85-7.81 (m, 1H), 7.46-7.21 (m, 5H), 6.96-6.87 (m, 2H), 6.15 (s, 1H), 4.52-4.44 (m, 5H), 4.41-4.31 (m, 3H), 3.91-3.80 (m, 2H), 3.72-3.65 (m, 1H), 3.61-3.35 (m, 6H), 2.62-2.51 (m, 2H), 2.45-2.33 (m, 3H), 2.22-2.15 (m, 1H), 2.10-2.01 (m, 1H), 1.84-1.72 (m, 2H), 1.30-1.24 (m, 1H), 1.03-0.97 (m, 3H), 0.91-0.75 (m, 3H).

[0428] Exemplary Synthesis of Exemplary Compound 23 and Exemplary Compound 24AVS0044US3

[0429] Into a 25-mL round-bottom flask, was placed (2S,4R)-l-[2-[3-(3-[2-[2-(2-[4-[3- amino-6-(2-hydroxyphenyl)pyridazin-4-yl]-lH-pyrazol-l-yl]ethoxy)ethoxy]ethoxy]propyl)-l,2- oxazol-5-yl] -3 -methylbutanoyl] -4-hydroxy-N- [ [4-(4-methyl- 1 ,3 -thiazol-5- yl)phenyl]methyl]pyrrolidine-2-carboxamide (87 mg, 0.10 mmol, 1.00 equiv) [prepared as described for Exemplary Compound 22] and methanol (10 mL). The resulting solution was stirred for 1 hour at 25°C. The crude product was purified by Chiral-Prep-HPLC with the following conditions: Column, CHIRALPAK ID-3; mobile phase, MtBE(0. l%DEA):EtOH=80:20, Size :0.46* l0cm;3um; Detector, UV-254nm. This resulted in 17 mg (20% ) of (2S ,4R)- 1 - [(2S )-2- [3 -(3 - [2- [2-(2- [4- [3 -amino-6-(2-hydroxyphenyl)pyridazin-4-yl] - 1 H- pyrazol-l-yl]ethoxy)ethoxy]ethoxy]propyl)-l,2-oxazol-5-yl]-3-methylbutanoyl]-4-hydroxy-N- [[4-(4-methyl-l,3-thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide as an off-white solid [1H NMR (300 MHz, CD3OD, ppm ): d 8.83 (s, 1H), 8.33 (s, 1H), 8.23 (s, 1H), 7.99 (s, 1H), 7.70-7.67 (d, J=9Hz, 1H), 7.48-7.45 (d, J=9Hz, 1H), 7.37-7.32 (m, 4H), 7.00-6.97 (m, 2H), 6.19 (s, 1H), 4.61-4.58 (m, 1H), 4.50-4.38 (m, 5H), 3.91-3.86 (m, 3H), 3.60-3.51 (m, 8H), 3.50-3.43 (m, 2H), 3.40-3.34 (m, 2H), 2.57-2.52 (m, 2H), 2.46-2.43 (m, 4H), 2.30-2.23 (m, 1H), 2.10-2.04 (m, 1H), 1.73-1.69 (m, 2H), 1.07-1.05 (d, J=6.6Hz, 3H), 0.88-0.86 (d, J=6.9Hz, 3H)] and 21 mg (24% ) of (2S ,4R)- 1 - [(2R)-2- [3 -(3 - [2- [2-(2- [4- [3 -amino-6-(2-hydroxyphenyl)pyridazin-4-yl] - 1 H- pyrazol-l-yl]ethoxy)ethoxy]ethoxy]propyl)-l,2-oxazol-5-yl]-3-methylbutanoyl]-4-hydroxy-N- [[4-(4-methyl-l,3-thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide as a white solid [ ' HAVS0044US3NMR (300 MHz, CD30D, ppm): d 8.88 (s, 1H), 8.37 (s, 1H), 8.31 (s, 1H), 8.04 (s, 1H), 7.69- 7.67 (d, 7=8. lHz, ppm), 7.43-7.39 (m, 5H), 7.03-6.99 (m, 2H), 6.21-6.00 (m, 1H), 4.53-4.48 (m, 3H), 4.44-4.40 (m, 3H), 3.92-3.89 (m, 3H), 3.79-3.76 (m, 1H), 3.62-3.54 (m, 7H), 3.50-3.48 (m, 2H), 3.42-3.40 (m, 2H), 2.64-2.61 (m, 2H), 2.46-2.44 (m, 4H), 2.26-2.18 (m, 1H), 2.13-2.04 (m, 1H), 1.82-1.78 (m, 2H), 1.05-1.02 (d, 7=6.6Hz, 3H), 0.85-0.82 (d, 7=6.9Hz, 3H).

[0430] Exemplary Compounds 25 and 26 were prepared using procedures analogous to those described above for Exemplary Compounds 22, 23 and 24.

[0431] Exemplary Synthesis of Exemplary Compound 27

[0432] Step 1

[0433] Into a 50 mL round-bottom flask, was placed 2-[2-(2-hydroxyethoxy)ethoxy]ethan-l- ol (257 mg, 1.71 mmol, 3.00 equiv) and N,N-dimethylformamide (5 mL). This was followed by the addition of sodium hydride (34 mg, 1.42 mmol, 1.50 equiv) at 0°C in 10 minutes. To this was added 4-bromo-2-fluoropyridine (100 mg, 0.57 mmol, 1.00 equiv). The resulting solution was stirred for 3 hours at room temperature. The reaction was then quenched by the addition of 5 mL of water / ice. The resulting solution was extracted with ethyl acetate, and the organic layers were combined. The resulting mixture was washed with saturate sodium chloride. The mixture was dried over anhydrous sodium sulfate. The residue was applied onto a silica gel column with ethyl acetate / petroleum ether (1:1). The collected fractions were combined and concentrated under vacuum. This resulted in 90 mg (52%) of 2-(2-[2-[(4-bromopyridin-2- yl)oxy] ethoxy] ethoxy)ethan-l-ol as a light yellow liquid.

[0434] Step 2

[0435] Into a 50 mL round-bottom flask purged and maintained with an inert atmosphere ofAVS0044US3 nitrogen, was placed 2-(2-[2-[(4-bromopyridin-2-yl)oxy]ethoxy]ethoxy)ethan-l-ol (500 mg, 1.63 mmol, 1.00 equiv), tert-butyl 3,8-diazabicyclo[3.2.l]octane-3-carboxylate (347 mg, 1.64 mmol, 1.00 equiv), Cs2C03(1599 mg, 4.91 mmol, 3.00 equiv), toluene (8 mL), Ruphos (69 mg, 0.05 equiv). The resulting solution was stirred for 5 hours at l00°C in an oil bath. The reaction was then quenched by the addition of 10 mL of water. The resulting solution was extracted with dichloromethane / MeOH and the organic layers combined. The resulting mixture was washed with saturate sodium chloride. The mixture was dried over anhydrous sodium sulfate. The residue was applied onto a silica gel column eluting with dichloromethane / methanol (10:1). The collected fractions were combined and concentrated under vacuum. This resulted in 419 mg (59%) of tert-butyl 8-(2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]pyridin-4-yl)-3,8- diazabicyclo[3.2.l]octane-3-carboxylate as yellow oil.

[0436] Step 3

[0437] Into a 50 mL round-bottom flask, was placed tert-butyl 8-(2-[2-[2-(2- hydroxyethoxy)ethoxy]ethoxy]pyridin-4-yl)-3,8-diazabicyclo[3.2.l]octane-3-carboxylate (419 mg, 0.96 mmol, 1.00 equiv) and 1M HC1 in methanol (8 mL). The resulting solution was stirred for 2 hours at room temperature. The resulting mixture was concentrated under vacuum. This resulted in 319 mg (99%) of 2- (2-[2-[(4- [3,8-diazabicyclo[3.2.l]octan-8-yl]pyridin-2- yl)oxy] ethoxy] ethoxy)ethan-l-ol as a yellow oil.

[0438] Step 4

[0439] Into a 10 mL microwave tube, was placed 2-(2-[2-[(4-[3,8-diazabicyclo[3.2.l]octan- 8-yl]pyridin-2-yl)oxy]ethoxy]ethoxy)ethan-l-ol (319 mg, 0.95 mmol, 1.00 equiv), 4-bromo-6- chloropyridazin-3-amine (780 mg, 3.74 mmol, 4.00 equiv), DMSO (10 mL), DIEA (2 mL). The final reaction mixture was irradiated with microwave radiation for 3 hours at l30°C. TheAVS0044US3 reaction was then quenched by the addition of 10 mL of water. The resulting solution was extracted with ethyl acetate, and organic layers combined. The resulting mixture was washed with saturated sodium chloride. The mixture was dried over anhydrous sodium sulfate. The residue was applied onto a silica gel column eluting with dichloromethane / methanol (10:1). The collected fractions were combined and concentrated under vacuum. This resulted in 260 mg (59%) of 2-[2-[2-([4-[3-(3-amino-6-chloropyridazin-4-yl)-3,8-diazabicyclo[3.2.l]octan-8- yl]pyridin-2-yl]oxy)ethoxy]ethoxy]ethan-l-ol as a yellow solid.

[0440] Step 5

[0441] Into a 10 mL microwave tube purged and maintained under nitrogen atmosphere was placed 2-[2-[2-([4-[3-(3-amino-6-chloropyridazin-4-yl)-3,8-diazabicyclo[3.2.l]octan-8- yl]pyridin-2-yl]oxy)ethoxy]ethoxy]ethan-l-ol (295 mg, 0.63 mmol, 1.00 equiv), [2- (methoxymethoxy)phenyl]boronic acid (223 mg, 1.23 mmol, 2.00 equiv), potassium carbonate (254 mg, 1.84 mmol, 3.00 equiv), dioxane (4 mL), water (1 mL), Pd(PPh3)4(70 mg, 0.06 mmol, 0.10 equiv). The resulting solution was stirred overnight at l00°C. The reaction was then quenched by the addition of water. The resulting solution was extracted withdichloromethane / MeOH and the organic layers combined. The resulting mixture was washed with saturate sodium chloride. The mixture was dried over anhydrous sodium sulfate. The residue was applied onto a silica gel column eluting with dichloromethane / methanol (10:1). The collected fractions were combined and concentrated under vacuum. This resulted in 221 mg (61%) of 2-[2-(2-[[4-(3-[3-amino-6-[2-(methoxymethoxy)phenyl]pyridazin-4-yl]-3,8- diazabicyclo[3.2.l]octan-8-yl)pyridin-2-yl]oxy]ethoxy)ethoxy]ethan-l-ol as a yellow solid.

[0442] Step 6AVS0044US3

[0443] Into a 50 mL round-bottom flask, was placed 2-[2-(2-[[4-(3-[3-amino-6-[2- (methoxymethoxy)phenyl]pyridazin-4-yl]-3,8-diazabicyclo[3.2.l]octan-8-yl)pyridin-2- yl] oxy] ethoxy)ethoxy] ethan- 1 -ol (100 mg, 0.18 mmol, 1.00 equiv), TsCl (50 mg, 0.26 mmol, 1.50 equiv), dichloromethane (5 mL), triethylamine (0.3 mL), 4-dimethylaminopyridine (2 mg, 0.02 mmol, 0.10 equiv). The resulting solution was stirred for 2 hours at room temperature. The reaction was then quenched by the addition of water. The resulting solution was extracted with ethyl acetate and the organic layers combined. The resulting mixture was washed with saturated sodium chloride. The mixture was dried over anhydrous sodium sulfate. The residue was applied onto a silica gel column eluting with dichloromethane / methanol (10:1). The collected fractions were combined and concentrated under vacuum. This resulted in 97 mg (76%) of 2-[2-(2-[[4-(3- [3-amino-6-[2-(methoxymethoxy)phenyl]pyridazin-4-yl]-3,8-diazabicyclo[3.2.l]octan-8- yl)pyridin-2-yl]oxy]ethoxy)ethoxy]ethyl 4-methylbenzene- 1 -sulfonate as a yellow solid.

[0444] Step 7

[0445] Into a 50 mL round-bottom flask, was placed 2-[2-(2-[[4-(3-[3-amino-6-[2-AVS0044US3(methoxymethoxy)phenyl]pyridazin-4-yl]-3,8-diazabicyclo[3.2.l]octan-8-yl)pyridin-2- yl]oxy] ethoxy )ethoxy] ethyl 4-methylbenzene- 1 -sulfonate (87 mg, 0.12 mmol, 1.00 equiv), N,N- dimethylformamide (54 mg, 0.75 mmol, 1.00 equiv), (2S,4R)-4-hydroxy-l-[2-(3-hydroxy-l,2- oxazol-5-yl)-3 -methylbutanoyl] -N- [4-(4-methyl- 1 ,3 -thiazol-5-yl)phenyl] methylpyrrolidine-2- carboxamide (79 mg, 0.16 mmol, 2.00 equiv), Cs2C03(5 g, 15.35 mmol, 127.15 equiv). The resulting solution was stirred for 4 hours at room temperature. The resulting solution was extracted with dichloromethane / MeOH, and the organic layers combined. The resulting mixture was washed with saturated sodium chloride. The mixture was dried over anhydrous sodium sulfate. The residue was applied onto a silica gel column eluting with dichloromethane / methanol (5: 1). The collected fractions were combined and concentrated under vacuum. This resulted in 124 mg (99%) of (2S,4R)-l-[2-(3-[2-[2-(2-[[4-(3-[3-amino-6-[2- (methoxymethoxy)phenyl]pyridazin-4-yl]-3,8-diazabicyclo[3.2.l]octan-8-yl)pyridin-2- yl] oxy] ethoxy)ethoxy] ethoxy] - 1 ,2-oxazol-5-yl)-3 -methylbutanoyl] -4-hydroxy-N- [ [4-(4-methyl- l,3-thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide as a yellow solid.

[0446] Step 8

[0447] Into a 50 mL round-bottom flask was placed (2S,4R)-l-[2-(3-[2-[2-(2-[[4-(3-[3- amino-6-[2-(methoxymethoxy)phenyl]pyridazin-4-yl]-3,8-diazabicyclo[3.2.l]octan-8-yl)pyridin- 2-yl] oxy] ethoxy)ethoxy] ethoxy] - 1 ,2-oxazol-5-yl)-3 -methylbutanoyl] -4-hydroxy-N- [ [4-(4-AVS0044US3 methyl-l,3-thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide (131 mg, 0.13 mmol, 1.00 equiv), methanol (5 mL), and 1 M HC1 in MeOH (1.5 mL). The resulting solution was stirred for 7 hours at room temperature. The resulting solution was diluted with 5 mL of H20. The pH value of the solution was adjusted to 7 with aqueous Na2C03(2M). The resulting solution was extracted with dichloromethane, and the organic layers combined. The resulting mixture was washed with saturated sodium chloride. The crude product was purified by Prep-HPLC with the following conditions: Column, XBridge Shield RP18 OBD Column, 5um, l9* l50mm; mobile phase, Water (0.05%NH3H20) and acetonitrile (39.0% acetonitrile up to 50.0% in 9 min);Detector, UV 220nm. This resulted in 60 mg (48%) of (2S,4R)-l-(2-[3-[2-(2-[2-[(4-[3-[3-amino- 6-(2-hydroxyphenyl)pyridazin-4-yl]-3,8-diazabicyclo[3.2.l]octan-8-yl]pyridin-2- yl)oxy] ethoxy] ethoxy)ethoxy] - 1 ,2-oxazol-5-yl] -3 -methylbutanoyl)-4-hydroxy-N- [ [4-(4-methyl- l,3-thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide as a yellow solid, which was further purified by Chiral-Prep-HPLC with the following conditions: Column, Chiralpak ID-2, 2*25cm, 5um; mobile phase, (0.l%DEA) and ethanol (hold 30% ethanol in 30 min); Detector, UV 254 / 220nm. This resulted in 13.9 mg (23%) of (2S,4R)-l-[(2S)-2-[3-[2-(2-[2-[(4-[3-[3-amino-6- (2-hydroxyphenyl)pyridazin-4-yl]-3,8-diazabicyclo[3.2. l]octan-8-yl]pyridin-2- yl)oxy] ethoxy] ethoxy)ethoxy] - 1 ,2-oxazol-5-yl] -3 -methylbutanoyl] -4-hydroxy-N- [ [4-(4-methyl- l,3-thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide as a white solid [ ' H NMR (400 MHz, CD30D): d 8.85 (m, 1H), 7.78-7.72(m, 2H), 7.47-7.45(m, 2H), 7.40-7.34 (m, 3H), 7.23-7.22 (m, 1H), 6.92-6.88 (m, 2H), 6.55-6.53(m, 1H), 6.23 (s, 1H), 5.97 (s, 1H), 4.64-4.59(m, 2H), 4.50(s, 3H), 4.40(s, 2H), 4.33-4.24 (m, 4H), 3.81-3.79 (m, 2H), 3.75-3.65(m, 8H), 3.29 (m, 1H), 3.l0-3.07(m, 2H), 2.48-2.46(m, 3H), 2.23-2.20(m,lH),2. l3-2.06(m, 6H), l.05(s, 1H), 0.90-0.89 (d, J=6.8Hz, 3H), 0.78-0.76 (d, J=8Hz, 3H)] and 17.9 mg (29%) of (2S,4R)-l-[(2R)-2-[3-[2-(2- [2-[(4-[3-[3-amino-6-(2-hydroxyphenyl)pyridazin-4-yl]-3,8-diazabicyclo[3.2.l]octan-8- yl]pyridin-2-yl)oxy]ethoxy]ethoxy)ethoxy]-l,2-oxazol-5-yl]-3-methylbutanoyl]-4-hydroxy-N- [[4-(4-methyl-l,3-thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide as a white solid [ ' H NMR (400 MHz, CD30D): d 8.88 (m, 1H), 7.79-7.75(m, 2H), 7.49-7.39(m, 5H), 7.24(m, 1H), 6.92-6.90 (m, 2H), 6.56-6.54(m, 1H), 6.25-6.24 (M, 1H), 6.00 (s, 1H), 4.53-4.29(m, 10H), 3.88- 3.81 (m, 5H), 3.70-3.63(m, 6H), 3.33(m, 2H), 3. l4-3.l2(m, 2H), 2.48-2.44(m, 3H), 2.42- 2.29(m,lH), 2.25-2. l2(m, 6H), 1.04-1.02 (d, J=6.4Hz, 3H), 0.88-0.86 (d, J=6.4Hz, 3H)].AVS0044US3

[0448] Exemplary Compounds 29 and 30 were prepared using procedures analogous to those described for Exemplary Compounds 27 and 28.

[0449] Exemplary Synthesis of Exemplary Compound 31

[0450] Step 1H0— OTHRt-BuOK, THF, rt, 12 h

[0451] Into a 50 mL round-bottom flask, was placed 2-(oxan-2-yloxy)ethan-l-ol (4.5 g,30.78 mmol, 1.00 equiv), tetrahydrofuran (10 mL), a solution of t-BuOK (3.6 g, 32.08 mmol, 2.00 equiv) in tetrahydrofuran (60 mL). This was followed by the addition of 3-bromoprop-l-yne (2.61 mL, 1.00 equiv) dropwise with stirring at 0°C. The resulting solution was stirred overnight at room temperature. The reaction was then quenched by the addition of water / ice. The resulting solution was extracted with ethyl acetate, and the organic layers combined. The resulting mixture was washed with saturated sodium chloride. The mixture was dried over anhydrous sodium sulfate. The residue was applied onto a silica gel column eluting with ethyl acetate / petroleum ether (1:5). The collected fractions were combined and concentrated under vacuum. This resulted in 2.8 g (49%) of 2-[2-(prop-2-yn-l-yloxy)ethoxy]oxane as yellow oil.

[0452] Step 2 pinacolborane

[0453] Into a l0-mL microwave tube purged and maintained under an inert atmosphere of nitrogen, was placed 2-[2-(prop-2-yn-l-yloxy)ethoxy]oxane (2.8 g, 15.20 mmol, 1.00 equiv), ZrCp2HCl (390 mg, 0.10 equiv), triethylamine (153 mg, 1.52 mmol, 0.10 equiv), pinacolborane (2.5 mL). The resulting solution was stirred overnight at 68°C in an oil bath. The reaction was then quenched by the addition of NH4Cl. The reaction mixture was cooled to 0°C with a water / ice bath. The resulting solution was extracted with ethyl acetate and the organic layers combined. The resulting mixture was washed with saturated sodium chloride. The mixture wasAVS0044US3 dried over anhydrous sodium sulfate. The residue was applied onto a silica gel column eluting with ethyl acetate / petroleum ether (1:5). The collected fractions were combined and concentrated under vacuum. This resulted in 3.01 g (63%) of 4,4,5,5-tetramethyl-2-[(lE)-3-[2-(oxan-2- yloxy)ethoxy]prop-l-en-l-yl]-l,3,2-dioxaborolane as a yellow liquid.

[0454] Step 3Boc

[0455] Into a l0-mL microwave tube purged and maintained under an inert atmosphere of nitrogen, was placed 4,4,5,5-tetramethyl-2-[(lE)-3-[2-(oxan-2-yloxy)ethoxy]prop-l-en-l-yl]- l,3,2-dioxaborolane (1 g, 3.20 mmol, 1.00 equiv), Pd(PPh3)4(800 mg, 0.69 mmol, 1.00 equiv), potassium carbonate (8 g, 57.88 mmol, 18.07 equiv), dioxane (2 g), tert-butyl 8-(2- bromopyridin-4-yl)-3,8-diazabicyclo[3.2.l]octane-3-carboxylate (902 mg, 2.45 mmol, 3.00 equiv), water (252 mg, 0.10 equiv). The resulting solution was stirred for 1 overnight at l00°C in an oil bath. The reaction was then quenched by the addition of water. The resulting solution was extracted with ethyl acetate, and the organic layers combined. The resulting mixture was washed with saturate sodium chloride. The mixture was dried over anhydrous sodium sulfate. The residue was applied onto a silica gel column eluting with dichloromethane / methanol (10:1). The collected fractions were combined and concentrated under vacuum. This resulted in 639 mg (42%) of tert-butyl 8-[2-[(lE)-3-[2-(oxan-2-yloxy)ethoxy]prop-l-en-l-yl]pyridin-4-yl]-3,8- diazabicyclo[3.2.l]octane-3-carboxylate as a yellow oil.

[0456] Step 4Boc BocAVS0044US3

[0457] Into a 50-mL round-bottom flask, was placed tert-butyl 8-[2-[(lE)-3-[2-(oxan-2- yloxy)ethoxy]prop-l-en-l-yl]pyridin-4-yl]-3,8-diazabicyclo[3.2.l]octane-3-carboxylate (639 mg, 1.35 mmol, 1.00 equiv), palladium on carbon (200 mg) and methanol (15 mL), and the mixture was stirred under hydrogen atmosphere overnight at room temperature. The solids were filtered off, and the filtrate was concentrated. This resulted in 639 mg (100%) of tert-butyl 8-(2-[3-[2- (oxan-2-yloxy)ethoxy]propyl]pyridin-4-yl)-3,8-diazabicyclo[3.2.1] octane-3 -carboxylate as a yellow oil.

[0458] Step 5

[0459] Into a 50-mL round-bottom flask, was placed tert-butyl 8-(2-[3-[2-(oxan-2- yloxy)ethoxy]propyl]pyridin-4-yl)-3,8-diazabicyclo[3.2.l]octane-3-carboxylate (639 mg, 1.34 mmol, 1.00 equiv), methanol (15 mL), and hydrogen chloride gas was bubbled through the solution. The resulting solution was stirred for 3 hours at room temperature. The resulting mixture was concentrated under vacuum. This resulted in 387 mg (100%) of 2-[3-(4-[3,8- diazabicyclo[3.2.l]octan-8-yl]pyridin-2-yl)propoxy]ethan-l-ol as a yellow oil.

[0460] Step 6

[0461] Into a l0-mL microwave tube, was placed 2-[3-(4-[3,8-diazabicyclo[3.2.l]octan-8- yl]pyridin-2-yl)propoxy]ethan-l-ol (387 mg, 1.85 mmol, 1.00 equiv), 4-bromo-6-AVS0044US3 chloropyridazin-3-amine (1.54 g, 7.39 mmol, 4.00 equiv), DMSO (8 mL), DIEA (1.53 mL, 5.00 equiv). The final reaction mixture was irradiated with microwave radiation for 3 hours at l30°C. The reaction was then quenched by the addition of water. The resulting solution was extracted with dichloromethane / MeOH=lO:l, and the aqueous layers were combined and concentrated under vacuum. The residue was applied onto a silica gel column with dichloromethane / methanol (7:3). The collected fractions were combined and concentrated under vacuum. This resulted in 519 mg (67%) of 2-(3-[4-[3-(3-amino-6-chloropyridazin-4-yl)-3,8-diazabicyclo[3.2.l]octan-8- yl]pyridin-2-yl]propoxy)ethan-l-ol as a yellow oil.

[0462] Step 7

[0463] Into a 50-mL round-bottom flask purged and maintained under an inert atmosphere of nitrogen, was placed 2-(3-[4-[3-(3-amino-6-chloropyridazin-4-yl)-3,8-diazabicyclo[3.2.l]octan- 8-yl]pyridin-2-yl]propoxy)ethan-l-ol (650 mg, 1.55 mmol, 1.00 equiv), [2- (methoxymethoxy)phenyl]boronic acid (566 mg, 3.11 mmol, 2.00 equiv), dioxane (8 mL), water (2 mL), potassium carbonate (644 mg, 4.66 mmol, 3.00 equiv), Pd(PPh3)4 (180 mg, 0.16 mmol, 0.10 equiv). The resulting solution was stirred for 3 hours at l00°C in an oil bath. The resulting mixture was concentrated under vacuum. The residue was applied onto a silica gel column with methanol / H20 (85:15). The collected fractions were combined and concentrated under vacuum. This resulted in 400 mg (50%) of 2-[3-[4-(3-[3-amino-6-[2-(methoxymethoxy)phenyl]pyridazin- 4-yl]-3,8-diazabicyclo[3.2.l]octan-8-yl)pyridin-2-yl]propoxy]ethan-l-ol as yellow oil.

[0464] Step 8AVS0044US3

[0465] Into a 50-mL round-bottom flask, was placed 2-[3-[4-(3-[3-amino-6-[2- (methoxymethoxy)phenyl]pyridazin-4-yl]-3,8-diazabicyclo[3.2.l]octan-8-yl)pyridin-2- yl]propoxy]ethan-l-ol (400 mg, 0.77 mmol, 1.00 equiv), dichloromethane (15 mL), TsCl (219 mg, 1.15 mmol, 1.50 equiv), triethylamine (155 mg, 1.53 mmol, 2.00 equiv), 4- dimethylaminopyridine (9.4 mg, 0.08 mmol, 0.10 equiv). The resulting solution was stirred overnight at room temperature. The reaction was then quenched by the addition of water. The resulting solution was extracted with dichloromethane, and the organic layers combined. The resulting mixture was washed with saturated sodium chloride. The mixture was dried over anhydrous sodium sulfate. The residue was applied onto a silica gel column eluting with dichloromethane / methanol (10:1). The collected fractions were combined and concentrated under vacuum. This resulted in 330 mg (64%) of 2-[3-[4-(3-[3-amino-6-[2- (methoxymethoxy)phenyl]pyridazin-4-yl]-3,8-diazabicyclo[3.2.l]octan-8-yl)pyridin-2- yl]propoxy] ethyl 4-methylbenzene- 1 -sulfonate as a yellow solid.

[0466] Step 9, ,

[0467] Into a 50-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed methyl 2-(6-chloropyridin-3-yl)acetate (500 mg, 2.69 mmol, 1.00 equiv), tert-butyl piperazine- l-carboxylate (502 mg, 2.70 mmol, 1.00 equiv), Cs2C03(2.63 g, 8.07 mmol, 3.00 equiv), toluene (10 mL), RuPhosPd (115 mg, 0.05 equiv). The resulting solution was stirred overnight at l00°C in an oil bath. The reaction was then quenched by the addition ofAVS0044US3 water. The resulting solution was extracted with ethyl acetate, and the organic layers were combined. The resulting mixture was washed with saturated sodium chloride. The mixture was dried over anhydrous sodium sulfate. The residue was applied onto a silica gel column eluting with ethyl acetate / petroleum ether (1:1). The collected fractions were combined and concentrated under vacuum. This resulted in 319 mg (35%) of tert-butyl 4-[5-(2-methoxy-2-oxoethyl)pyridin- 2-yl]piperazine-l-carboxylate as a yellow solid.

[0468] Step 10

[0469] Into a 50-mL round-bottom flask, was placed tert-butyl 4-[5-(2-methoxy-2- oxoethyl)pyridin-2-yl]piperazine-l-carboxylate (319 mg, 0.95 mmol, 1.00 equiv),dichloromethane (8 mL), trifluoroacetic acid (2 mL). The resulting solution was stirred for 2 h at room temperature. The resulting mixture was concentrated under vacuum. This resulted in 223 mg (100%) of methyl 2-[6-(piperazin-l-yl)pyridin-3-yl]acetate as a yellow oil.

[0470] Step 11

[0471] Into a 50-mL round-bottom flask, was placed methyl 2-[6-(piperazin-l-yl)pyridin-3- yl]acetate (101 mg, 0.43 mmol, 1.00 equiv), 2-3-[4-(3-3-amino-6-[2- (methoxymethoxy)phenyl]pyridazin-4-yl-3,8-diazabicyclo[3.2.l]octan-8-yl)pyridin-2- yl]propoxyethyl 4-methylbenzene-l- sulfonate (320 mg, 0.47 mmol, 1.10 equiv), acetonitrile (4 mL), potassium carbonate (298 mg, 2.16 mmol, 5.00 equiv), Nal (193 mg, 3.00 equiv). TheAVS0044US3 resulting solution was stirred overnight at 60°C. The resulting mixture was concentrated under vacuum. The residue was partitioned between dichloromethane and water, organic layer was separated and washed with saturated sodium chloride. The mixture was dried over anhydrous sodium sulfate. The residue was applied onto a silica gel column eluting withdichloromethane / methanol (5:1). The collected fractions were combined and concentrated under vacuum. This resulted in 94 mg (30%) of methyl 2-[6-[4-(2-[3-[4-(3-[3-amino-6-[2- (methoxymethoxy)phenyl]pyridazin-4-yl]-3,8-diazabicyclo[3.2.l]octan-8-yl)pyridin-2- yl]propoxy]ethyl)piperazin-l-yl]pyridin-3-yl]acetate as a yellow solid.

[0472] Step 12

[0473] Into a 50-mL round-bottom flask, was placed methyl 2-[6-[4-(2-[3-[4-(3-[3-amino-6- [2-(methoxymethoxy)phenyl]pyridazin-4-yl]-3,8-diazabicyclo[3.2.l]octan-8-yl)pyridin-2- yl]propoxy]ethyl)piperazin-l-yl]pyridin-3-yl]acetate (94 mg, 0.13 mmol, 1.00 equiv), methanol (5 mL), water (2 mL), and LiOH (15 mg, 0.64 mmol, 5.00 equiv). The resulting solution was stirred for 2 days at room temperature. The resulting mixture was concentrated under vacuum. The resulting solution was diluted with 10 mL of H20. The resulting solution was extracted with dichloromethane, and the aqueous layers were combined and concentrated under vacuum. The residue was dissolved in 10 mL of methanol. The solids were filtered out. The resulting mixture was concentrated under vacuum. This resulted in 72 mg (78%) of 2-[6-[4-(2-[3-[4-(3-[3-amino-AVS0044US36-[2-(methoxymethoxy)phenyl]pyridazin-4-yl]-3,8-diazabicyclo[3.2.l]octan-8-yl)pyridin-2- yl]propoxy]ethyl)piperazin-l-yl]pyridin-3-yl]acetic acid as a yellow solid.

[0474] 2- [6- [4-(2- [3 - [4-(3 - [3 - Amino-6- [2-(methoxymethoxy)phenyl]pyridazin-4-yl] -3 ,8 - diazabicyclo[3.2.l]octan-8-yl)pyridin-2-yl]propoxy]ethyl)piperazin-l-yl]pyridin-3-yl]acetic acid was converted to the final compound, (2S,4R)-l-((2S)-2-(2-(6-(4-(2-(3-(4-(3-(3-amino-6-(2- hydroxyphenyl)pyridazin-4-yl)-3,8-diazabicyclo[3.2.l]octan-8-yl)pyridin-2- yl)propoxy)ethyl)piperazin-l-yl)pyridin-3-yl)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N- (4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide according to the scheme below and using procedures described above for previous examples.

[0475] Exemplary Compound 50 was prepared using procedures described for Exemplary Compound 31.AVS0044US3

[0476] Exemplary Synthesis of Exemplary Compound 32

[0477] Step 1

[0478] Into a 250-mL round-bottom flask purged and maintained under an inert atmosphere of nitrogen, was placed a solution of 2-[2-(2-hydroxyethoxy)ethoxy]ethan-l-ol (10.0 g, 66.59 mmol, 1.00 equiv) in dichloromethane (100 mL), (diethyloxonio)trifluoroborate (1.9 g, 13.33 mmol, 0.20 equiv), and ethyl 2-diazoacetate (3.8 g, 0.50 equiv). The resulting solution was stirred for 3 hours at room temperature. The reaction was then quenched by the addition of water.The resulting solution was extracted with ethyl acetate and the organic layers were combined. The resulting mixture was washed with brine. The mixture was dried over anhydrous sodium sulfate. The residue was applied onto a silica gel column with ethyl acetate / petroleum ether (1:1).The collected fractions were combined and concentrated under vacuum. This resulted in 3.6 g (23%) of ethyl 2- [2- [2-(2-hydroxyethoxy)ethoxy] ethoxy] acetate as a yellow oil.

[0479] Step 2

[0480] Into a 50-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed a solution of ethyl 2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]acetate (1.0 g, 4.23 mmol, 1.00 equiv) in dichloromethane (20 mL), 4-methylbenzene-l-sulfonyl chloride (970 mg, 5.09 mmol, 1.20 equiv), triethylamine (860.0 mg, 8.50 mmol, 2.00 equiv). The resulting solution was stirred for 5 hours at room temperature. The reaction was then quenched by the addition of water. The resulting solution was extracted with ethyl acetate and the organic layers were combined. The resulting mixture was washed with brine. The mixture was dried over anhydrous sodium sulfate. The residue was applied onto a silica gel column with ethyl acetate / petroleum ether (1:1). The collected fractions were combined and concentrated under vacuum. This resulted in 1.1 g (65%) of ethyl 2-[2-[2-(2-[[(4- methylbenzene)sulfonyl]oxy]ethoxy)ethoxy] ethoxy] acetate as a yellow oil.AVS0044US3

[0481] Step 3

[0482] Into a 50-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed a solution of ethyl 2-[2-[2-(2-[[(4- methylbenzene)sulfonyl]oxy]ethoxy)ethoxy] ethoxy] acetate (1.0 g, 2.56 mmol, 1.20 equiv) in N,N-dimethylformamide (20 mL), 6-bromopyridin-2-ol (370 mg, 2.13 mmol, 1.00 equiv), Cs2C03(2.1 g, 6.45 mmol, 3.00 equiv). The resulting solution was stirred for 12 hours at 80°C. The reaction was then quenched by the addition of water. The resulting solution was extracted with ethyl acetate and the organic layers combined. The resulting mixture was washed with brine. The mixture was dried over anhydrous sodium sulfate. The residue was applied onto a silica gel column with ethyl acetate / petroleum ether (1:1). The collected fractions were combined and concentrated under vacuum. This resulted in 800 mg (96%) of ethyl l-(6-bromopyridin-2- yl)-l,4,7,l0-tetraoxadodecan-l2-oate as a yellow solid.

[0483] Ethyl l-(6-bromopyridin-2-yl)-l,4,7,l0-tetraoxadodecan-l2-oate was converted to the final compound, (2S,4R)-l-[(2S)-2-(l-[6-[(lR,4R)-5-[3-amino-6-(2-hydroxyphenyl)pyridazin-4- yl]-2,5-diazabicyclo[2.2.l]heptan-2-yl]pyridin-2-yl]-l,4,7,l0-tetraoxadodecan-l2-amido)-3,3- dimethylbutanoyl] -4-hydroxy-N - [ [4-(4-methyl- 1 ,3 -thiazol-5-yl)phenyl] methyl] pyrrolidine-2- carboxamide according to the scheme below and using procedures analogous to those described for other examples above.AVS0044US3AVS0044US3

[0484] Exemplary Synthesis of Exemplary Compound 33

[0485] Step 1

[0486] Into a 250-mL round-bottom flask, was placed l-bromo-4-ethylbenzene (5.5 g, 29.8 mmol, 1.0 equiv), CCU (100 mL), AIBN (490 mg, 3.0 mmol, 0.1 equiv), N-Bromosuccinimide (5.34 g, 30.0 mmol, 1.0 equiv). The resulting solution was stirred for 3 hours at 90°C. The resulting mixture was concentrated under vacuum. This resulted in 5.4 g (68%) of l-bromo-4-(l- bromoethyl)benzene as yellow oil.

[0487] Step 2

[0488] Into a lOO-mL round-bottom flask, was placed 6-[2-(methoxymethoxy)phenyl]-4- (lH-pyrazol-4-yl)pyridazin-3-amine (300 mg, 1.0 mmol, 1.0 equiv), N,N-dimethylformamide (5.0 mL), l-bromo-4-(l-bromoethyl)benzene (400.0 mg, 1.5 mmol, 1.5 equiv), potassium carbonate (414 mg, 3.0 mmol, 3.0 equiv). The resulting solution was stirred for 3 hours at 60°C. The reaction was then quenched by the addition of 10 mL of water. The resulting solution was extracted with ethyl acetate and (20.0 mL x3), the organic layers combined and concentrated under vacuum. The residue was applied onto a silica gel column eluting withdichloromethane / methanol (1:10). This resulted in 300 mg (62%) of 4-[l-[l-(4- bromophenyl)ethyl]-lH-pyrazol-4-yl]-6-[2-(methoxymethoxy)phenyl]pyridazin-3-amine as a brown solid.

[0489] Step 3AVS0044US3NaH, DMF, rt, 12 h

[0490] Into a 250-mL round-bottom flask, was placed prop-2-yn-l-ol (10 g, 178.4 mmol, 1.0 equiv), tetrahydrofuran (100.0 mL), sodium hydride (6.4 g, 266.7 mmol, 0.9 equiv), and tert- butyl 2-bromoacetate (28 g, 143.6 mmol, 0.8 equiv). The resulting solution was stirred for 3 hours at room temperature. The reaction was then quenched by the addition of 20 mL of ammonium chloride aqueous solution. The resulting mixture was concentrated under vacuum. The resulting solution was extracted with ethyl acetate (30 mL x 3), and the organic layers were combined and concentrated under vacuum. This resulted in 24.0 g (90%) of tert-butyl 2-(prop-2- yn-l-yloxy)acetate as a yellow solid.

[0491] Step 4t3, .

[0492] Into a 250-mL round-bottom flask, was placed tert-butyl 2-(prop-2-yn-l- yloxy)acetate (6.6 g, 38.8 mmol, 1.0 equiv), triethylamine (400.0 mg, 3.9 mmol, 0.1 equiv), pinacolborane (20.0 mL), ZrCp2HCl (1 g, 0.1 equiv). The resulting solution was stirred for 12 minutes at 60°C. The reaction was then quenched by the addition of 10 mL of ice / water. The resulting solution was extracted with ethyl acetate (30 mL x 3), and the organic layers were combined. The residue was applied onto a silica gel column eluting with ethyl acetate / petroleum ether (1:5). This resulted in 5.0 g (43%) of tert-butyl 2-[[(2E)-3-(tetramethyl-l,3,2-dioxaborolan- 2-yl)prop-2-en-l-yl]oxy]acetate as a yellow oil.

[0493] Step 5

[0494] Into a l0-mL sealed tube, was placed 4-[l-[l-(4-bromophenyl)ethyl]-lH-pyrazol-4- yl]-6-[2-(methoxymethoxy)phenyl] pyridazin-3-amine (300 mg, 0.6 mmol, 1.0 equiv), tert-butyl 2-[[(2E)-3-(tetramethyl-l,3,2-dioxaborolan-2-yl)prop-2-en-l-yl]oxy]acetate (279 mg, 0.9 mmol,AVS0044US31.5 equiv), Pd(PPh3)4 (72 mg, 0.06 mmol, 0.1 equiv), potassium carbonate (259 mg, 1.9 mmol, 3.0 equiv), dioxane (4.0 mL), and H20 (1.0 mL). The resulting solution was stirred for 5 hours at 90°C. The resulting mixture was concentrated under vacuum. The residue was applied onto a silica gel column eluting with dichloromethane / methanol (10:1). This resulted in 200 mg (56%) of tert-butyl 2-[[(2E)-3-[4-[l-(4-[3-amino-6-[2-(methoxymethoxy)phenyl]pyridazin-4-yl]-lH- pyrazol-l-yl)ethyl]phenyl]prop-2-en-l-yl]oxy]acetate as a yellow solid.

[0495] Step 6

[0496] Into a lOO-mL round-bottom flask, was placed tert-butyl 2-[[(2E)-3-[4-[l-(4-[3- amino-6-[2-(methoxymethoxy)phenyl]pyridazin-4-yl]-lH-pyrazol-l-yl)ethyl]phenyl]prop-2-en- l-yl]oxy] acetate (93 mg, 0.2 mmol, 1.0 equiv), methanol (5.0 mL), palladium on carbon (100 mg). The resulting solution was stirred under hydrogen atmosphere for 1 hour at roomtemperature. The solids were filtered off. The resulting mixture was concentrated under vacuum. This resulted in 56 mg (60%) of tert-butyl 2-(3-[4-[l-(4-[3-amino-6-[2- (methoxymethoxy)phenyl]pyridazin-4-yl]- lH-pyrazol- l-yl)ethyl]phenyl]propoxy)acetate as a yellow solid.

[0497] Step 7

[0498] Into a lOO-mL round-bottom flask, was placed tert-butyl 2-(3-[4-[l-(4-[3-amino-6-[2- (methoxymethoxy)phenyl]pyridazin-4-yl]- lH-pyrazol- l-yl)ethyl]phenyl]propoxy)acetate (56 mg, 0.1 mmol, 1.0 equiv), dichloromethane (10.0 mg), trifluoroacetic acid (5 mL). The resulting solution was stirred for 2 hours at room temperature. The resulting mixture was concentrated under vacuum. This resulted in 45 mg (90%) of 2-(3-[4-[l-(4-[3-amino-6-[2-(methoxymethoxy) phenyl]pyridazin-4-yl]- lH-pyrazol- l-yl)ethyl]phenyl]propoxy)acetic acid as a brown solid.

[0499] Step 8AVS0044US3

[0500] Into a 25-mL round-bottom flask, was placed 2-[3-[4-(l-[4-[3-amino-6-(2- hydroxyphenyl)pyridazin-4-yl]-lH-pyrazol-l-yl]ethyl)phenyl]propoxy]acetic acid (26 mg, 0.06 mmol, 1.0 equiv), N,N-dimethylformamide (5 mL), (2S,4R)-l-[(2S)-2-amino-3,3- dimethylbutanoyl]-4-hydroxy-N-[4-(4-methyl-l,3-thiazol-5-yl)phenyl] methylpyrrolidine-2- carboxamide (30 mg, 0.07 mmol, 1.2 equiv), DIEA (21 mg, 0.2 mmol, 3.0 equiv), T3P (53 mg, 1.2 equiv). The resulting solution was stirred for 1 hour at room temperature. The reaction was then quenched by the addition of 0.5 mL of water. The solids were filtered out. The crude product (5 mL) was purified by Prep-HPLC with the following conditions: Column, XBridge Prep C18 OBD Column, l50mm 5um; mobile phase, Water(lOMMOL / L bicarbonate amine) and ACN (45.0% ACN up to 52.0% in 7 min); Detector, UV 254 / 220nm. This resulted in 6 mg ( 12% ) of (2S ,4R)- 1 - [(2S )-2-(2- [3 - [4-( 1 - [4- [3 -amino-6-(2-hydroxyphenyl)pyridazin-4-yl] - 1 H- pyrazol- 1 -yl] ethyl)phenyl]propoxy] acetamido) -3 ,3 -dimethylbutanoyl] -4-hydroxy-N- [ [4-(4- methyl-l,3-thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide as a gray solid.

[0501] 1H NMR (300 MHz, Methanol-d4) d 8.79 (s, 1H), 8.35-8.23 (m, 1H), 8.09-7.97 (m, 2H), 7.80 (d, J = 7.7 Hz, 1H), 7.43-7.37 (m, 2H), 7.31 (d, J = 8.1 Hz, 2H), 7.24 (d, J = 8.1 Hz, 1H), 7.20 (s, 4H), 6.89 (t, J = 7.6 Hz, 2H), 5.64 - 5.52 (m, 1H), 4.66 (s, 1H), 4.60 - 4.44 (m, 3H), 4.27 (d, J = 15.5 Hz, 1H), 3.92 (d, J = 4.6 Hz, 2H), 3.88 - 3.74 (m, 2H), 3.52 (d, J = 6.2 Hz, 2H), 2.71 (t, J = 7.6 Hz, 2H), 2.37 (s, 3H), 2.18 (d, J = 7.7 Hz, 1H), 2.07 (dd, J = 9.4, 4.2 Hz, 1H),1.89 (dd, J = 7.3, 1.2 Hz, 6H), 1.26 (s, 1H), 1.10-0.95 (d, J = 1.6 Hz, 9H), 0.95-0.90 (m, 1H).AVS0044US3

[0502] Exemplary Synthesis of Exemplary Compound 34

[0503] Exemplary Compound 34 was prepared according to the scheme below using procedures described for other examples above, as well as procedures known and appreciated to those skilled in the art.AVS0044US3

[0504] Exemplary Synthesis of Exemplary Compound 36 and Exemplary Compound 37

[0505] Exemplary Compounds 36 and 37 were prepared according to the scheme below using procedures described for other examples above, as well as as well as procedures known and appreciated to those skilled in the art.AVS0044US3AVS0044US3

[0506] Exemplary Synthesis of Exemplary Compound 38 and Exemplary Compound 39

[0507] Step 1AVS0044US3

[0508] Into a 500-mL round-bottom flask, was placed 2-(piperazin-l-yl)ethan-l-ol (26.0 g, 199.7 mmol, 1.0 equiv), dichloromethane (200.0 mL), triethylamine (40.4 g, 399.3 mmol, 2.0 equiv), benzyl carbonochloridate (40.8 g, 239.2 mmol, 1.2 equiv). The resulting solution was stirred for 2 h at 0°C. The reaction was then quenched by the addition of 10 mL of water. The resulting solution was extracted with dichloromethane (100 mL x 3), and the organic layers were combined and concentrated under vacuum. The residue was applied onto a silica gel column eluting with dichloromethane / methanol (10:1). This resulted in 22 g (42%) of benzyl 4-(2- hydroxyethyl)piperazine-l-carboxylate as yellow oil.

[0509] Step 2, , ,

[0510] Into a lOO-mL round-bottom flask, was placed benzyl 4-(2-hydroxyethyl)piperazine- l-carboxylate (5.3 g, 20.1 mmol, 1.0 equiv) and N,N-dimethylformamide (30.0 mL). This was followed by the addition of sodium hydride (1.6 g, 66.7 mmol, 1.2 equiv) in 5 minutes. To this was added 4-bromo-2-fluoropyridine (3.9 g, 22.2 mmol, 1.1 equiv) in 20 min. The resulting solution was stirred for 4 hours at 0°C. The reaction was then quenched by the addition of 10 mL of ammonium chloride aqueous solution. The resulting solution was extracted with ethyl acetate (50 mL x3), and the organic layers combined and concentrated under vacuum. The residue was applied onto a silica gel column eluting with dichloromethane / methanol (10:1). This resulted in 5.2 g (62%) of benzyl 4-[2-[(4-bromopyridin-2-yl)oxy]ethyl]piperazine-l-carboxylate as yellow oil.

[0511] Step 3100°C, overnight

[0512] Into a 250-mL round-bottom flask purged and maintained under an inert atmosphere of nitrogen, was placed a solution of benzyl 4-[2-[(4-bromopyridin-2-yl)oxy]ethyl]piperazine-l- carboxylate (2.1 g, 5.0 mmol, 1.0 equiv), RuphosPd II (775.0 mg, 1.0 mmol, 0.2 equiv), and Cs2C03(4.89 g, 15.0 mmol, 3.0 equiv) in PhMe (100 mL). The resulting mixture was stirredAVS0044US3 overnight at l00°C in an oil bath. The reaction mixture was quenched by water (100 mL) and extracted with ethyl acetate (100 mL x 2). The organic layer was combined and concentrated under reduced pressure, and the residue was applied onto a silica gel column eluting with 100% ethyl acetate. This resulted in 670 mg (32%) of tert-butyl 8-[2-(2-[4- [(benzyloxy)carbonyl]piperazin-l-yl]ethoxy)pyridin-4-yl]-3,8-diazabicyclo[3.2.l]octane-3- carboxylate as a yellow solid.

[0513] Step 4

[0514] Into a lOO-mL round-bottom flask, was placed tert-butyl8-[2-(2-[4- [(benzyloxy)carbonyl]piperazin-l-yl]ethoxy)pyridin-4-yl]-3,8-diazabicyclo[3.2.l] octane-3- carboxylate (670 mg, 1.2 mmol, 1.0 equiv) in methanol (10.0 mL). Then hydrogen chloride in l,4-dioxane solution (4M, 10 mL) was added. The resulting solution was stirred for 5 hours at room temperature. The resulting mixture was concentrated under vacuum. This resulted in 410 mg (69%) of benzyl 4-[2-[(4-[3,8-diazabicyclo[3.2.l]octan-8-yl]pyridin-2- yl)oxy]ethyl]piperazine-l-carboxylate hydrochloride as a yellow solid.

[0515] Step 5

[0516] Into a l0-mL sealed tube, was placed benzyl 4-[2-[(4-[3,8-diazabicyclo[3.2.l]octan- 8-yl]pyridin-2-yl)oxy] ethyl] piperazine- 1 -carboxyl ate hydrochloride (200.0 mg, 0.4 mmol, 1.0 equiv), 4-bromo-6-chloropyridazin-3-amine (137.0 mg, 0.7 mmol, 1.5 equiv), methyl sulfoxide (3.0 mL), and N,N-diisopropylethylamine (1 mL). The final reaction mixture was irradiated with microwave radiation for 6 hours at l30°C. The reaction was then quenched by the addition of 1 mL of water. The resulting solution was extracted with ethyl acetate (20 mL x3), and the organic layers were combined and concentrated under vacuum. The residue was applied onto a silica gel column eluting with dichloromethane / methanol (10:1). This resulted in 100 mg (42%) of benzylAVS0044US34-[2-([4-[3-(3-amino-6-chloropyridazin-4-yl)-3,8-diazabicyclo[3.2.l]octan-8-yl]pyridin-2- yl]oxy)ethyl]piperazine-l-carboxylate as a brown solid.

[0517] Step 6

[0518] Into a lOO-mL round-bottom flask, was placed benzyl 4-[2-([4-[3-(3-amino-6- chloropyridazin-4-yl)-3,8-diazabicyclo[3.2.l]octan-8-yl]pyridin-2-yl]oxy)ethyl]piperazine-l- carboxylate (390 mg, 0.7 mmol, 1.0 equiv), dioxane (8.0 mL), water (2.0 mL), potassium carbonate (279 mg, 2.0 mmol, 3.0 equiv), [2-(methoxymethoxy)phenyl]boronic acid (184.0 mg, 1.0 mmol, 1.50 equiv), Pd(PPh3)4(78 mg, 0.07 mmol, 0.1 equiv). The resulting solution was stirred for 2 hours at l00°C. The resulting solution was extracted with ethyl acetate (20 mL x 3), and the organic layers combined and concentrated under vacuum. The residue was applied onto a silica gel column eluting with dichloromethane / methanol (10:1). This resulted in 120 mg (26%) of benzyl 4-(2-[[4-(3-[3-amino-6-[2-(methoxymethoxy)phenyl]pyridazin-4-yl]-3,8- diazabicyclo[3.2.l]octan-8-yl)pyridin-2-yl]oxy]ethyl)piperazine-l-carboxylate as a brown solid.

[0519] Step 7

[0520] To a solution of benzyl 4-(2-[[4-(3-[3-amino-6-[2-(methoxymethoxy)phenyl]pyridazin-4-yl]-3,8-diazabicyclo[3.2.l]octan-8-yl)pyridin-2- yl] oxy] ethyl)piperazine- 1 -carboxylate (200 mg, 0.29 mmol, 1.00 equiv) in 10 mL of isopropanol was added palladium hydroxide (100 mg, 0.71 mmol, 2.42 equiv) under nitrogen atmosphere in a lOO-mL round bottom flask. The flask was then vacuumed and flushed with hydrogen. The resulting solution was stirred for 12 hours at room temperature. The solids were filtered off. The resulting mixture was concentrated under vacuum. This resulted in 70 mg (44%) of 6-[2-AVS0044US3(methoxymethoxy)phenyl]-4-(8-[2-[2-(piperazin-l-yl)ethoxy]pyridin-4-yl]-3,8- diazabicyclo[3.2.l]octan-3-yl)pyridazin-3-amine as brown oil.

[0521] Step 8

[0522] Into a lOO-mL round-bottom flask, was placed 4-(tetramethyl-l,3,2-dioxaborolan-2- yl)-lH-pyrazole (1.9 g, 10.0 mmol, 1.00 equiv), N,N-dimethylformamide (30 mL), ethyl 2- bromo-3-methylbutanoate (2.1 g, 10.0 mmol, 1.0 equiv), and cesium carbonate (10.0 g, 30.7 mmol, 3.0 equiv). The resulting solution was stirred for 12 hours at 90°C. The reaction was then quenched by the addition of 10 mL of water. The resulting solution was extracted with ethyl acetate (20 mL x 3), and the organic layers combined and concentrated under vacuum. The residue was applied onto a silica gel column eluting with ethyl acetate / petroleum ether (1:6). This resulted in 3.3 g (93%) of ethyl 3-methyl-2-[4-(tetramethyl-l,3,2-dioxaborolan-2-yl)-lH- pyrazol-l-yl]butanoate as a white solid.

[0523] Step 9

[0524] Into a 250-mL round-bottom flask, was placed ethyl 3 -methyl-2- [4-(tetramethyl- l,3,2-dioxaborolan-2-yl)-lH-pyrazol-l-yl]butanoate (3.0 g, 9.3 mmol, 1.0 equiv),tetrahydrofuran (30 mL), water (30 mL), sodium perborate (3.5 g, 23.3 mmol, 2.5 equiv). The resulting solution was stirred for 12 hours at room temperature. The resulting mixture was concentrated under vacuum. The resulting solution was extracted with ethyl acetate (20 ml x 3), and the organic layers were combined and concentrated under vacuum. The residue was applied onto a silica gel column eluting with ethyl acetate / petroleum ether (1:1). This resulted in 1740 mg (88%) of ethyl 2-(4-hydroxy-lH-pyrazol-l-yl)-3-methylbutanoate as a white solid.

[0525] Step 10AVS0044US3

[0526] Into a 50-mL round-bottom flask, was placed ethyl 2-(4-hydroxy-lH-pyrazol-l-yl)-3- methylbutanoate (3.5 g, 16.5 mmol, 1.0 equiv), methanol (10 mL), water (10 mL), and sodium hydroxide (2.7 g, 67.5 mmol, 4.0 equiv). The resulting solution was stirred for 12 hours at room temperature. The pH value of the solution was adjusted to 2 with 2M HC1. The crude product was purified by prep-HPLC with the following conditions: Column, XBridge Shield RP18 OBD Column,, 5um,l9*l50mm; mobile phase, Water (0.1% FA) and acetonitrile (0.0% acetonitrile up to 4.0% in 2 min, up to 20.0% in 8 min); Detector, UV 254nm. This resulted in 1.5 g (49%) of 2- (4-hydroxy-lH-pyrazol-l-yl)-3-methylbutanoic acid as a white oil.

[0527] Step 11

[0528] Into a lOO-mL round-bottom flask, was placed 2-(4-hydroxy-lH-pyrazol-l-yl)-3- methylbutanoic acid (500 mg, 2.7 mmol, 1.0 equiv), N,N-dimethylformamide (20 mL), (2S,4R)- 4-hydroxy-N-[(lS)-l-[4-(4-methyl-l,3-thiazol-5-yl)phenyl]ethyl]pyrrolidine-2-carboxamide hydrochloride (900 mg, 2.5 mmol, 0.9 equiv), DIEA (1.1 g, 8.5 mmol, 3.0 equiv), T3P (2.6 g, 1.5 equiv). The resulting solution was stirred for 1 hour at room temperature. The reaction was then quenched by the addition of 5 mL of water. The resulting solution was extracted with ethyl acetate (30 mL x3) and the organic layers combined and concentrated under vacuum. The residue was applied onto a silica gel column with dichloromethane / methanol (10:1). This resulted in 800 mg (59%) of (2S,4R)-4-hydroxy-l-[2-(4-hydroxy-lH-pyrazol-l-yl)-3- methylbutanoyl] -N-[(lS)-l - [4-(4-methyl- 1 ,3 -thiazol-5-yl)phenyl] ethyl]pyrrolidine-2- carboxamide as a yellow solid.

[0529] Step 12AVS0044US3

[0530] Into a 5-mL sealed tube, was placed (2S,4R)-4-hydroxy-l-[2-(4-hydroxy-lH-pyrazol- 1 -yl)-3 -methylbutanoyl] -N-[(lS)-l - [4-(4-methyl- 1 ,3 -thiazol-5-yl)phenyl] ethyl] pyrrolidine-2- carboxamide (300 mg, 0.60 mmol, 1.0 equiv), N,N-dimethylformamide (5.0 mL), 1,2- dibromoethane (222 mg, 1.2 mmol, 2.0 equiv), potassium carbonate (250 mg...

Claims

CLAIMSWhat Is Claimed Is:

1. A bifunctional compound having the chemical structure:PTM— L— ULM,or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph or prodrug thereof,wherein:the ULM is a small molecule E3 ubiquitin ligase binding moiety that binds a Von Hippel- Lindau E3 ubiquitin ligase;the L is a bond or a chemical linking moiety connecting the ULM and the PTM; and the PTM is a small molecule comprising a SMARCA2 protein targeting moiety having a chemical structure represented by Formula I, II, III, IVa, IVb or VI:1wherein:WPTMI is a 5-6-membered aryl or heteroaryl ring optionally substituted with 0, 1, 2, or 3 substituents selected from hydroxy, halogen, alkoxy, alkyl, haloalkyl, amino, phosphate, alkylamino, cyano or a combination thereof;WPTM2 is a 5-6-membered aryl or heteroaryl ring optionally substituted with 0, 1, 2, or 3 substituents selected from hydroxy, halogen, alkoxy, alkyl, haloalkyl, amino, alkylamino, cyano or a combination threof;WPTM3 is absent or a 5-6-membered aryl or heteroaryl ring optionally substituted with 0, 1, 2, or 3 substituents selected from hydroxy, halogen, alkoxy, alkyl, haloalkyl, amino, alkylamino, cyano or a combination thereof, a 4-9 membered cycloalkyl or heterocyclyl optionally substituted with 0, 1, or 2 substituents selected from hydroxy, halogen, alkoxy, alkyl, haloalkyl, amino, alkylamino, cyano or a combination thereof, or a bridged bicycloalkyl or bridged biheterocyclyl optionally substituted with 0, 1, or 2 substituents selected from hydroxy, halogen, alkoxy, alkyl, haloalkyl, amino, alkylamino, cyano or a combination thereof;WPTM4 is a 5-7 membered cycloalkyl or heterocyclyl optionally substituted with 0, 1, 2, or 3 substituents selected from hydroxy, halogen, alkoxy, alkyl, haloalkyl, amino, phosphate, alkylamino, cyano or a combination thereof;WPTM5 is absent or a 5-6-membered aryl or heteroaryl ring optionally substituted with 0, 1, or 2 substituents selected from hydroxy, halogen, alkoxy, alkyl, haloalkyl, amino, alkylamino, cyano or a combination thereof;WPTM6and WPTM7 are independently a 4-7 cycloalkyl or heterocyclyl optionally substituted with 0, 1, or 2 substituents selected from hydroxy, halogen, alkoxy, alkyl, haloalkyl, amino, alkylamino, cyano or a combination thereof, wherein the rings of WPTM6and WPTM7 are fused or linked via a spiro connection; and / is the attachment point to the linker or ULM group.2 The compound according to claim 1, wherein PTM is represented by Formula I:2or a pharmaceutically acceptable salt thereof, wherein:WPTMI is an optionally substituted phenyl or a pyridyl;WPTM2 is an optionally substituted 6-membered heteroaryl ring;WPTM3 is absent or an optionally substituted 5-6-membered heteroaryl, an optionallysubstituted 4-9 cycloalkyl or heterocyclyl ring, or an optionally substituted bridged bicycloalkyl or bridged biheterocyclyl ring;WPTM5 is absent (such that WPTM3 is connected directly to L (linker) or ULM) or anoptionally substituted 5-6-membered aryl or heteroaryl ring.

3. The compound according to claim 2, wherein the PTM is represented by the fomula:or a pharmaceutically acceptable salt thereof, wherein:WPTM3 is absent or an optionally substituted 5-6-membered heteroaryl, an optionally substituted 4-9 cycloalkyl or heterocyclyl ring, an optionally substituted bridged bicycloalkyl or bridged biheterocyclyl ring; andWPTM5 is an optionally substituted 5-6-membered.

4. The compound according to claim 3, wherein PTM is represented by the formula:3or a pharmaceutically acceptable salt thereof, wherein:WPTM5 is phenyl, pyridine, pyrimidine or pyrazine.

5. The compound according to claim 1, wherein PTM is represented by the formula:or a pharmaceutically acceptable salt thereof.

6. The compound according to claim 1 , wherein the PTM is represented by Formula III:or a pharmaceutically acceptable salt thereof, wherein:WPTMI is a phenyl substituted with a hydroxy substituent and optionally substituted with 0, 1, or 2 substituents selected from hydroxy, halogen, alkoxy, alkyl, haloalkyl, amino, phosphate, alkylamino, cyano or a combination thereof;4WPTM2 is a pyridazine substituted with amino group; andWPTM6 and WPTM7 are a spirocyclic ring system with a structure selected from:

7. The compound according to claim 1, wherein the PTM is represented by Formula IVa or IVb:or a pharmaceutically acceptable salt thereof, wherein:WPTMI is a phenyl substituted with a hydroxy substituent and optionally substituted with 0, 1, or 2 substituents selected from hydroxy, halogen, alkoxy, alkyl, haloalkyl, amino, phosphate, alkylamino, cyano or a combination thereof;WPTM2 is a pyridazine substituted with amino group; andWPTM5 is absent, a pyrazole ring, or a pyridine ring.8 The compound according to any of claims 1-7, wherein the PTM is selected from the group consisting of:5679. The compound according to any of claims 1-7, wherein ULM is a chemical structure represented by:wherein:8W3is selected from the group of an optionally substituted aryl, optionally substitutedheteroaryl,R-9and Rio are independently hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted hydroxyalkyl, optionally substituted heteroaryl, or haloalkyl, or R9, Rio, and the carbon atom to which they are attached form an optionally substituted cycloalkyl;R11 is selected from the group of an optionally substituted heterocyclyl, optionally substituted. R12I'— Np alkoxy, optionally substituted heteroaryl, optionally substituted aryl,13R12 is selected from the group of H or optionally substituted alkyl;R13 is selected from the group of H, optionally substituted alkyl, optionally substituted alkylcarbonyl, optionally substituted (cycloalkyl)alkylcarbonyl, optionally substituted aralkylcarbonyl, optionally substituted arylcarbonyl, optionally substituted (heterocyclyl)carbonyl, or optionally substituted aralkyl;Ri4a,Ri4b,are each independently selected from the group of H, amine, haloalkyl, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted hydroxyl alkyl, optionally substituted alkylamine, optionally substituted heterolkyl, optionally substituted alkyl-heterocycloalkyl, optionally substituted alkoxy-heterocycloalkyl, COR26, CONR27aR27b, NHCOR26, or NHCH3COR26; and the other of Ri4a and Ri4b is H; or Ri4a, Ri4b,together with the carbon atom to which they are attached, form an optionally substituted 3 to 5 membered cycloalkyl, heterocycloalkyl, spirocycloalkyl or spiroheterocyclyl, wherein the spiroheterocyclyl is not epoxide or aziridine;W5is optionally substituted phenyl, optionally substituted napthyl, or an optionally substituted 5-10 membered heteroaryl;R15 is selected from the group of H, halogen, CN, OH, NO2, NR27aR27b, OR27a, CONR27aR27b, NR27aCOR27b, S02NR27aR27b, NR27aS02R27b, optionally substituted alkyl, optionally9substituted haloalkyl, optionally substituted haloalkoxy; optionally substituted aryl; optionally substituted heteroaryl; optionally substituted cycloalkyl; or optionally substituted heterocyclyl;each Ri6is independently selected from the group of halo, CN, optionally substituted alkyl, optionally substituted haloalkyl, hydroxy, or optionally substituted haloalkoxy;o is 0, 1, 2, 3, or 4;Ri8is independently selected from the group of H, halo, optionally substituted alkoxy, cyano, optionally substituted alkyl, haloalkyl, haloalkoxy or a linker;each R26is independently selected from H, optionally substituted alkyl or NR27aR27b;each R27aand R27bis independently H, optionally substituted alkyl, or R27aand R27btogether with the nitrogen atom to which they are attached form a 4-6 membered heterocyclyl; and p is 0, 1, 2, 3, or 4, and wherein the dashed line indicates the site of attachment of at least one PTM, another ULM (ULM’) or a chemical linker moiety coupling at least one PTM or a ULM’ or both to ULM.

10. The compound according to claim 9, wherein the ULM has a chemical structure selected from the group of:wherein:10Ri is H, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted hydroxyalkyl, optionally substituted heteroaryl, or haloalkyl;Ri4ais H, haloalkyl, optionally substituted alkyl, methyl, fluoromethyl, hydroxymethyl, ethyl, isopropyl, or cyclopropyl;R15is selected from the group consisting of H, halogen, CN, OH, NO2,optionally substituted heteroaryl, optionally substituted aryl; optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted haloalkoxy, optionally substituted cycloalkyl, or optionally substituted heterocyclyl;X is C, CH2, or C=0;R3is absent or an optionally substituted 5 or 6 memebered heteroaryl; andthe dashed line indicates the site of attachment of at least one PTM, another ULM (ULM’) or a chemical linker moiety coupling at least one PTM or a ULM’ or both to the ULM.

11. The compound of claim 10, wherein the ULM is of the formula:or a pharmaceutically acceptable salt thereof, wherein:Ri is H, optionally substituted alkyl or optionally substituted cycloalkyl;R3is an optionally substituted 5-6 membered heteroaryl;W5is optionally substituted phenyl, optionally substituted napthyl or optionally substituted pyridinyl;one ofRi4aandRi4bis H, optionally substituted alkyl, haloalkyl, optionally substituted alkoxy, optionally substituted hydroxyl alkyl, optionally substituted alkylamine, optionally substituted heterolkyl, optionally substituted alkyl-heterocycloalkyl, optionally substituted alkoxy-heterocycloalkyl, COR26, CONR27aR27b, NHCOR26, or NHCH3COR26; and the other of Ri4a and Ri4bis H; or Ri4a,Ri4b,together with the carbon atom to which they are11attached, form an optionally substituted 3 to 5 membered cycloalkyl, heterocycloalkyl, spirocycloalkyl or spiroheterocyclyl, wherein the spiroheterocyclyl is not epoxide or aziridine;R15 is CN, fluoroalkyl,R28a r^V / R28aN , or optionally substituted t ^> (, e.g., | -R28a or l> , wherein R28ais halo, optionally substituted alkyl or fluoroalkyl);each Ri6is independently selected from halo, CN, optionally substituted alkyl, optionally substituted haloalkyl, hydroxy, or haloalkoxy;each R26is independently H, optionally substituted alkyl or R27aR27b;each R27aand R2-bis independently H, optionally substituted alkyl, or R2-aand R27btogether with the nitrogen atom to which they are attached form a 4-6 membered heterocyclyl;R28is H, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted heteroalkyl, optionally substituted alkylamine, optionally substituted hydroxyalkyl, amine, optionally substituted alkynyl, or optionally substituted cycloalkyl; ando is 0, 1 or 2.

12. The compound of claim 11, wherein the ULM is of the formula:wherein:each of X4, X5, and X6is selected from CH and N, wherein no more than 2 are N;R1is Cl -6 alkyl;one of R14aand R14bis H, optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted alkoxy, optionally substituted hydroxyl alkyl, optionally substituted12alkylamine, optionally substituted heterolkyl, optionally substituted alkyl- heterocycloalkyl, optionally substituted alkoxy-heterocycloalkyl, COR26, CONR27aR27b, NHCOR26, or NHCH3COR26; and the other of R14aand R14bis H; or R14aand R14b, together with the carbon atom to which they are attached, form an optionally substituted 3 to 5 membered cycloalkyl, heterocycloalkyl, spirocycloalkyl or spiroheterocyclyl, wherein the spiroheterocyclyl is not epoxide or aziridine;each R27aand R27bis independently H or Ci-6alkyl;q is 1, 2, 3 or 4;R28Cis H, methyl, fluoro, or chloro; andR16is H, Ci-4alkyl, fluoro, chloro, CN, or Ci-4alkoxy.

13. The compound of claim 12, wherein R14aand R14bare selected from: H, Ci-4alkyl, Ci-4cycloalkyl, Ci-4haloalkyl, Ci-4hydroxyalkyl, Ci-4alkyloxyalkyl, Ci-4alkyl-NR27aR27band CONR27aR27b14. The compound of claim 12 or 13, wherein R14aand R14btogether with the carbon atom to which they are attached, form, wherein R is selected from H, Ci-4alkyl, - C(0)Ci-4alkyl.

15. The compound of claim 12, wherein the ULM is of the formula:13or a pharmaceutically acceptable salt thereof, wherein X is CH or N.

16. The compound of claim 12 or 15, or a pharmaceutically acceptable salt thereof, wherein Ri is Ci -6alkyl.

17. The compound of any one of claims 12, 15, or 16, or a pharmaceutically acceptable salt thereof, wherein:one ofRi4aandRi4bis H, Ci-6alkyl, Ci-6haloalkyl, optionally substitute Ci-4alkylamine, Ci-6alkoxy, (CH2)qCi-6 alkoxy, (CH2)qCi-6alkoxy-C3-7 heterocycloalkyl, (CH2)qOH, (CH2)qNR27aR27b, (CH2)qNHCOCl-6alkyl, C3 -6 cycloalkyl, or NR27aR27b; each R26 is independently H, Ci-6alkyl or NR27aR27b;each R27aand R27bis independently H or Ci-6alkyl; andand q is 1, 2, 3 or 4.

18. The compound of any one of claims 12, 15 or 16, or a pharmaceutically acceptable salt thereof, wherein: one of Ri4aand Ri4bis H, C1-4alkyl, C1-4haloalkyl, C1-4alkoxy, optionally substituted Ci -4 alkylamine, (CH2)qCi-6 alkoxy, (CH2)qCi-6 alkoxy-C3-7 heterocycloalkyl, (CH2)qOH, (CH2)qNR27aR27b, (CH2)qNHCOCi-6alkyl, or C3-6 cycloalkyl, orNR27aR27b;each R26 is independently H, C1-4 alkyl or NR27aR27b;each R27aand R27bis independently H or C1-4alkyl; andq is 1 or 2.1419. The compound of any one of claims 12, 15 or 16, or a pharmaceutically acceptable salt thereof, wherein:R-28is Ci -6 alkyl, C3-6cycloalkyl, Ci-6haloalkyl, (CH2)qOCi-6alkyl, (CH2)qOH,(CH2)qNR27aR27b, (CH2)qNHCOCi-6 alkyl,R29 is H, Ci -6 alkyl, NR27aR27borqNHCOCi-6 alkyl; andwherein q is 1 or 2.

20. The compound of claim 12, or a pharmaceutically acceptable salt thereof, wherein R3is isoxazolyl, 4-chloroisoxazolyl, 4-fluoroisoxazolyl, or pyrazolyl.

21. The compound of claim 20, or a pharmaceutically acceptable salt thereof, wherein X is CH.

22. The compound of any one of claims 20 or 21, wherein the ULM has the formula:pharmaceutically acceptable salt thereof,wherein:15X is CH or N;R.30 is H, F or Cl;R16is H, Ci-4alkyl, fluoro, chloro, CN, or Ci-4alkoxy; andR28is H, methyl, CH2N(Me)2, CH2OH, CH20(Ci-4alkyl), CH2NHC(0)Ci-4alkyl, NH2,23. The compound of claim 22, wherein the ULM has the formula:or a pharmaceutically acceptable salt thereof, wherein R3o is H, F or Cl.

24. The compound of any one of claims 1, 12, 15 or 23, wherein the ULM is a ULM as provided in Table 1 A, Table 1B, and Table 1C.

25. The compound of any of claims 1, 12, 15 or 23, wherein the linker (L) comprises a chemical structural unit represented by the formula:-(AL)q-16wherein:(AL)qis a group which is connected to at least one of ULM, PTM, or both;q is an integer greater than or equal to 1;each ALis independently selected from the group consisting of, a bond, CRL1RL2, O, S, SO, S02, NRL3, S02NRL3, SONRL3, CONRL3, NRL3CONRL4, NRL3S02NRL4, CO, CRL1=CRL2, CºC, SiRL1RL2, P(0)RL1, P(0)0Rl1, NRL3C(=NCN)NRL4, NRL3C(=NCN), NRL3C(=CN02)NRL4, C3- ncycloalkyl optionally substituted with 0-6 RL1and / or RL2groups, C3-nheteocyclyl optionally substituted with 0-6 RL1and / or RL2groups, aryl optionally substituted with 0-6 RL1and / or RL2groups, heteroaryl optionally substituted with 0-6 RL1and / or RL2groups, where RL1or RL2, each independently are optionally linked to other groups to form cycloalkyl and / or heterocyclyl moiety, optionally substituted with 0-4 RL5groups; andRL1, RL2, RL3, RL4and RL5are, each independently, H, halo, C i-xalkyl, OC i-xalkyl, SCi- xalkyl, NHC i-xalkyl, N(Ci-8alkyl)2, C3-11 cycloalkyl, aryl, heteroaryl, C3-nheterocyclyl, OCi-8cycloalkyl, SCi-scycloalkyl, NHCi-scycloalkyl, N(Ci-8cycloalkyl)2, N(Ci-8cycloalkyl)(Ci-8alkyl), OH, NH2, SH, S02Ci-8alkyl, P(0)(0Ci-8alkyl)(Ci-8alkyl), P(0)(0Ci-8alkyl)2, CC-Ci-8alkyl, CCH, CH=CH(C 1 -8alkyl), C(Ci-8alkyl)=CH(Ci-8alkyl), C(Ci-8alkyl)=C(Ci-8alkyl)2, Si(OH) , Si(Ci-8alkyl)3, Si(OH)(Ci-8alkyl)2, COCi-8alkyl, C02H, halogen, CN, CF , CHF2, CH2F, N02, SF5, S02NHCi-8alkyl, S02N(Ci-8alkyl)2, SONHCi-salkyl, SON(Ci-8alkyl)2, CONHCi-salkyl, CON(Ci-8alkyl)2, N(Ci-8alkyl)CONH(Ci-8alkyl), N(Ci-8alkyl)CON(Ci-8alkyl)2, NHCONH(Ci-8alkyl), NHCON(C 1 -8alkyl)2, NHCONH2, N(Ci-8alkyl)S02NH(Ci-8alkyl), N(Ci-8alkyl) S02N(Ci-8alkyl)2, NH S02NH(C 1 -8alky 1), NH S02N(Ci-8alkyl)2, NH S02NH2.

26. The compound of claim 1, wherein L is a means for covalently coupling the PTM to the ULM.

27. The compound according to any of claims 1 or 26, wherein the linker (L) comprises the following chemical structure:17orwherein:WL1and WL2are each independently a 4-8 membered ring with 0-4 heteroatoms, optionally substituted with RQ, each RQ is independently a H, halo, OH, CN, CF3, C1-C6 alkyl (linear, branched, optionally substituted), C1-C6 alkoxy (linear, branched, optionally substituted), or 2 RQ groups taken together with the atom they are attached to, form a 4-8 membered ring system containing 0-4 heteroatoms;YL1is each independently a bond, C1-C6 alkyl (linear, branched, optionally substituted) and optionally one or more C atoms are replaced with O; or C1-C6 alkoxy (linear, branched, optionally substituted);n is 0-10; anda dashed line indicates the attachment point to the PTM or ULM moieties.

28. The compound according to any of claims 1 or 26, wherein the linker (L) comprises the following chemical structure:wherin:18WL1and WL2are each independently aryl, heteroaryl, cyclic, heterocyclyl, Ci-6alkyl, bicyclic, biaryl, biheteroaryl, or biheterocyclyl, each optionally substituted with RQ, each RQis independently a H, halo, OH, CN, CF3, hydroxyl, nitro, C º CH, C2-6 alkenyl, C2-6 alkynyl, Ci-C6alkyl (linear, branched, optionally substituted), Ci-C6alkoxy (linear, branched, optionally substituted), OC 1-3 alkyl (optionally substituted by 1 or more -F), OH, NH2, NRY1RY2, CN, or 2 RQgroups taken together with the atom they are attached to, form a 4-8 membered ring system containing 0-4 heteroatoms;YL1is each independently a bond, NRYL1, O, S, NRYL2, CRYL1RYL2, C=0, C=S, SO, S02, Ci- C6alkyl (linear, branched, optionally substituted) and optionally one or more C atoms are replaced with O; Ci-C6alkoxy (linear, branched, optionally substituted);QLis a 3-6 membered alicyclic or aromatic ring with 0-4 heteroatoms, optionally bridged, optionally substituted with 0-6 RQ, each RQis independently H, Ci-6alkyl (linear, branched, optionally substituted by 1 or more halo, Ci-6alkoxyl), or 2 RQgroups taken together with the atom they are attached to, form a 3-8 membered ring system containing 0-2 heteroatoms);RYL1, RYL2are each independently H, OH, Ci-6alkyl (linear, branched, optionally substituted by 1 or more halo, Ci-6alkoxyl), or R1, R2together with the atom they are attached to, form a 3-8 membered ring system containing 0-2 heteroatoms);n is 0-10; anda dashed line indicates the attachment point to the PTM or ULM moieties.

29. The compound according to any of claims 1 or 26, wherein the linker (L) comprises a group represented by a structure selected from the group consisting of:-0-(CH2)m-0(CH2)„-0(CH2)o-0(CH2)P-0(CH2)q-0(CH2)r-0(CH2)s-0(CH2)t-;-0-( CH2)m-0(CH2)„-0(CH2)o-0(CH2)P-0(CH2)q-0(CH2)r-0(CH2)s-0-;-(CH2)m-0(CH2)„-0(CH2)o-0(CH2)P-0(CH2)q-0(CH2)r-0(CH2)s-0(CH2)t-;-CH=CH(CH2)m-0(CH2)„-0(CH2)o-0(CH2)P-0(CH2)q-0(CH2)r-0(CH2)s-0(CH2)t-;0(CH2)nNCH3C(=0)(CH2)m—.1920212223, q, r, s and t are each independently selected from the integers 0, 1, 2, 3 and 4.

30. The compound according to any of claims 1 or 26, wherein L is selected from the group consisting of:2436. The compound of claim 1, wherein i) WPTM4 is fused with WPTM2 or ii) WPTM3 is fused with WPTM2.

37. The compound of claim 2, wherein WPTM3 is an optionally substituted pyrazole, pyrrole, imidazole, oxazole, oxadiazole, or triazole.

38. The compound of claim 3, wherein WPTMS is an optionally substituted pyridine, pyrimidine, or pyrazine.

39. The compound of any of claims 1 or 26, wherein the compound is a member selected from the compounds of Table 1A, Table 1B, and Table 1C.2540. The compound of claim 39, wherein the compound has a Dmaxgreater than or equal to 80%.

41. A composition comprising an effective amount of a bifunctional compound of any of claims 1 or 26, and a pharmaceutically acceptable carrier.

42. The composition of claim 41, wherein the composition further comprises at least one of additional bioactive agent or another compound of claim 1.

43. The composition of claim 42, wherein the additional bioactive agent is anti-cancer agent.

44. A composition comprising a pharmaceutically acceptable carrier and an effective amount of at least one compound of claim 1 for treating a disease or disorder in a subject, the method comprising administering the composition to a subject in need thereof, wherein the compound is effective in treating or ameliorating at least one symptom of the disease or disorder.

45. The composition of claim 44, wherein the disease or disorder is associated with SMARCA1, BRAHMA or BRM accumulation and aggregation.

46. The composition of claim 45, wherein the disease or disorder is cancer.

47. The composition of claim 46, wherein the cancer is a SWI / SNF associated cancer or a cancer with a SMARCA4 mutation (e.g., lung cancer or non-small cell lung cancer).

48. The composition of claim 46, wherein the cancer is a SMARCA4-deficient cancer or a cancer with decreased expression of SMARCA4 relative to normal SMARCA4 expression (e.g., relative to the expression of non-mutated SMARCA4 or SMARCA4 in a similarly situated non-cancerous cell with a wildtype SMARCA4), such as lung cancer or non-small cell lung cancer.26